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ABSTRACT 
 
JAIME M. CYPHERT: Regulation of airway reactivity: Interactions between 
neuronal and immune pathways in the lung 
(under the direction of Beverly H. Koller) 
 
 
 The prevalence of asthma has been on the rise since the 1970s, affecting more 
than 300 million people worldwide.  In recent years, approximately 250,000 deaths per 
year have been attributed to the condition.  The majority of these deaths are likely a direct 
result of airway obstruction, of which constriction of airway smooth muscle plays a 
significant role.  Although several bronchodilators are currently on the market for 
alleviation of airway constriction, not all patients are responsive to these treatments.  This 
underlies the importance of understanding the mechanisms triggering smooth muscle 
constriction so that additional drug targets can be discovered to help prevent or reverse 
airway constriction during asthmatic exacerbations.   
 In this dissertation I utilize two approaches to analyze immune-related airway 
constriction in the mouse in an attempt to further understand the mechanism behind the 
human condition.  The majority of asthmatics also have allergies, which can trigger both 
enhanced inflammation of the airways and airway constriction.  Therefore, the first 
approach involved modeling allergic airway constriction in both the naïve and inflamed 
mouse lung to examine the mechanisms of IgE-mediated bronchoconstriction.  Genetic,   
pharmacological, and surgical methods were then used to explore the cell types, 
mediators, and receptors involved in this response. 
 iii
 The second approach involved the triggering of airway constriction through a 
non-allergic mechanism.  In these studies, the thromboxane analog U46619 was used to 
elicit dose-dependent airway constriction.  As the thromboxane receptor, Tp, is expressed 
on multiple cell types, mice carrying a tissue-specific deletion of this receptor were 
examined to define the cell types involved in U46619-mediated bronchoconstriction in 
both the naïve and inflamed lung.  
 Asthma is a highly complex disease involving the combined effects of both 
genetic and environmental effects and therefore it is unlikely to be able to model the 
disease itself accurately in a laboratory animal that does not spontaneously develop the 
condition.  However, it is possible to closely approximate several pathophysiological 
symptoms of asthma in the mouse, and using these models, the many mechanisms 
underlying the conditions of asthma can be teased away from the complexity of the 
condition as a whole.   
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STRUCTURE, FUNCTION AND REGULATION OF THE HEALTHY LUNG 
 The lung is the essential respiration organ in air-breathing animals.  Air passes 
through the nose or mouth and travels through the oropharynx, nasopharynx, larynx, and 
trachea into the main conducting airways of the lung until it finally reaches the alveoli 
where the gas exchange of carbon dioxide and oxygen takes place.  The structure of the 
human lung, although similar in many ways, is relatively complex when compared to that 
of experimental animals, especially the mouse (Figure 1.1).  These differences are 
reviewed extensively by Hyde et al. (1).  Briefly, the tracheobronchial conducting 
airways form a complex branching pattern that extends to the gas exchange peripheral 
airways.  The bronchi, the largest branches, have abundant cartilage while distally the 
smaller bronchioles have thinner walls with little to no cartilage and a greater proportion 
of smooth muscle.  Conversely, in the mouse cartilage is found predominantly in the 
trachea.  The average number of airway generations from the trachea to the alveolar 
spaces is roughly the same for most mammals; however, branching is unique in primates 
(including humans).  Furthermore, the organization of the transition zone between the 
conducting airways and the gas exchange zone differs significantly between the species.  
Primates have many respiratory bronchioles, while mice have few.  Finally, the cellular 
make-up of the airways also differs (Table 1.1).   
The lungs are primarily responsible for the exchange of oxygen and carbon 
dioxide between the air we breathe and the blood, supplying a source of energy to the 
body.  On average, humans inhale and exhale 22,000 times per day and process around 
300 cubic feet (8.5 cubic meters) of air, which brings not only nourishing oxygen but also 
a multitude of pollutants and noxious particles from which the lung needs to protect  
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Figure 1.1 Structure of human and mouse lung.*  Humans have an extensive 
branching of the lung (including the intrapulmonary bronchus), as well as a greater area 
of transition between the most distal conducting airway, the terminal bronchiole, and the 
alveolar ducts.  The mouse airway has less branching; primary bronchus leading directly 
to terminal bronchioles.  The distal airway of mice lacks the extensive respiratory 
bronchioles and is usually characterized by the terminal bronchiole branching directly 
into the alveolar ducts. *Adapted from (1). 
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itself.  The airway wall is made up of several “compartments” including, 1) the epithelial 
compartment, comprised of surface epithelium and submucosal glands; 2) the interstitial 
compartment, including the basement membrane, fibroblasts, smooth muscle, cartilage, 
and vasculature; 3) the nervous compartment, both afferent and efferent branches; 4) the 
vascular compartment which encompasses capillaries, arterioles and venules from the 
bronchial circulation, and lymphatic vessels; and 5) the immunological compartment, 
including both migratory and resident inflammatory immune cells.  Together these 
compartments help to coordinate proper function, as well as defense mechanisms to 
protect the airways from environmental irritants, pollutants, and allergens inhaled on a 
regular basis. 
 
Epithelium 
 The bronchial epithelium is a stratified structure consisting of a columnar layer 
comprising ciliated and secretory cells that are supported by basal cells.  This represents 
the primary physical barrier that protects the internal milieu of the lungs and intra-
epithelial sensory nerves from inhaled irritants, pollutants, infectious agents, and other 
particulate matter.  Under normal conditions, the epithelium secretes mucus, as well as 
cytoprotective molecules in order to trap and inactivate inhaled components.  The 
epithelium can also work in conjunction with the immune system by secreting cytokines 
and chemokines, as well as through expression of adhesion molecules; thereby providing 
a mechanism of tissue repair and debris removal in the event of epithelial compromise.   
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Table 1.1 Comparison of species differences in airway organization.* 
Parameter Human Mouse 
Tracheobronchial airway   
    Cartilage in wall trachea to distal bronchiole trachea 
    Nonrespiratory bronchioles several generations several generations 
    Respiratory bronchioles several generations none or one 
    Generations to alveolarised bronchiole 17-21 13-17 
    Branching pattern dichotomous monopdial 
Trachea   
    Wall   
        Smooth muscle present present 
        Cartilage present present 
        Submucosal glands present present 
    Epithelium   
        Thickness (µm) 50-100 11-14 
        Cells/mm basement membrane 303±20 215 
        % goblet cells 9 <1 
        % serous cells  <1 
        % clara cells  49 
        % ciliated cells 49 39 
        % basal cells 33 10 
        % other cells  1 
Intrapulmonary airways   
    Wall   
        Smooth muscle present present 
        Cartilage present absent 
        Submucosal glands present absent 
    Epithelium   
        Thickness (µm) 40-50 8-16 
        Cells/mm basement membrane n/a 109 
        % goblet cells 10 <1 
        % serous cells 3 <1 
        % clara cells  61 
        % ciliated cells 37 36 
        % basal cells 32 <1 
        % other cells 18 2 
Terminal bronchioles   
    Wall   
        Smooth muscle present present 
        Cartilage absent absent 
        Submucosal glands absent absent 
    Epithelium   
        Thickness (µm) ? 7-8 
        Cells/mm basement membrane ? ? 
        % goblet cells  0 
        % serous cells 35 0 
        % clara cells  60-80 
        % ciliated cells 52 40-20 
        % basal cells <1 <1 
        % other cells 13 0 
*Modified from (1). 
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Airway Smooth Muscle 
 In normal airways, the role of airway smooth muscle (ASM) is controversial.  
ASM may provide structural support, promote gas exchange, aid in mucus clearance, 
protect against particulate infiltration through narrowing of the airways, and/or contribute 
to the cough reflex.  On the other hand, it is possible that ASM does not contribute 
significantly to the healthy lung.  In human and animal airways, there is a small degree of 
resting tone maintained by constitutive release of acetylcholine (ACh) from 
parasympathetic nerves within the airway.  However, this resting tone does not appear to 
be critical to healthy lung function, as treatment with muscarinic antagonists does not 
appear to have adverse effects on airway function.  It is unclear if proximal and distal 
ASM behaves in the same way, as innervation of the distal airways is sparse and receptor 
distribution varies within different degrees of the airways.   
 
Resident Immune Cells   
Dendritic Cells 
Dendritic cells (DCs) are bone marrow-derived cells.  Their primary function is to 
act as sentinels in the mucosa and internal organs of the body in search of foreign 
antigens, viruses, and bacteria (2).  DCs bind, internalize, and process antigens which are 
then displayed on their surface and presented to lymphocytes.  This process drives the 
adaptive immune response.  In addition to their role in the adaptive immune response, 
DCs also tolerize T cells to antigens that are innate to the body (self antigens), 
minimizing autoimmune reactions and thereby linking adaptive and innate immune 
responses.   
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Mast cells 
Mast cells, which arise from CD34+ pluripotent hematopoietic cells in the bone 
marrow, are present in most tissues in the vicinity of blood vessels and are especially 
predominant near external boundaries such as the lung mucosa, as well as the nose and 
mouth.  Unlike other inflammatory cells which mature before circulation throughout the 
body, mast cells circulate in an immature form and finally mature after they have been 
established at a tissue site (reviewed in (3)).  Since mast cells mature after reaching 
different tissue types, they can develop different properties depending on the tissue that 
they occupy.  There are two types of mast cells recognized to date, 1) connective tissue; 
and 2) mucosal mast cells.  Typically, the connective tissue mast cell is found in the 
serosal tissue and in skin, while the mucosal type is located in the mucosa of both the 
lung and gut (4).  Although best known for their role in allergy and anaphylaxis, mast 
cells are also involved in functions such as blood flow and coagulation, mucosal 
secretion, wound healing, regulation of innate and adaptive immune responses, as well as 
peripheral tolerance.    
The primary activating mechanism of mast cells is through an FcεRI dependent 
mechanism.  This involves interaction of a multivalent antigen (allergen) with its specific 
IgE antibody attached to the cell membrane via the high affinity FcεRI receptor.  Cross-
linkage of IgE by the interaction of allergen initiates mast cell activation and mediator 
generation and release.  Mast cells also express low affinity IgG receptors, these low 
affinity receptors may regulate high-affinity IgE receptor-mediated activation.  Mast cells 
can also be activated by additional stimuli including neuropeptides, complement 
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components, and certain drugs such as opiates.  Morphologically, degranulation resulting 
from different modes of activation is similar (reviewed in (3)). 
Macrophages 
Macrophages are present within interstitial tissues, alveolar spaces, and on 
mucosal surfaces throughout the body, including the lung.  They are derived from myloid 
precursors, or monocytes, in bone marrow, spleen, and fetal liver that migrate to the lung.  
Similar to mast cells, the environment of their final destination influences the function of 
the developing macrophage.  Generally, macrophages function as a link between the 
innate and adaptive immune system.  Their primary role is phagosytosis of microbial 
pathogens, particulate matter, or debris in response to infection or injury; however, they 
are also capable of secreting an assortment of proinflammatory cytokines and 
chemokines.   
 
Neural Control 
The nervous system is divided into the somatic nervous system (SNS) and the 
autonomic nervous system (ANS).  A generalized diagram can be seen in Figure 1.2.  
Organs under the control of the SNS are considered to be under voluntary control, while 
the ANS regulates involuntary organ function and maintains homeostasis.  The ANS 
primarily functions as an efferent system transmitting signals from the central nervous 
system (CNS) to the peripheral nervous system (PNS); however some afferent autonomic 
fibers are carried to the CNS by major autonomic nerves such as the vagus nerve, which 
are involved in the mediation of visceral sensation and regulation of vasomotor and 
respiratory reflexes.  The ANS is primarily involved in reflex arcs, transmitting impulses 
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from the CNS to peripheral organ systems.  For example, afferent fibers convey stimuli 
from peripheral pain, mechano-, or chemo-receptors to the CNS to activate efferent 
sympathetic or parasympathetic transmission to the peripheral organ systems.  A 
generalized schematic of airway vagal innervation can be seen in Figure 1.3.   
Afferent Nerves 
Sensory nerves in the respiratory tract are adapted to detect various elements of 
the physical and chemical environment of the airways and transmit this information to the 
CNS in the form of action potentials.  An action potential is initiated by depolarization of 
the nerve membrane, which when great enough, leads to the formation of the action 
potential via the activation of voltage-gated sodium channels.  The action potential is 
conducted along the axon until it reaches a central terminal, causing neurotransmitter 
release into the synapse of secondary neurons ultimately leading to reflex reactions 
(reviewed in (5)). 
The vagus nerve contains the majority of airway sensory afferents (reviewed in 
(6)).    Sensory nerves are divided into two general categories (Table 1.2), stretch 
receptors (which respond to mechanical forces caused by inflation and deflation during 
respiration) and nociceptors (which respond to the threat of tissue damage).  The stretch 
receptors are classified as “A fibers” because their action potentials are conducted at a 
fast rate along their axons (~10-50 m/s), and are located from the nose to the 
cartilaginous bronchi occurring with greater frequency in the large airways (7).  These 
receptors can be further subdivided into slowly adapting receptors (SARs) and rapidly 
adapting receptors (RARs) based on their adaptation properties to a sustained inflation.  
Most nociceptors in the lung are classified as “C fibers” due to their slow velocity action  
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Figure 1.2 Schematic of the different divisions of the nervous system.  Sensory nerves 
receive signals from receptor tissues and send a signal through the peripheral nervous 
system (PNS) to the central nervous system (CNS).  The CNS then sends the signal down 
through the PNS to either the somatic nervous system or the autonomic nervous system, 
where the nerves release neuropeptides that act on specific effectors. 
 
 
 
 
 
 
 
 
 11
 
 
 
 
Figure 1.3 Airway innervation*.  Afferent sensory nerve endings in the airway 
epithelium are activated by environmental stimuli which results in neuropeptide release 
from sensory “efferent” fibers, as well, as perpetuation of the signal to the CNS.  The 
signal in the CNS then results in a cholinergic reflex and subsequent release of ACh from 
preganglionic parasympathetic nerves.  The release of ACh then activates the 
parasympathetic ganglion neurons and facilitates the release of ACh from post-ganglionic 
fibers.  *Adapted from (8) 
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Table 1.2 Pulmonary receptors and their reflex effects* 
 
Receptor Type Receptor Subtype Reflex Effects 
 
 
 
Stretch Receptors 
 
SAR 
 
Inspiratory termination, 
expiratory facilitation 
Enhancement of inspiratory effort 
Bronchodilation 
Tachycardia 
 
 RAR Cough 
Broncho- and laryngoconstriction 
Augmented breath/gasp 
Irregular inspiration, shortened 
expiration 
Airway mucus secretion 
 
Nociceptors Bronchopulmonary C fibers Rapid, shallow breathing 
Apnea 
Broncho- and laryngoconstriction 
Airway mucus secretion 
Vasodilation 
Bradycardia 
*Adapted from (9) 
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potentials (~0.3-2 m/s).  These C fibers can also be subdivided based on their ability to 
respond to the chemical capsaicin, a component of hot peppers.  Capsaicin-sensitive C 
fibers exhibit slower action potentials than those of capsaicin-insensitive C fibers (0.3-0.7 
m/s and 0.7-2 m/s, respectively) (reviewed in (10)).  The nerve cell bodies of sensory 
nerves in the airways are localized to both the vagal sensory ganglia (subdivided into the 
nodose and jugular ganglions) and the dorsal root ganglia.  RARs and SARs are derived 
from nodose neurons (11, 12), whereas bronchopulmonary C fibers are derived from both 
nodose, jugular, and dorsal root ganglia (13, 14). 
SARs respond to changes in tension across the airway wall and are thought to 
regulate changes in bronchial tone with inspiration.  There is also evidence in canines that 
SARs and CO2-sensitive chemoreceptors interact at the reflex level; lengthening of 
expiratory duration is attenuated by increased levels of CO2, or hypercapnia (15)  
Activation of these receptors leads to inhibition of inspiration and inhibition of 
parasympathetic activity, consequently resulting in relaxation of ASM (16).  RARs, also 
known as irritant receptors, are thin, myelinated nerve terminals stimulated by 
mechanical, chemical, and inflammatory stimuli.   Activation of these receptors leads to 
increased respiratory rate, increased inspiratory effort, and increased parasympathetic 
output resulting in contraction of ASM and mucus secretion (16).  RARs are also 
responsible for the cough reflex, which is primarily used as a means to rid the airway of 
inhaled pollutants or irritants.  These particles typically get trapped in the protective 
mucus layer and then expelled upon activation of RARs and initiation of cough.  It was 
once thought that mice lack RARs, due to the absence of cough reflex.  Although RARs 
have been found to be located in neurites of cultured adult mouse neurons and in adult 
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mouse skin samples (17, 18), initially no RARs were detected in either the tracheal or 
bronchial epithelium of this species (19).  However, more recent methods have made it 
possible to record RAR activity in vivo in the mouse lung (20).  These studies concluded 
that lung sensory behavior in the mouse is similar to large animals (such as dogs, cats, 
and rabbits) and most closely mimics that of the rat.   
Morphological studies in the cat have shown that approximately 75% of afferent 
fibers in the lung are slow conducting, unmyelinated C-fibers, which span the entire 
respiratory tract from trachea to the parenchyma to the central airways (21).  While 
typically quiescent during tidal breathing, C fiber activation provides excitatory input to 
neuronal pathways driving autonomic output to the airways, resulting in 
bronchoconstriction, mucus secretion, and vasodilation (22, 23).  These reflexes can be 
prevented by treatment with centrally acting tachykinin receptor antagonists, suggesting 
that C-fibers use Substance P (SP) and neurokinin A (NKA) as their primary 
neurotransmitters (23).  In the CNS, neurokinins augment synaptic transmission through 
the action of G-protein coupled neurokinin receptors (NK1, NK2, and NK3) located on 
secondary neurons (24).  In addition, some C fibers may branch to synapse on local 
parasympathetic ganglia where release of tachykinins can elicit excitatory postsynaptic 
potentials (25).  Subsets of afferent nerves in the airways can contain neurotransmitters 
other than tachykinins, such as calcitonin gene related peptide (CGRP), vasoactive 
intestinal peptide (VIP), and neuropeptide Y (NPY). 
Efferent nerves 
The efferent portion of the ANS is further divided into the parasympathetic 
nervous system and the sympathetic nervous system.  Both of these systems consist of 
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myelinated preganglionic fibers which make synaptic connections with unmyelinated 
postganglionic fibers which then innervate the effector organ.  These synapses typically 
occur in clusters, or ganglia.  Most organs are innervated by fibers from both divisions of 
the ANS, which tend to have opposing influences. 
The predominant control of human and animal airways is exerted by 
parasympathetic (or cholinergic) nerves, which travel in the vagus nerve.  The 
parasympathetic division primarily releases ACh from both its pre- and postganglionic 
terminals and is involved in responses such as pupil constriction, digestion, smooth 
muscle contraction, reduction of heart rate, and various organ and gland secretions.  
Parasympathetic nerves are the major neural bronchoconstrictor mechanism within 
human airways.  Specifically, the vagus nerve carries efferent cholinergic fibers that 
synapse in small ganglia within the airway wall, from which short postganglionic fibers 
innervate airway smooth muscle and submucosal glands (26).  In humans, cholinergic 
innervation is abundant in the trachea and in the large central airways, but diminishes 
peripherally (27).  In addition, human airways have a resting tone that is maintained by a 
constitutive low-level release of ACh from these cholinergic nerves.  This resting tone is 
also evident in mouse airways and also appears to be mediated by cholinergic nerves as 
baseline lung resistance is reduced in animals after vagotomy (28).   
Stimulation and activation of cholinergic fibers results in the release of ACh, 
which can act directly on either nicotinic acetylcholine receptors (nAChRs) or muscarinic 
acetylcholine receptors (mAChRs).  nAChRs mediate ganglionic transmission in airways 
and are located directly on parasympathetic ganglia (excitatory), as well as on 
preganglionic junctions (inhibitory).  These receptors are ligand-gated ion channels 
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formed by 5 homologous or identical subunits, arranged to build a central ion channel.   
nAChRs directly on parasympathetic ganglia are required for activation of post 
ganglionic parasympathetic fibers that innervate the airways, which can be blocked 
pharmacologically by treatment with nicotinic antagonists such as hexamethonium and 
mecamylamine.   
In mammals, 5 distinct mAChRs have been identified (M1-M5), and in the lung, 
only the M1, M2, and M3 mAChRs have a defined physiological role (29).   In mice and 
humans, the location of the muscarinic receptors as been well established.  M1 mAChRs 
are primarily localized to the parasympathetic ganglia, where they facilitate 
neurotransmission, but are also located postjunctionally, directly on vascular smooth 
muscle (VSM) and submucosal glands (30).  M2 mAChRs are located postjunctionally, 
directly on ASM and prejunctionally, along postganglionic cholinergic nerve terminals 
(31), where they act as feedback regulators of ACh release.  M3 mAChRs are located 
postjunctionally, directly on ASM, VSM, and along submucosal glands (32), where they 
facilitate airway and vascular constriction and enhance mucus production, respectively.  
The M1 and M3 mAChRs preferentially couple to G-proteins of the Gq family and upon 
stimulation exert their primary physiological effects through the activation of protein 
kinase A (PKA), phospholipase C (PLC), and increases in intracellular calcium [Ca2+]i 
(33); which, in the case of M3 receptor activation, results in ASM contraction (Figure 1.4 
A).  The M2 mAChR is selectively linked to G-proteins of the Gi/o family and exerts its 
effects through the inhibition of adenylate cyclase activity and the subsequent decrease in 
intracellular cyclic AMP (cAMP) levels (33).   
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The sympathetic division is typically involved in “fight or flight” responses such 
as pupil dilation, vascular dilation, smooth muscle relaxation, and increased heart rate.  
Sympathetic nerves emerge from the spinal cord and release ACh onto the sympathetic 
trunk on either side of the spinal cord.  The postganglionic fibers extend to the lung 
where they release norepinepherine, which elicits its effects via activation of adrenergic 
receptors.  The extent of sympathetic innervation in the lungs appears to be species 
specific.  Although sympathetic nerves extend into the ASM of both cat and guinea pig 
airways, in humans these nerve fibers innervate submucosal glands, blood vessels, and 
parasympathetic ganglia but do not directly innervate ASM (reviewed in (34)).  Despite 
the species-dependent innervation patterns, adrenergic receptors appear to be present 
throughout the lung even in humans (35).  
The adrenergic receptors are G-protein coupled receptors that can be grouped into 
two families.  The α-adrenergic receptors, α1 and α2 are coupled to Gq and Gi/o, 
respectively, which function as described above.  Conversely, β-adrenergic receptors are 
coupled to Gs, where stimulation activates adenylate cyclase to increase cAMP.  cAMP 
then increases PKA activity, which in turn phosphorylates downstream protein 
modulators (36).  This reaction ultimately leads to a fall in intracellular Ca2+ levels, and 
activation of large conductance potassium channels to initiate the bronchodilation 
response (Figure 1.4 B).   
In addition to their actions on smooth muscle, adrenergic and muscarinic 
receptors also modulate norepinepherine and ACh release from sympathetic nerves and 
parasympathetic nerves, respectively.  On sympathetic nerves, M1 mAChRs (37) and β2-
adrenergic (38) receptors enhance the release of norepinepherine, whereas M2 mAChRs 
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Figure 1.4 Gq and Gs regulation of airway smooth muscle.  A) Release of ACh from 
parasympathetic nerves mediates airway smooth muscle constriction through the M3 
receptor, a Gq-protein coupled receptor.  Activation of M3 initiates dissociation of the 
Gq+GTP complex and activation of phospholipase C (PLC).  Activated PLC catalyzes 
the hydrolysis of PIP2 into DAG and IP3.  IP3 initiates the release of calcium from the 
sarcoplasmic reticulum into the cytosol.  The resulting increase in calcium promotes the 
binding of calmodulin (CaM).  The calcium/calmodulin complex activates myosin light 
chain kinase (MLCK), which phosphorylates myosin light chains and promotes the 
ATPase activity of myosin, thereby promoting cross-bridge cycling and contraction.  B)  
Release of norepinepherine (NE) from sympathetic nerves initiates smooth muscle 
relaxation by activation of protein kinase A (PKA) via a Gs-protein coupled receptor.  
Activated PKA can phosphorylate Gq coupled receptors, PLC, IP3 receptors, as well as 
MLCK.  This phosphorylation results in reduced generation of IP3, attenuated ability of 
IP3 to activate IP3 receptors and increase intracellular calcium levels, and decreased 
affinity of MLCK for the calcium/calmodulin complex- all of which reduces the 
contractility of airway smooth muscle. 
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 (39) and α2-adrenergic (40) receptors inhibit its release.  On parasympathetic ganglia, β2-
adrenergic receptors have been shown to enhance the release of ACh from guinea pig 
postganglionic nerves in vivo (38), but have also been shown to inhibit this release in 
human trachea and bronchi in vitro (41, 42).  Norepinepherine is colocalized with NPY in 
sympathetic nerves (43).  NPY, although a potent vasoconstrictor, has little if any direct 
effects on ASM, but may also modulate sympathetic reflexes by inhibiting the release of 
norepinepherine via prejunctional activation of Y2 receptors.   
 
Lung function measurements  
 In humans, lung function is most commonly measured using parameters derived 
from forced expiration measurements, in which patients inhale a maximum volume and 
exhale as rapidly as possible into a device that records expired volume versus time.  
Using this method, peak expiratory flow (PEF), forced expiratory volume in the first 
second (FEV1), and maximal midexpiratory flow (MMEF) can be assessed easily and 
noninvasively in patients without instrumentation.  During this forced expiration, the rate 
at which air is expelled from the lungs can determine the mechanical properties of the 
airway using the wave-speed equation for flow through collapsible tubes (44).   
 Due to several advantages that the mouse provides, including a well-characterized 
genome, ease of genetic manipulation, and short reproductive cycle, mice are commonly 
used for pulmonary research.  Several techniques are available for the evaluation of 
airway mechanics in the mouse (Table 1.3), including those that require removal of lungs 
from the host, noninvasive in vivo measurements, and invasive in vivo measurements that 
require instrumentation of the airway (reviewed in (45, 46)).  In vitro, bronchial and/or 
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tracheal strips and rings can be used to study smooth muscle constriction and 
hyperresponsiveness to various agents and stimuli by measuring isometric or isotonic 
responses of the tissues attached to a force transducer (47-49).  In addition, precision cut 
lung slices (PCLS), introduced by Krumdieck et al. (50) in 1980, have been a valuable 
tool for studying airway constriction.  Using the PCLS technique, preparations of viable 
tissue slices can be taken into culture where constriction of airways of different diameter 
can be directly visualized and analyzed using videomicroscopy.  
 Whereas these in vitro techniques offer several advantages, such as the study of 
several replicate samples per animal and ease of data interpretation due to the collection 
of direct measurements, in vivo obstruction of the airways results not only as a result of 
smooth muscle contraction, but also from release of neurotransmitters, release of 
secretions into the lumen, and inflammatory cell infiltration of the airways, which is not 
adequately represented in isolated airway assays.  Several methods for measuring lung 
function in vivo have been developed; however, the most frequently used are the 
noninvasive measurement of enhanced pause (Penh) using barometric whole body 
plethysmography (WBP) and the invasive measurement of airway resistance using either 
the equation of motion or the forced oscillatory technique (FOT).  
 WBP involves the use of unrestrained, conscious, spontaneously breathing mice 
to evaluate Penh, a dimensionless measurement that reflects a combination of the 
pressure signal from inspiration and expiration and the timing of expiration (51).  
Although there are several advantages to this approach; such as ease of use, high 
throughput capability, and the ability to assess responses from the same animal over time, 
there has consistently been controversy as to the ability of Penh to accurately reflect  
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Table 1.3 Lung function assessments in the mouse. 
In vitro    
Method Parameter(s) Advantages Disadvantages 
 
Isolated airway segments 
 
Tension 
 
1)  Several replicates 
      per animal 
2)  Direct measurement 
     of contractions 
 
Circulatory and nervous system 
interrupted 
 
    
Precision cut lung slices 
(PCLS) 
Airway area 
Airway diameter 
1)  Viable lung tissue 
2)  Several replicates 
      per animal 
3)  Direct measurements 
4)  Visualization of  
      airways 
Circulatory and nervous system 
interrupted 
    
Isolated, perfused lungs Airway resistance (R) 
Compliance (Cdyn) 
1)  Intact airways 
2)  Separation of pulmonary 
     and systemic responses 
1)  Indirect measurement  
     of mechanics 
2)  Only one sample per 
     animal 
3)  Does not reflect  
      metabolic and  
      humoral input from  
      other organs 
In vivo    
Method Parameter(s) Advantages Disadvantages 
 
Whole Body 
Plethysmography (WBP) 
 
Penh 
 
1)  High throughput and ease 
      of measurement 
2)  Evaluation of mice during 
      normal physiological  
      conditions 
3)  Ability to measure serial  
     changes over time in the  
     same animal 
 
1)  Lack of specificity of 
      the Penh parameter 
2)  Inability to bypass the 
      upper airway (nose  
      and trachea) 
3)  Inability to distinguish 
      between central, 
      peripheral, and tissue 
     contributions 
    
Airway Pressure Time 
Index (APTI) 
Airway resistance Only requires measures of respiratory 
pressures, not volumes and flows 
Inability to distinguish between 
central, peripheral, and tissue 
contributions 
    
Invasive ventilation: 
Equation of motion -
single compartment 
model 
Resistance (RL) 
Elastance (E) 
Compliance (Cdyn) 
Can simultaneously asses airway 
resistance, the ease at which the lungs 
can be expanded, and rigidity 
1)  Over simplified model of the  
      lung 
2)  Lacks the ability to  
     differentiate between changes 
     occurring in various parts of  
     the respiratory tree 
3)  Airway modulation by neural 
     components may be  
      suppressed due to anesthesia 
    
Invasive ventilation: 
Forced Oscillation 
Technique (FOT) – 
constant phase model 
Airway resistance (Raw) 
Tissue damping (G) 
Tissue elastance (H) 
Capable of distinguishing between 
central and peripheral mechanics 
1)  Difficulty of data  
      Interpretation 
2)  Airway modulation by neural 
     components may be  
      suppressed due to anesthesia 
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pulmonary resistance (52-55).  Due in part to these discrepancies, invasive measurement 
of pulmonary resistance in anesthetized, paralyzed, mechanically ventilated animals is 
still considered the ‘gold standard’ of evaluating lung function in the mouse [reviewed in 
(56)].  Traditionally, pulmonary resistance (R) and elastance (E) are obtained from fitting 
fixed pressure, volume, and flow data to the equation of motion using a single-
compartment model of the lung.  However, the values R and E using this simplified 
model of the lung vary with the frequency at which the respiratory system is oscillated, 
which has been noted to be significant over the range of normal breathing (57).  
Therefore, determining R and E at a single frequency may not accurately reflect a 
complete characterization of respiratory mechanics.  Measurement of respiratory input 
impedance (Z), perturbing the respiratory system with a broad-band flow waveform that 
simultaneously contains a range of frequencies (i.e. FOT), can be used to ameliorate this 
limitation.  Furthermore, by fixing Z to the equation of motion using the constant-phase 
model of the lung several more parameters can be calculated to evaluate more precise 
lung function (58) and provide a clearer distinction between central an peripheral events 
in the lung.     
 
REGULATION OF THE DISEASED LUNG 
 Asthma is one of the most common respiratory diseases, affecting approximately 
300 million adults and children worldwide (59).  Phenotypically, asthma is a 
heterogenous disease manifesting in many subtypes and affected by interactions of both 
environmental and genetic factors.  Initially asthma was defined as “spasmodic afflictions 
of the bronchial tubes” (reviewed in (60)); however, as understanding of the asthmatic 
condition has developed, so has the characterization of the disease.  Currently asthma is 
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characterized by 1) partially reversible airway obstruction brought on by airway 
narrowing and increased mucus production and plugging; 2) chronic inflammation 
represented by eosinophilia and increased number of mast cells; 3) airway 
hyperresponsiveness (AHR) to otherwise mildly provoking stimuli; and 4) airway 
remodeling manifesting in ASM hypertrophy, collagen deposition, and basement 
membrane thickening.  The presence of these features distinguishes asthma from other 
obstructive airway diseases, such as cystic fibrosis (CF) and chronic obstructive 
pulmonary disease (COPD) (61).   
 Allergy is acknowledged as a major risk factor for asthma.  Atopic (allergic) 
asthmatics can have extreme sensitivity to common allergens, which may cause a severe 
allergic reaction, or anaphylaxis.  The acute phase of allergy is represented by an 
immediate-type hypersensitivity response initiated by allergen-induced crosslinking of 
specific IgE antibody bound to mast cells.  Bronchoconstriction is the immediate 
symptom of the acute allergic response, while the late response is characterized by airway 
perivascular edema, mucus plugging, and inflammatory cell recruitment.  Although the 
mast cell is the primary effector cell in the allergic response, a variety of airway, immune, 
and neural cells function together to contribute to the symptoms and development of 
asthma.  The contribution of allergy to asthma however is particularly complex: although 
most asthmatics are allergic to at least one allergen, the majority of allergic subjects do 
not develop asthma.   
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Epithelium  
In asthma, the epithelium shows evidence of stress and injury.  Damage to the 
epithelial layer can affect airway responsiveness and induce airway remodeling.  After 
epithelial damage, inhaled particles can access the underlying nerves and smooth muscle 
more easily.  Sensory nerves involved in neuropeptide release can be stimulated, resulting 
in reflex bronchoconstriction.  Furthermore, dysfunction of the epithelial layer could 
result in an increase in the concentration of several contractile agents.  For example, 
histamine is metabolized by diamine oxidase and neuropeptides are metabolized by 
neutral endopeptidases within this layer (62).   
Under normal conditions epithelial cells release factors that suppress 
mesenchymal cells.  Upon injury or damage, repair responses promote airway remodeling 
by activating fibroblasts that lie under the epithelial layer; this signaling supports the 
growth and survival of mesenchymal cells which can lead to differentiation into 
connective tissue and/or additional smooth muscle cells.  PGE2, the predominant 
ecosaniod product of epithelial cells, is a potent inhibitor of mesenchymal cell 
chemotaxis (63), mitogenesis (64), and collagen synthesis (65), as well as a bronchial 
relaxing factor (66).  In some asthmatics, the respiratory epithelium has a diminished 
capacity to synthesize PGE2 (67), which can lead to increased airway remodeling and 
bronchoconstriction.  In vivo (68) and in vitro (69) studies have shown that injury to the 
epithelium causes a release of fibroproliferative and profibrogenic growth factors which 
can promote the proliferation of underlying fibroblasts and promote differentiation of 
these fibroblasts into myofibroblasts that can secrete collagen.  This process can lead to 
fibrosis of the basement membrane and overall stiffening of the airways.   
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Mucus production and edema 
Normally, airway mucus is a protective film that prevents inhaled particles from 
damaging the airway epithelium.  Mucus hypersecretion is a pathological feature of 
asthma that contributes significantly to airway obstruction.  Mucins are secreted by 
submucosal glands and unique epithelial cells known as goblet cells.  Goblet cells 
produce mucins in response to several endogenous factors including leukotrienes (LT) 
and T-helper-type 2 (Th2) cytokines, such as interleukin (IL)-13, that are secreted in 
response to allergens.  LTD4 released after antigen challenge enhances mucus secretion, 
which can be prevented via administration of cystenyl leukotriene (cysLT) antagonists 
such as pranlukast (70).  Further study has revealed that cysLTs are mediators for both 
the early and late phase mucus synthesis and secretion from goblet cells (71).  
Interestingly, goblet cell hyperplasia and mucus overproduction in an asthma model also 
appear to be regulated by the neurotransmitter GABA (72), linking the immune and 
neural systems in asthma pathology.  Along these lines, the production of airway mucus 
in the central airways is under cholinergic control, and ACh has been shown to be the 
primary neurotransmitter involved in mucus secretion in these airways (73) specifically 
via submucosal glands that express functional M1 and M3 mAChRs (32).   
In addition to excess mucus production, a major aspect of airway inflammation is 
the extravasation of plasma (or vascular leakage), which can bring with it plasma-derived 
proteins and/or peptides that have potent adhesive and leukocyte-activating properties 
(74).  Microvascular exudation of plasma occurs both in human asthma (75), as well as 
animal models of asthma (76-78).  Specifically in a mouse model of asthma, allergen 
challenge results in plasma exudation in the trachea and bronchi but not in the lung 
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parenchyma (78).  Many mediators of asthma are capable of inducing vascular leakage.  
Platelet activating factor (PAF), a mediator released by mast cells, is involved in both 
early and late-phase plasma exudation in guinea pig tracheobronchial airways (79).  The 
thromboxane A2 (TXA2) analog U46619, despite being a potent vasoconstrictor, has also 
been shown to induce vascular leakage, as well as airway constriction, in guinea pigs 
(80).  After allergen challenge, prolonged vascular leakage may be due to sequential 
effects of these and several other mediators such as histamine, bradykinin, tachykinins, 
and leukotrienes. 
 
Airway Smooth Muscle 
 ASM plays a central role in regulating bronchomoter tone.  In the asthmatic 
airway, ASM mediates acute bronchoconstriction and participates in AHR.  Contraction 
of ASM requires an increase in intracellular calcium concentration, which is maintained 
at a low level during rest.  Activation of surface receptors by contractile agonists results 
in an increased calcium concentration and consequent contraction of the cell. ASM can 
constrict in response to many agents, either directly via receptors on the muscle, or 
indirectly through activation of immune cells or nerves which then release mediators 
capable of contracting the muscle.  Although there is little evidence to suggest that ASM 
constriction is abnormal in asthma, there is evidence of dysfunction of relaxant 
mechanisms.  For example, ASM relaxation in vitro to β2-adrenoreceptor agonists is 
impaired in patients that died of asthma exacerbations (81).   This impairment was not 
found to be a result of decreased receptor density or affinity (82, 83).  Animal models 
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have suggested that this impairment is mediated in part by the inflammatory cytokine IL-
1β (84, 85).   
During chronic asthma, ASM undergoes phenotypic alterations including 
hypertrophy (increase in size) and hyperplasia (increase in number) (86).  Post mortem 
studies of asthmatics have suggested that the number of smooth muscle cells is increased 
2 to 3 fold that of normal airways (86, 87), and in vitro studies have shown that 
proliferation of ASM cells is increased in cultures from asthmatic patients (88).  
Increased thickness of ASM may have an important effect on the contractile response of 
the airways and may contribute to asthmatic AHR (89).  In addition to increased ASM, 
thickening of the airway wall and changes within the wall itself can increase airway 
narrowing due to purely structural reasons.   
ASM can also perpetuate airway inflammation through the secretion of cytokines 
and chemokines.  Human ASM is capable of producing eotaxin, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), RANTES, CXCL10, IL-8, and IL-6 (90-94).  
Eotaxin, RANTES and GM-CSF promote recruitment and survival of eosinophils, while 
CXCL10 is a potent chemokine for activated T cells and mast cells (94, 95).   
 
Allergic Inflammation 
Dendritic cells 
 The recognition of allergen by antigen presenting cells is the first step of immune 
sensitization that eventually leads to the formation of Th2 immunity to inhaled allergen, 
as well as to the development of allergic asthma.  DCs are present in the airways and are 
able of capturing and processing antigen for presentation to T cells, and have been shown 
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to be crucial for the induction of primary immune responses to inhaled allergen that 
ultimately leads to sensitization (96).  Upon recognition of foreign antigen, DCs migrate 
to the draining lymph nodes where they present the antigen to T cells.    
In addition to their role in sensitization, it is likely that DCs contribute to the 
chronic secondary Th2 response in asthmatic airways.  Increased numbers of DCs are 
present in the airways of asthmatics (97), as well as in a rat model of eosinophilic airway 
inflammation (98).  Selective depletion of DCs in sensitized animals resulted in complete 
disappearance of eosinophilia and goblet cell hyperplasia in the airways (99).  
Furthermore, chronic inflammation and airway structural changes may lead to local 
maturation of DCs.  Cytokines such as GM-CSF, tumor necrosis factor alpha (TNF-α), 
and IL-4 expression in the asthmatic epithelium can potentially up-regulate the 
costimulatory function of DCs (2).  Also, mast cells within the airways can express 
cytokines that can activate and prolong survival of DCs (100).  In addition to activating T 
cells, DCs produce chemokines that attract recently activated Th2 cells (101), ensuring 
that recently activated effector cells remain in the airways. 
Lymphocytes 
 T helper cells, specifically CD4+ Th2 cells, play a critical role in asthma and 
allergy.  Th2 cells secrete a specific pattern of cytokines including IL-3, IL-4, IL-5, IL-6, 
IL-10, IL-13, GM-CSF, and TNF-α (102).  Through release of these cytokines, Th2 cells 
can influence differentiation and proliferation of B cells, IgE class switching, eosinophil 
and mast cell maturation and recruitment, and regulation of adhesion molecules involved 
in cell migration to the epithelium.  Indeed, these cytokines, as well as activated CD4+ 
Th2 cells, have been identified in biopsies of both atopic and non-atopic asthmatics 
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(103).  Selective depletion of CD4+ T cells by injection of anti-CD4 monoclonal 
antibodies or use of major histocompatability complex (MHC) class II-/- mice abolishes 
eosinophilic inflammation, AHR, and goblet cell hyperplasia following ovalbumin 
(OVA) exposure (104, 105).   
 Th2 cytokines play various roles in the asthmatic response.  IL-4 is most 
important for inducing the Th2 response; therefore, IL-4 released by Th2 cells acts as a 
feedback loop to perpetuate the response.  Studies in IL-4 deficient mice have 
demonstrated that IL-4 is also essential for the development of allergic airway 
inflammation (104, 106).  Antibody neutralization of IL-4 prior to allergen sensitization 
prevents allergic inflammation; however, abolishment of IL-4 during airway challenge 
does not affect eosinophil recruitment or AHR (107, 108), suggesting that IL-4 is 
involved in the sensitization process and not in the recruitment of inflammatory cells.  On 
the other hand, the importance of IL-5 in eosinophilia and AHR is apparent in IL-5-/- 
mice, which exhibit significant reduction of blood and tissue eosinophils after antigen 
challenge (109).  IL-6 effects B cell immunoglobulin production, however IL-6-/- mice 
show normal eosinophil recruitment and AHR in an asthma model (110).  IL-13 is a 
major cytokine regulating AHR and mucus hypersecretion independently of tissue 
eosinophilia (111).  Studies in IL-13 deficient mice demonstrated that sensitization and 
challenge with allergen failed to elicit AHR or mucus hypersecretion, despite having 
increased levels of both IL-4 and IL-5.  Furthermore, reconstitution of the IL-13 deficient 
mice with recombinant IL-13 recapitulated the AHR and mucus hypersecretion seen in 
wild-type animals (112).   IL-10 has been shown to be important for B cell 
differentiation; however its role in eosinophilia and AHR is a matter of debate. 
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 B-lymphocytes are the primary effector cells targeted by IL-4 and IL-13 released 
by Th2 cells.  B-cells produce antigen specific IgE following isotype switching from IgM 
to IgE in response to cytokines released from Th2 cells.  IgE antibodies bind to high-
affinity FcεRI receptors on mast cells.  Following subsequent allergen exposure, IgE 
bound to FcεRI receptors triggers mast cell activation after cross-linking with specific 
allergen, resulting in the synthesis and release of a variety of proinflammatory mediators 
(Figure 1.5). 
Eosinophils 
In the airways, eosinophils are the primary effector leukocytes recruited to sites of 
inflammation (Figure 1.6) and may contribute to allergic lung disease by enhancing 
goblet cell metaplasia, matrix deposition, ASM hypertrophy, and AHR (113).  Many 
factors mediate eosinophil recruitment to the inflamed lungs; however, the mechanisms 
underlying airway eosinophilia and allergic lung disease are quite complex and not 
completely understood.   
Many receptor-ligand interactions are necessary for eosinophil recruitment to the 
lungs following inhalation of allergen.  G protein-coupled receptors are capable of 
responding to various stimuli, including gradients of chemoattractants needed for tissue-
specific recruitment of proinflammatory leukocytes (114).  Specifically, Gq-coupled 
receptors are expressed in many tissues/cells associated with allergic reactions, and 
significantly increased levels of Gαq protein has been detected following OVA challenge 
in the lungs of both rats and guinea pigs (115, 116).   The most compelling data regarding 
the significance of the Gαq protein in the development of allergic airway inflammation 
has been produced from studies utilizing Gαq deficient mouse lines.  These  
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Figure 1.5 IgE-dependent mast cell activation*.  Uptake of allergen by dendritic cells 
results in the expansion of Th2-type cells resulting in the stimulation of B cells and 
production of antigen-specific IgE.  The IgE binds to high affinity FcεRI receptors on 
mast cells.  Allergen then binds to and causes cross-linking of IgE to the receptor, which 
results in mast cell activation.  Finally the activated mast cell releases preformed and 
newly synthesized mediators.  *Modified from (117) 
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Figure 1.6 Th2 mediated inflammation*.  Presentation of allergens at the airway 
surface by dendritic cell results in Th2 cell differentiation and cytokine production (IL-4, 
5 and 13) in atopic asthmatics. CD4+ T cells orchestrate the ensuing inflammatory 
response characterized by an influx of eosinophils into the airway spaces in response to 
cytokines.  Eosinophils are recruited into the airway from bone marrow through several 
steps which are coordinated by Th2 cytokines.  Eosinophils develop in the bone marrow 
from CD34+ progenitor cells (mediated by IL-5, IL-13, and GM-CSF) which are 
produced by CD4+ T cells.  Once cells are committed to the eosinophil lineage, they 
move from the bone marrow into the vasculature under the guidance of IL-5.  Their 
movement through the blood vessel walls into sites of Th2 mediated inflammation is 
controlled by IL-4 and 13.  Once activated by IL-5 or eotaxin, eosinophils may contribute 
to the pathogenesis of allergic asthma by acting on various cells in the airway walls 
(including fibroblasts, smooth muscle cells, and epithelial cells) or secrete further Th2 
cytokines.   *Modified from (113). 
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animals clearly demonstrate significantly attenuated airway eosinophilia, as determined 
by both bronchoalveolar lavage fluid (BALF), cellularity, and histological examination of 
the lungs (118).  A significant decrease in local (BALF) GM-CSF production was 
observed in the Gαq deficient animals, which was suggested to be the underlying 
mechanism behind the attenuated airway eosinophilia (118). 
Once recruited to the inflamed tissue, eosinophils contribute to allergic symptoms 
through the release of granule proteins and pro-inflammatory mediators which act to 
increase vascular permeability, stimulate mucus production, and facilitate AHR.  
Eosinophils release granule proteins such as eosinophilic cationic protein (ECP) and 
eosinophil peroxidase (EPO), which are toxic to the respiratory epithelium (119), as well 
as major basic protein (MBP), which can induce mast cell activation and dysregulate 
vagal muscarinic receptor function (120).  Inhibition of eosinophilia in a rat model of 
allergy using anti-PMN treatment indicates that eosinophils are important for the late-
phase reaction of mucus secretion from epithelial goblet cells (71).  The development of 
eosinophil-deficient mice has further defined the role of this leukocyte population in 
asthma models.  Antigen challenge in eosinophil-deficient mice resulted in significantly 
reduced epithelial hypertrophy, goblet cell metaplasia/mucus accumulation, and AHR to 
the ACh analog methacholine (MCh) when compared to WT mice (121), linking 
eosinophils to these symptoms associated with asthma.   
Mast Cells 
 Mast cells are the primary effector cells of acute allergic reactions.  Mast cells 
play a critical role in the early phase of allergic airway disease, including airway 
obstruction and recruitment/activation of additional inflammatory cells.  Many mediators 
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released from mast cells are capable of stimulating events that may contribute to 
asthmatic symptoms (Table 1.4).  Release of preformed granules containing mediators 
such as histamine, serotonin, chymase, and tryptase, as well as synthesis and secretion of 
various lipid mediators such as prostaglandins and leukotrienes can generate airway 
obstruction by inducing smooth muscle constriction, vascular leakage, and mucus 
hypersecretion.  Furthermore, mast cell-derived cytokines and chemokines, such as IL-4, 
IL-5, IL-6, LTB4, PAF, TNF-α and GM-CSF can further perpetuate the inflammatory 
cascade through local recruitment and activation of eosinophils and lymphocytes. 
Histamine has long been thought to be a mediator of acute reactions in humans.  
Histamine effects mediated through the H1 receptor include smooth muscle contraction, 
increased vascular permeability, prostaglandin generation, and activation of vagal 
reflexes.  H2-mediated effects include increased lower airway mucus secretion, 
esophageal contraction, and inhibition of neutrophil activation (reviewed in (122).  
Furthermore, histamine has been found in the airways of asthmatic patients, along with 
increased number of degranulated mast cells.  The level of histamine in BALF was found 
to correlate with the severity of asthma and AHR (123).  Aside from humans, studies in 
guinea pigs suggest that mast cell degranulation enhances the excitability of sensory C-
fibers through the activation of histamine H1 receptors (124).  In the mouse, blockade of 
the H2 receptor was shown to attenuate AHR to MCh after OVA challenge (125).  This 
differs in the common view that histamine induced bronchoconstriction is mediated 
exclusively through H1 receptors, but still points to a role of histamine in allergic airway 
constriction in the mouse.  There has also been some contradiction as to whether  
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Table 1.4 Mast cell mediators, receptors, and function in allergy and asthma.* 
 
Mediator Receptor(s) Receptor Location Effect Reference(s) 
 
Histamine 
 
H1 
H2 
 
H3 
 
Epithelium, ASM, sensory nerves 
Epithelium, ASM, submucosal 
glands, immune cells 
Sensory nerves 
 
ASM constriction, ↑ neuropeptide release 
Inhibition of chemotaxis, elevation of 
cAMP 
↓ neuropeptide release 
 
 
(6, 126) 
 
 
 
Serotonin 5-HT1 
5-HT2 
5-HT3 
ASM, sensory nerves 
Epithelium, ASM 
Sensory nerves 
Pulmonary vasoconstriction 
ACh release, ASM constriction 
Neural excitation 
 
(127-129) 
PGD2 DP1 
 
DP2 
Epithelium, ASM  Bronchoconstriction, bronchodilation, 
vasodilation, eosinophil activation 
Inflammatory cell recruitment 
 
(130-132) 
 
 
LTB4 
LTC4 
B-LT1 
 
CysLT1 
 
Leukocytes 
 
ASM 
Chemotactic activity for neutrophils and 
eosinophils 
Bronchoconstriction  
 
(131) 
Tryptase PAR2 Epithelium, ASM, sensory nerves, 
mast cells 
Triggers release of PGE2, degrades VIP, 
reflex bronchoconstriction, sensitizes C-
fibers 
 
(133) 
IL-4 IL-4R Hematopoietic, endothelial, 
epithelial, and muscle cells 
B-cell class switching; stimulating and 
maintaining Th2 cell proliferation; 
promotes mast cell aggregation 
 
 
(134-136) 
IL-5 IL-5R Eosinophils 
 
Activation and recruitment of 
eosinophils 
 
(137) 
IL-6 IL-6R T cells, B cells, nerve cells, 
epithelial cells 
Promotes mucus production, sensitizes 
sensory nerves, tissue maintenance and 
remodeling, enhances effects of IL-4 
 
 
(138-141) 
PAF PAF-R platelets, eosinophils, neutrophils,  activates/recruits eosinophils, induces 
microvascular leakage and mucus 
secretion 
 
 
(142-146) 
TNF-α TNFR1 
TNFR2 
ASM, nerves, inflammatory cells increase Gi and Gq alpha protein 
expression in ASM, sensitizes sensory 
nerves, induces histamine release from 
mast cells, recruits neutrophils and 
eosinophils 
 
 
(138, 147-150) 
GM-CSF GM-CSFr epithelium, monocytes, 
granulocytes, macrophages 
Activates dendritic cells, eosinophil 
recruitment 
(118, 151, 152) 
*Mast cell mediators reviewed in (3). 
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exogenous histamine can cause airway constriction in the mouse.  Using tracheostomized 
mechanically ventilated mice, Martin et al. (1988) could not detect airway constriction 
following iv histamine administration (153).  However, aerosolized histamine was able to 
induce only peripheral airway resistance (measured as a decrease in dynamic compliance, 
Cdyn), with no central airway constriction using barometric plethysmography (154).   
Serotonin has been shown to cause bronchoconstriction in many mammalian 
species (155).  Levels of free serotonin in plasma have been shown to be increased in 
patients with asthma, and these levels correlated positively with clinical status and 
negatively with pulmonary function (156).  Although exogenous serotonin fails to elicit 
bronchoconstriction in healthy or asthmatic human subjects (157), both tryptophan 
hydroxylase and serotonin have been measured in human mast cells (158).  Additionally, 
serotonin has been reported to activate human airway smooth muscle ex vivo (159) and 5-
HT receptor activation has been shown to facilitate cholinergic bronchoconstriction in 
human airways (160), which points to the possible involvement of serotonin in 
anaphylactic bronchoconstriction in man.  Additionally, in mice, serotonin has been 
shown to contribute to nociceptive processing via a subset of afferent fibers that do not 
express SP, most likely RARs, through the 5-HT3 receptor (129).  Furthermore, in human 
and guinea pig airways, 5-HT receptor activation causes depolarization of airway 
cholinergic nerve terminals via 5-HT3 receptors (160). Serotonin is also able to elicit a 
dose dependent increase of pulmonary RAR activity in the rabbit (161). 
PGD2 is a bronchoconstricting agent in humans.  When inhaled, PGD2 is 25-fold 
more potent as a bronchoconstrictor than histamine in non-asthmatic human subjects 
(162).  In contrast, exogenously administered PGD2 fails to cause airway constriction in 
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mice.  Highly purified human lung mast cells, as well as, human BALF mast cells 
produce PGD2.  PGD2 has also been shown to be synthesized and released during IgE-
dependent activation of mouse bone marrow derived mast cells (BMMCs) (163).  
However, the lack of significant benefit of nonselective cyclooxygenase inhibitors to treat 
asthmatic exacerbations (164) have led to the mast-cell derived prostanoids being largely 
discounted as significant mediators of bronchoconstriction in asthma.   
Despite the disfavor of PGD2 as an asthmatic bronchoconstrictor, there has been a 
significant amount of evidence that points to the involvement of PGD2, through the DP2 
receptor, in allergic inflammation, specifically in inflammatory cell recruitment 
(reviewed in (130).  Administration of exogenous PGD2 into the airways of dogs results 
in increased inflammatory recruitment (165).  In mice, administration of PGD2 increased 
OVA-mediated recruitment of eosinophils and CD4+ T cells into the lung (166), while 
inhibition of DP2 with the selective antagonist TM30089 reduced OVA-induced airway 
eosinophilia and mucus production (167).   Furthermore, DP-deficient mice have reduced 
eosinophil and lymphocyte recruitment, as well as reduced cytokine expression compared 
to WT controls in an OVA-induced model of asthma (168), indicating that PGD2 is 
important for such responses.   
Leukotrienes are potent constrictors of both human bronchi (169) and guinea pig 
lung (170).  In humans, the leukotrienes appear to play a substantial role in asthmatic 
airway obstruction.  Inhaled LTC4 and LTD4 are potent constrictors of human airways 
(171), and indirect evidence supports a model in which the release of this mediator by 
mast cells contributes to airway constriction during anaphylaxis.  For example, in human 
PCLS, antigen induced airway constriction was attenuated after treatment with the 
 38
leukotriene receptor antagonist montelukast (172).  Increased urinary cysLT metabolites 
are detected after challenge of asthmatics with inhaled allergen (173).  Also, allergic 
asthmatics exhibit increased LTC4 in their BALF after antigen challenge (174).  In 
addition, a multitude of pharmacological studies have suggested the involvement of 
leukotrienes in several features of human asthma, including airway obstruction (175-
178).  
Although there appears to be an important role for leukotrienes in asthma, it has 
been difficult to demonstrate the importance of this class of constricting agents in the 
mouse, specifically in constriction of ASM, because pulmonary responses following 
leukotriene administration in mice are weak at best.  Reports regarding the ability of this 
mediator to induce changes in airway mechanics have been conflicting.  Early studies by 
Martin et al. report no changes in airway mechanics after i.v. delivery of LTC4 or LTD4 
(153).  In contrast, Yang et al. reported changes in Penh and a small increase in lung 
resistance (RL) after exposure of mice to LTD4, either inhaled or after i.v. administration, 
respectively (179).  In addition LTD4 was capable of constricting mouse tracheal rings in 
a dose dependant manner.  These changes were somewhat increased in mice over-
expressing a human cysLT1R transgene. 
Interestingly, when analyzing separate components of this pathway in mice, it 
appears to be fully intact and comparable to humans.  Mouse mast cells are fully capable 
of leukotriene synthesis; LTC4 has been reported to be synthesized in mouse BMMCs 
and was shown to be released upon mast cell activation (180).  Increased levels of LTC4 
in BALF have been reported in both allergic asthmatics (174) and sensitized mice (181) 
after antigen challenge.  Furthermore, characterization of the cysLT1 receptor in mice has 
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shown comparable binding affinities and mRNA expression in the lung to that of the 
human cysLT1 receptor (182-184).  Immunocytochemistry and in situ hybridization for 
the cysLT1 receptor have confirmed its expression in both mouse (185) and human (186) 
airway smooth muscle, respectively.  A second cysteinyl leukotriene receptor, cysLT2, 
has also been characterized.  Although cysLT2 has proven to be involved in tracheal 
constriction in sheep (187) little to no expression of this receptor was detected in either 
the mouse (188) or human (189) lung.  Finally, addition of LTD4 or LTC4 to mouse 
tracheal smooth muscle cells is able to elicit dose-dependent Ca2+ signaling (179), 
indicating that the mouse receptor is functional and able to respond to leukotrienes.  In 
light of these studies, it is unclear why mice have such a minimal response to 
leukotrienes, as they appear to have the necessary components to induce leukotriene-
dependent bronchoconstriction. 
In addition to airway constriction, cysLTs may contribute to airway remodeling 
through their roles in inflammation and their direct effects on mesenchymal cells.  In a 
model of asthma, repeated exposure to OVA in OVA-sensitized rats increased ASM 
mass, which was partially inhibited by the cysLT receptor antagonist MK-571 (190).  
Mice with allergen-induced chronic lung inflammation develop eosinophilia, goblet cell 
hyperplasia, increased thickness of ASM, and deposition of collagen beneath the 
epithelial cell layer.  Pretreatment with the cysLT receptor antagonist montelukast 
significantly inhibited airway eosinophilia, hyperplasia of both goblet and smooth muscle 
cells, and subepithelial fibrosis (191), implicating leukotrienes in these aspects of the 
asthmatic condition. 
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The most abundant mediator found in human mucosal mast cells is tryptase, 
which can influence several airway processes including: airway fibrosis and extracellular 
matrix turnover, ASM and epithelial cell hyperplasia, airway inflammation, and 
alterations in bronchial tone.  Tryptase can stimulate the release or IL-8, a granulocyte 
chemoattractant (192) and induce expression of mRNA for IL-1β, which may also be 
involved in recruitment of inflammatory cells (193).  In addition, stimulation of human 
ASM cells with tryptase induced cytokine release and subsequently enhanced chemotaxis 
of mast cells to ASM (194).  Tryptase contributes to airway remodeling through its 
ability to stimulate fibroblast proliferation and chemotaxis (195, 196), increase the 
synthesis and secretion of type 1 collagen (197), and increase the amount of 
collagenolytic activity in fibroblasts (197).  Tryptase is also a known mitogen for dog 
tracheal smooth muscle cells (198, 199), as well as human ASM (200) and epithelial cells 
(192).   
Although tryptase is typically involved in airway remodeling and inflammatory 
recruitment, it may also be involved in mast cell-mediated airway constriction through 
activation of protease-activated receptor (PAR) receptors.  PAR2 receptors are found on 
the airway epithelium, ASM, mast cells, as well as on sensory neurons.  Tryptase causes 
excitation of sensory neurons, which can lead to the release of neurotransmitters which 
can act to augment lung function (reviewed in (201)).  While some of the peptides 
released, notably the bronchodilating peptide VIP and the vasodilator CGRP, may 
subsequently be rapidly cleaved by tryptase; bronchoconstricting tachykinins are resistant 
to inactivation by tryptase, shifting the overall response towards bronchoconstriction. In 
the mouse, exogenous administration of PAR2-activatign peptide (PAR2-AP) results in 
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increases in airway pressure and lung water that is mediated through a reflex effect 
involving NK2 receptors (202), presumably through the release of NKA from sensory 
nerves.   
 
Lipid Mediators 
Arachidonic acid pathway 
 Eicosanoids are a family of lipid mediators that includes prostanoids 
(prostaglandins and thromboxane), leukotrienes, and HETES which are derived from 
phospholipase-released arachidonic acid (AA).  The first step in the production of all 
eicosanoids is the phospholipase A2 (PLA2)-induced hydrolysis of the sn-2 position of 
membrane glycerophospholipids to release AA (203).  PLA2 activity can be stimulated by 
a variety of components including: Fc-receptor activation, complement, immune 
complexes, and microorganisms.  The expression and activity of various enzyme 
pathways within a given cell determines the eicosanoid produced from the released AA 
(Figure 1.7).   
Prostaglandins are not stored, but synthesized de novo from membrane-released 
AA when cells are activated by cytokines, mechanical trauma, or other stimuli (reviewed 
in (131)).  Briefly, released AA is metabolized into the intermediate prostaglandin PGH2 
through the action of prostaglandin H synthase (PGHS; cyclooxygenase; COX), which 
exists in the two isoforms COX-1 and COX-2.  Simplistically, COX-1 is responsible for 
constitutive production of prostaglandins, while COX-2 is involved in various 
inflammatory and induced productions.  PGH2 is then further metabolized by downstream 
enzymes such as thromboxane synthase, PGF synthase, PGD synthase, and PGE synthase 
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to generate thromboxane and various other prostaglandins.  Leukotrienes are 
predominantly synthesized by inflammatory cells such as macrophages and mast cells.  
Activation of these cells initiates translocation of PLA2 to the nuclear envelope.  Released 
AA is then transformed to LTA4 through the actions of 5-lipoxygenase (5-LO) and 5-
lipoxygenase-activating protein (FLAP).  LTA4 then transforms through either 
hydrolysis, conjugation with glutathione, or transcellular metabolism to generate LTB4, 
LTC4, LTD4, and LTE4 (reviewed in (131)).   
Thromboxane 
 Thromboxane is well known for its role in platelet aggregation, vasoconstriction, 
and vascular smooth muscle proliferation; however, it is also capable of initiating ASM 
contraction (204-206).  TXA2 has been implicated in inducing AHR in models of allergic 
inflammation (207), endotoxin models (208), and IL-8-mediated airway neutrophil 
accumulation (209).  Urinary excretion of TXA2-derived products are shown to be 
markedly increased in subjects with severe acute asthma when compared to nonsmoking 
controls; however, antigen challenge in atopic volunteers did not significantly increase 
these products (210).  This data implies that TXA2 may have biological actions in asthma 
in general, but may not contribute significantly to the allergic component of the disease.  
All in vivo actions of TXA2 are mediated through the cell surface G protein-
coupled thromboxane/prostanoid (Tp) receptor, and many of its physiological actions 
have been attributed to Gq-mediated activation of PLC and increases in intracellular 
calcium concentration.  The Tp receptor is maintained at high levels in a variety of tissues 
including the thymus, lung, brain, and kidney (211).   
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Figure 1.7 Generation and metabolism of arachidonic acid. 
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Tp receptor expression has been reported on several cell types including ASM 
cells (212) and nodose ganglion neurons (213), where activation may lead to ASM 
constriction through either direct or indirect mechanisms, respectively.  Considerable 
evidence has suggested that TXA2 mediates ASM constriction through neural 
mechanisms affecting ACh release (214-216).  Recent studies in the mouse have 
demonstrated that the constrictor effect of TXA2 in both the naïve and inflamed airway is 
dependent on the activity of mAChR-mediated cholinergic pathways (28).  A possible 
model suggested by these findings describes a situation whereby the release of ACh from 
the postsynaptic neurons is enhanced by TXA2 binding to presynaptic Tp receptors on the 
vagus nerve.  Activation of these Tp receptors on the nerve or nerve terminals results in a 
substantial increase in ACh release and the subsequent increase in M3 mAChR-mediated 
ASM constriction.  However, alternative scenarios can be envisioned, and further 
investigation is required to elucidate the mechanism of TXA2-mediated ASM 
constriction. 
 
Neural regulation    
Sensory “efferent” neurotransmitters  
 The release of neuromediators (Table 1.5) from airway nerves can elicit airway 
responses including bronchoconstriction/bronchodilation (Figure 1.8), increased 
neurotransmission, and neurogenic inflammation.  Whereas immunologic inflammation 
results from the binding of antigen to antibody, neurogenic inflammation occurs when 
neuropeptides released from sensory nerves produce an inflammatory response 
characterized by microvascular leakage, vasodilation, mucus secretion, and 
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recruitment/activation of inflammatory cells.  Other neuropeptides released from sensory 
nerves act as bronchodilators, and dysregulation or inhibition of their release may 
contribute to symptoms of asthma.  Sensory nerve fibers also project into local airway 
ganglia, where release of neurotransmitters can affect neurotransmission of these nerves 
(217).   
The tachykinins NKA and SP, which are localized to capsaicin-sensitive sensory 
nerves, can exert numerous effects on respiratory target cells.  NKA potently constricts 
human ASM in vitro through NK2 receptors, specifically in the small airways (218), 
suggesting that nerve-derived tachykinins may have a role in peripheral airway 
constriction whereas cholinergic effects dominate the central airways.  Tachykinins 
released from sensory “efferent” nerves can also enhance neurotransmission through 
parasympathetic ganglia resulting in an increased release of ACh from the nerve ending 
(219).  NK1 and NK2 receptors have been shown to be involved in the facilitation of AHR 
in a guinea pig model of allergic airway disease (220); although, using the same model, 
were found to not be involved in inflammatory cell recruitment (221).  The NK1/NK2 
selective antagonist AVE5883 also failed to reduce allergen-induced airway 
inflammation (222).  However, SP, through NK1 receptors, is involved in other aspects of 
neurogenic inflammation including plasma vasodilation and exudation, as well as 
submucosal secretion (219).  Additional studies have shown that the NK3 receptor is 
involved in inflammatory cell recruitment in OVA sensitized and challenged mice (223).   
CGRP is expressed and co-localized with tachykinins in sensory nerve fibers.  
CGRP is involved in vasodilation (224) and causes dose-dependent relaxation of human 
pulmonary arteries (225).  In addition, this protein also enhances protein extravasation 
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Table 1.5 Neurotransmitters, receptors, and function in allergy and asthma. 
 
Transmitter Receptor(s) Location Effect Reference(s) 
 
ACh 
 
 
 
 
 
 
 
NE 
 
Nicotinic (N) 
 
 
M1 
 
M2 
M3 
 
 
α 
β 
 
 
Epithelium, PNS ganglion, PNS 
preganglionic synapse, sensory 
nerves 
PNS ganglion, submucosal glands 
 
ASM, PNS post ganglionic synapse 
ASM, submucosal glands 
 
 
 
Throughout lung, ASM, 
sympathetic nerves, 
parasympathetic nerves 
 
Activation of postganglionic nerve, 
feedback inhibition, ↑ neuropeptide 
release 
Facilitates ACh release, ↑ mucus 
production 
Feedback inhibition of ACh release 
ASM constriction, ↑ mucus 
production 
 
 
Bronchoconstriction, inhibit release 
of NE 
Bronchodilation, enhance release of 
NE and ACh 
 
 
 
 
(30-32, 226, 227) 
 
 
 
 
 
 
 
 
(36, 38, 40) 
NKA NK2 Prejunctional, ASM Cholinergic reflexes, 
bronchoconstriction 
 
(24, 25, 218) 
CGRP CRLR+RAMP1 
 
Lung, dendritic cells Vasodilation (228) 
VIP VPAC1 
VPAC2 
PAC1 
 
CNS, lung, T-lymphocytes ↓ neuropeptide release, inhibits 
release of ACh from cholinergic 
nerves, anti-inflammatory 
(226) 
NO (nNOS) sGC ASM ASM constriction 
ASM relaxation 
Inhibition of ASM proliferation 
 
 
(229-231) 
NPY Y2 Sensory nerves, postganglionic 
cholinergic nerves, prejunctional 
sympathetic nerves 
 
↓ neuropeptide release, inhibit 
adenylyl cyclase 
(226) 
SP NK1 Mast cells, parasympathetic 
ganglion, blood vessels, airway 
epithelium, submucosal glands 
Membrane ruffling/activation, 
facilitatory effects on cholinergic 
neurotransmission, vasodilation, 
epithelium goblet cell secretion 
(24, 219, 232, 233) 
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Parasympathetic
Sympathetic
Sensory
α-adrenoceptor
β-adrenoceptor
NE
NYP
bronchoconstriction
bronchodilation
Y2-receptor N/A
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NO
SP
NKA
NK1
NK2
bronchoconstriction
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Guanylyl cyclase
bronchodilation
ACh
VIP VPAC1
M3 bronchoconstriction
bronchodilation
 
 
Figure 1.8 Neural control of ASM.  Release of neurotransmitters from airway nerves 
augments bronchial tone. 
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induced by tachykinins (234).  Although CGRP appears to have no direct effect on ASM 
tone, it has been shown to protect against SP-induced airway constriction in human and 
guinea pig airways.  However, this bronchoprotective property was impaired during 
OVA-induced inflammation (235), suggesting that the ability of CGRP to regulate ASM 
tone may be altered in inflammatory diseases.  In support of this theory, CGRP levels are 
depleted in the airways of mice with allergic airway inflammation despite having no 
difference in the overall density of nerve fibers between the control and 
sensitized/challenged groups (236).  Furthermore, treatment of OVA-sensitized mice with 
exogenous CGRP prevented the development of OVA-induced AHR to MCh, indicating 
the possibility of CGRP therapy in the treatment/prevention of AHR. 
VIP is a cotransmitter, together with nitric oxide (NO), of airway relaxation, as 
well as a modulator of various immune and inflammatory responses.  VIP and NO work 
synergistically to enhance ASM relaxation through the combined activation of adenylate 
cyclase and guanylyl cyclase, respectively (237).  Mice deficient in VIP exhibit 
spontaneous AHR to MCh challenge, as well as increased airway inflammation 
(eosinophils) and levels of inflammatory cytokines in BALF.  Theses phenotypes are 
partially reversible by exogenous VIP treatment (237), suggesting that endogenous VIP 
helps protect the airways and altered expression or dysregulation of this peptide may 
contribute to asthmatic conditions.  VIP has also been shown to suppress ASM 
proliferation (238), a key component to airway remodeling seen in chronic asthma.  In 
addition, inflammation and mast cell activation and degranulation in allergic asthma can 
influence the activity of neuropeptides.  For example, tryptase released by mast cells 
actively degrades VIP, effectively inhibiting its dilation effect (reviewed in (226)).  In 
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addition to being released from sensory nerves, VIP can also be released by immune 
cells, where it’s involved in many biological functions, namely immunomodulation, 
predominantly acting as a potent anti-inflammatory factor and suppressive agent for Th1 
responses (239).    
NO is a short-lived molecule that is produced by 3 nitric oxide synthases (NOSs).  
Endothelial NOS (eNOS, NOS3) and neural NOS (nNOS, NOS1) are constitutively 
expressed, whereas NOS found in other cell types like macrophages, epithelial cells, and 
neutrophils is inducible (iNOS, NOS2).  The role of NO in asthma is controversial.  
Although NO concentrations appear to be elevated in exhaled air from asthmatics (240), 
there are contradicting results reported on the ability of NO to act as a bronchodilator 
(241, 242).  Studies in mice with targeted deletions in the genes for these NOS isoforms 
have shown a link between nNOS and airway responsiveness in a murine model of 
allergic asthma; mice deficient in nNOS exhibited decreased AHR and exhaled NO 
concentrations with no difference in inflammatory recruitment or IgE production (229, 
243).  These studies imply that NO (produced through nNOS expression) increases or 
positively regulates AHR.  However, another study in mice has shown that increased 
NOS2 (iNOS) expression helped to protect against AHR (244), suggesting that NO acts 
to relax the airways.  Finally, yet another study in mice revealed that NO derived from 
eNOS is involved in regulating bronchial reactivity; mice lacking eNOS were 
hyperresponsive to MCh challenge while inhibition of iNOS had no effect (245).  Similar 
to the conflicting results found in human studies, it is clear that the role of NO and its 
specific synthases in the mouse is still controversial.   
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Additionally, it has also been proposed that the NO “receptor” may be 
dysregulated in asthma.  NO activates soluble guanylyl cyclase (sGC), which catalyzes 
the conversion of GTP to cGMP.  cGMP is able to induce smooth muscle relaxation by 
lowering intracellular Ca2+ concentration.  Despite the high levels of NO present in the 
asthmatic airway (240) capable of activating sGC and relaxing ASM, airway tone is 
significantly elevated in asthmatics.  In an animal model of asthma, mice sensitized and 
challenged with OVA, while exhibiting many characteristics of asthma, also displayed 
reduced mRNA and protein levels of the sGC subunits (230).  This study also showed 
that treatment of naïve mice with a sGC inhibiter induced spontaneous AHR to MCh, 
suggesting that inhibition of sGC could contribute to AHR seen in asthma. 
Dysregulation of neural activity 
Sensory and parasympathetic nerves extending into the lungs may contribute 
significantly to airway obstruction and hyperreactivity in the diseased lung.  As discussed 
above, neuropeptides released from nerves can elicit effects on further neurotransmission, 
mucus secretion, ASM, epithelial cells, and inflammatory cells.  Furthermore, 
dysregulation of these neurotransmitters, airway receptors (Figure 1.9), or the response 
of nerves during a disease state may lead to an alteration of normal airway tone or an 
increase/decrease in nerve excitability and signal transduction.  One hypothesis is that 
asthma represents an imbalance or dysregulation of the autonomic nervous system.   
There is evidence that suggests abnormalities in β-adrenergic and/or muscarinic 
receptor function occur in asthma (26), resulting in AHR.  Probably the best example of 
this is shown in studies conducted by Fryer and colleagues on dysfunctional M2 mAChRs 
in guinea pig models of asthma (reviewed in (246)).  Release of ACh from 
 51
 
 
 
 
Figure 1.9 Receptor localization within the airway.  Cartoon representation of mast 
cell mediator and neurotransmitter receptor localization within the lung. 
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parasympathetic nerves is normally regulated by prejunctional M2 mAChRs, providing a 
negative feedback mechanism which inhibits further release of ACh (247).  They showed 
that guinea pigs sensitized and challenged with antigen exhibited enhanced release of 
ACh from vagus nerves (248), and this release ultimately lead to hyperresponsiveness.  
Furthermore, M2 receptors were shown to be dysfunctional in this model, as the selective 
agonist pilocarpine no longer inhibited vagally induced bronchoconstriction (248), 
providing evidence that loss of neuronal M2 function may be a mechanism for airway 
hyperresponsiveness.  These findings were also reported in studies of in vitro mouse 
tracheas (249).  As in animal models of asthma, there is evidence of M2 dysfunction in 
humans with asthma.  Human parasympathetic nerves from patients with asthma show an 
enhanced release of ACh in response to electrical field stimulation in vitro compared to 
controls (250).  Furthermore, M2 agonists failed to inhibit bronchoconstriction in patients 
with mild asthma (251).   
In addition to hyperresponsiveness, eosinophils are also present in the lung after 
antigen challenge in sensitized animals (252-255), as well as in patients with asthma, 
where they appear to be selectively recruited to airway nerves (256).  Eosinophils release 
the charged protein MBP, which can act as an allosteric antagonist to the M2 receptor 
(120), which is sensitive to inhibition by positively charged proteins.  Inhibition of 
eosinophil migration into the lungs also appears to inhibit hyperresponsiveness (257).  
Furthermore, inhibition of MBP successfully inhibited AHR in antigen challenged guinea 
pigs (252) despite the continued presence of eosinophils in the airways and fully 
functional M3 mAChRs.  These data effectively link the loss of M2 mAChR function via 
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release of eosinophil major basic protein as a mechanism for AHR in antigen challenged 
animals.  
Inflammatory cell and neural interactions 
Inflammatory cells present in the diseased lung have been shown to interact with 
nerves.  Direct contact between DCs and peripheral sensory nerves has been documented 
in the skin, liver, and lung (258-260).  In the airways, DCs are contacted by SP-
containing fibers, and their recruitment to the airways after antigen challenge is 
dependent on SP (259).  Quantitative mapping of airway nerves and mucosal DCs has 
shown many contact points between DCs and sensory fibers containing both CGRP and 
SP, including neuroepithelial bodies and airway ganglia, and the percentage of co-
localization showed an increase in inflamed airways (261).  
Some airway nerves are capable of recruiting and binding eosinophils.  Primary 
cultures of airway parasympathetic nerves express eotaxin (262), as well as adhesion 
molecules capable of binding eosinophils (263).  As detailed above; eosinophils are 
selectively recruited to airway nerves in both a guinea pig model of asthma, as well as in 
human patients with asthma (256).   Eosinophil-nerve interactions were shown to 
influence the function of prejunctional M2 mAChRs, resulting in a loss of feedback 
inhibition through this receptor.  M2 receptor dysfunction results in an increased release 
of ACh from parasympathetic nerves and subsequent enhanced activation of M3 mAChRs 
on ASM, resulting in AHR.   
In addition to DCs and eosinophils, mast cells have been shown to be closely 
associated, or even attached to neurons in vitro.  For example, nerve-mast cell interaction 
has been reported in co-cultures of murine BMMCs and superior cervical ganglion 
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neurons (SCGs).  In this study, it was shown that mast cells can attach to neurites through 
the homophilic binding of synaptic cell adhesion molecule located on both the neurite 
and the mast cell (264).  Furthermore, mast cells have been shown to be located near the 
parasympathetic ganglia neurons in ex vivo guinea pig lungs (265).    
It is known that cross linking of high affinity IgE receptors on mast cells by 
allergen causes degranulation of the mast cells and the subsequent release of 
proinflammatory mediators that can induce smooth muscle constriction (3, 266, 267).  
However, these inflammatory mediators may also influence the release of 
neurotransmitters via activation of sensory nerves or may increase the release of ACh 
from cholinergic nerve terminals (226).  For example, degranulation of purified human 
lung mast cells enhanced the excitability of rabbit visceral sensory C-fibers in vitro (268).  
Furthermore, antigenic stimulation of sensitized guinea pig bronchi caused increased 
sensitivity of sensory nerve endings and parasympathetic ganglion neurons in the airway 
wall, as well as degranulation of mast cells surrounding and within the bronchial 
parasympathetic ganglia (269).   
Receptors for the mast cell mediators histamine (126), serotonin (127-129), PGD2 
(132) and tryptase (133) have been functionally shown to be located on nerves (Figure 
1.9).  Therefore, mast cell derived mediators may modulate neural activity and/or 
excitability during the immune response.  One of the most dramatic neural changes that 
occur in response to inflammation is the allergen-induced synthesis of SP in large-
diameter A-fibers.  Although SP is seldom expressed in A-fiber vagal nerves, OVA 
inhalation in sensitized guinea pigs results in a significant increase in SP expression in 
large-diameter nodose ganglion neurons that innervate the lungs (270).  Mast cell 
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mediators may also have an effect on neurotransmitters released from sensory nerves.  
For example, VIP released by airway nerves typically has a bronchodilator effect on 
human and animal airways, possibly through its ability to inhibit ACh release from post 
ganglionic parasympathetic nerves. It is highly abundant in the upper and lower 
respiratory tract of humans (271, 272).  However, tryptase released by mast cells actively 
degrades VIP, effectively inhibiting its dilation effect (reviewed in (226)). 
 
Summary 
 The overall aim of this dissertation was to assess the mechanisms through which 
inflammatory cell mediators interact with different cell types within the lung to induce 
airway constriction.  The first aim of this work focuses on assessing the mechanism 
through which mast cell activation contributes to anaphylactic airway constriction in the 
mouse.  Although it is known that mast cells are intimately involved in the anaphylactic 
response, the mechanism through which airway constriction is initiated is poorly defined.  
This question is addressed using genetic, pharmacological, and surgical approaches in 
conjunction with in vivo assessment of airway mechanics in the mouse.  The second aim 
of this work directly analyzes C57BL/6 KitWsh/Wsh (Wsh) mast-cell deficient mice as a tool 
for studying mast cell function within the lung.  Due to their fertility, lack of anemia, and 
C57BL/6 background, Wsh mice have become a common research tool in the mast cell 
field.   However, the usefulness of these mice as a model of mast cell function in the 
lung, specifically in the context of airway constriction, is not well defined.  To address 
this aim, we utilized different methods of mast cell reconstitution in these mice and 
analyzed the ability of each method to repopulate the lung with mast cells, as well as 
 56
recapitulate anaphylactic responses including antigen-mediated bronchoconstriction.  The 
third research aim utilizes a genetic approach to define the mechanism through which the 
lipid-mediator TXA2 contributes to airway reactivity.  To address this aim, we generated 
mice carrying a Tp receptor locus that is sensitive to disruption by cre recombinase.  By 
breeding these mice to animals that express cre driven by either the nestin or SM22 
promoter, mice were generated which lack Tp in neurons or smooth muscle cells, 
respectively.  The in vivo airway mechanics of the resultant tissue-specific Tp-deficient 
mice were then characterized.   
 
Organization of the dissertation 
 Chapter 2 of this dissertation introduces a mechanism through which mast cell-
derived serotonin initiates anaphylactic bronchoconstriction through the cooperation of a 
neural pathway.  Chapter 3 introduces mast cell reconstitution of Wsh mast-cell deficient 
mice, and describes a detailed analysis of the ability of different reconstitution methods to 
introduce mast cells into the lung and to recapitulate antigen-mediated 
bronchoconstriction.  Chapter 4 further defines M3 mAChR-dependent TXA2-mediated 
ASM constriction using tissue-specific Tp receptor deficient lines which lack functional 
Tp receptors throughout the nervous system or on smooth muscle cells.  Together, the 
work presented in these chapters describes the interactions of neuronal and smooth 
muscle cells together with inflammatory cell mediators in orchestrating airway reactivity 
in mouse models of allergy and asthma.  Finally, Chapter 5 provides a cumulative 
discussion on mechanisms of airway constriction in the mouse, as well as the use of the 
mouse as a model of human disease. 
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Abstract 
 Mast cells are important sentinels guarding the interface between the environment 
and the body: a breach in the integrity of this interface can lead to the release of a 
plethora of mediators which engage the foreign agent, recruit leukocytes, and initiate 
adaptive physiological changes in the organism.  While these capabilities make mast cells 
critical players in immune defense, it also makes them important contributors to the 
pathogenesis of diseases such as asthma.  Mast cell mediators induce dramatic changes in 
smooth muscle physiology, and the expression of receptors for these factors by smooth 
muscle suggests that they act directly to initiate constriction.  Contrary to this view, we 
show here that mast cell-mediated bronchoconstriction is observed only in animals with 
intact innervation of the lung and that serotonin release alone is required for this action.  
While ablation of sensory neurons does not limit bronchoconstriction, constriction after 
antigen challenge is absent in mice in which the cholinergic pathways are compromised.  
Linking mast cell function to the cholinergic system likely provides an important means 
of modulating the function of these resident immune cells to physiology of the lung, but 
may also provide a safeguard against life-threatening anaphylaxis during mast cell 
degranulation. 
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Introduction 
IgE-dependent mast cell activation is the central mechanism underlying 
immediate allergic reaction (1).  Cross-linking of IgE bound by Fc receptors on mast cells 
leads to release of preformed mediators stored in the mast cell granules, as well as, 
production of lipid mediators and up-regulation of cytokine synthesis (1).  These 
mediators can profoundly influence the physiology of the organism and thus systemic 
release of mast cell mediators can result in life threatening anaphylaxis.  Mast cells can 
also contribute to chronic inflammatory diseases, including asthma, where activation by 
environmental allergens contributes to inflammation and reversible airway constriction, a 
hallmark of this disease.  Consistent with a role for mast cells in this aspect of asthma, an 
increase in airway mast cells has been reported in asthmatic patients compared to healthy 
individuals (2).    
The mechanism(s) through which mast cell mediators contribute to the airway 
obstruction is not yet completely understood.  However, airway smooth muscle (ASM) 
expresses many receptors for mediators produced by mast cells (3).  Thus, in the simplest 
model, mast cell mediators, including cysteinyl leukotrienes (cysLTs), histamine and 
serotonin (5-HT) act directly on smooth muscle, triggering increases in intracellular Ca2+ 
followed by assembly of the contractile apparatus.   Direct ability of several mast cell 
mediators to elicit Ca2+ flux in muscle cells and constriction of tracheal rings further 
supports this model (4-6). 
In a number of organ systems, close interaction of mast cells with both sensory 
and parasympathetic neurons has been demonstrated, suggesting that mast cells may 
induce bronchoconstriction by altering the activity of the neuronal pathways which 
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function to determine ASM tone.  For example, histamine released by mast cells is 
reported to stimulate parasympathetic neurons in the guinea pig heart (7), while antigen 
challenge in sensitized rats results in the activation of afferent nerve fibers in the gut 
mediated by both histamine and serotonin (8).  Consistent with this, mucosal mast cell 
mediators from patients with irritable bowl syndrome were reported to excite rat 
nociceptive visceral sensory nerves (9).  A number of studies suggest that this 
relationship is also present in other organs including the lung.  For example it has been 
reported that substance P containing nerves in the rat trachea interact with mast cells to 
cause antigen-specific, and dependent, changes in lung solute clearance and epithelial 
chloride ion secretion (10-12). 
In humans, the cholinergic parasympathetic nervous system represents the 
predominate bronchoconstrictor pathway in the airways.  Efferent cholinergic nerve 
fibers run through the vagus nerve and synapse in small ganglia within the airway wall.  
These release acetylcholine (ACh), which binds nicotinic acetylcholine receptors 
(nAChRs) on the parasympathetic ganglion, which activates postganglionic fibers 
innervating ASM and submucosal glands.  These postganglionic fibers release ACh, 
which binds to muscarinic acetylcholine receptors (mAChRs) directly on ASM.  The 
activity of the parasympathetic pathway is modulated by sensory neurons present 
throughout the airway.  Supporting a role for the mast cell interaction with the autonomic 
nervous system, mast cells have been shown to be closely associated with airway nerves 
(13), and receptors for many mast cells mediators, including histamine and serotonin, are 
expressed by neurons (14-16).  In the studies detailed here we demonstrate that in allergic 
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mice, antigen challenge induces constriction of the central airways, and this constriction 
is dependant not only on mast cells but also on an intact parasympathetic system.  
 
Methods 
Experimental animals.  All studies were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee (IACUC) guidelines of 
the University of North Carolina at Chapel Hill.  Mast cell deficient C57BL/6 KitW-
sh/KitW-sh, PAR2-/- (17), C57BL/6J, and BALB/c mice were purchased from Jackson 
Laboratory.   Mice deficient in 5-lipoxygenase (5LO-/-) were generated as previously 
described (18).  M1 and M3 mAChR-deficient mice and their controls were bred as 
previously described (19, 20).  The generation of congenic 5HTT-deficient mice has been 
previously described (21).  All experiments were carried out using 8-12 week old mice, 
with the exception of the 5-HTT mice.  Both control and experimental animals were 6 
months of age.   
Airway measurements in intubated mice.  Mechanical ventilation and airway 
measurements were carried out as previously described (22).  After baseline 
measurements, serotonin (6.25 µg/ml, Sigma Chemical) was administered i.v. through a 
jugular catheter in increasing doses (0.3, 0.6, and 1.2 pg/ml).  Single doses of DNP (250 
µl, 5 mg/ml, Sigma Chemical) or OVA (50 µl, 10 mg/ml, Grade V, Sigma Chemical) 
were also delivered i.v. through a jugular catheter.  After administration, airway 
mechanics were determined using the Forced Oscillatory Technique (FOT) every 10 s for 
3 min.  The resultant pressure and flow data were fit to a constant phase model as 
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previously described (23).  Similar to other studies assessing FOT, we confined our 
analysis to Raw (Rn; Newtonian resistance), which assesses the flow resistance of the 
conducting airways, and G (tissue damping), which reflects tissue resistance in the 
peripheral airways (24).    Total lung resistance (RL) was calculated from the FOT data by 
adding tissue resistance (Rti) to Raw as previously described (24, 25).  Where Rti is given 
by: 
Rti (f) = G/(2πf)α 
where f is the frequency in Hz and α = (2/π) tan-1(H/G).  All data are represented as 
percent baseline RL, Raw or G.   
To determine the contribution of various mediators and/or receptors in airway 
responses, mice received a pre-treatment i.p. injection of pharmacological antagonist 
before exogenous administration of mediators or antigen.  To asses the role of mAChRs 
and nAChRs to airway responses, mice received a pre-treatment i.p. injection of atropine 
sulfate (10µM/kg, American Pharmaceutical Partners) or mecamylamine (4mg/kg, Sigma 
Chemical), respectively.  To asses the role of prostaglandins in IgE-dependent 
anaphylactic airway constriction, mice were pretreated with 10 mg/kg indomethacin (1 
mg/ml, i.p., Sigma Chemical) 1 hour prior to airway measurements.  To determine the 
efficacy of prostaglandin depletion, levels of PGD2 were measured by EIA (Assay 
designs) from harvested gut samples.  To determine the contribution of HR1 and HR2 to 
airway responses, passively sensitized mice received a pre-treatment i.p. injection of 
pyrilamine (40mg/kg, Sigma Chemical) or cimetidine (25mg/kg, Sigma Chemical), 
respectively.  Methiothepin (2mg/kg, i.p.), ketanserin (12 mg/kg, i.p.), and ondansetron (1 
mg/kg, i.p.) were administered to block serotonin receptors.  Methiothepin is a 
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nonspecific antagonist, whereas ketanserin and ondansetron are specific antagonists for 
5-HT2A and 5-HT3 receptors, respectively.   
Anaphylaxis protocols.  IgE-dependent passive anaphylaxis:  Mice were 
sensitized with 20 µg mouse monoclonal anti-DNP IgE (1.0 mg/ml, Sigma Chemical; 
200 µl total volume in saline) or an equal volume PBS i.v. through the tail vein.  
Approximately 19-24 hours after anti-DNP IgE injection, mice were anesthetized, 
catheterized, tracheostomized and mechanically ventilated as described above.  
Immediately following the baseline measurements, 0.25 ml of 5 mg/ml DNP (or an equal 
volume of PBS) was injected into the jugular and airway parameters were measured 
every 10 s for 3 min immediately following anaphylaxis induction.   Bar graphs represent 
the area under the curve. 
Active systemic anaphylaxis to OVA: Mice received a single i.p. injection of 0.2 
ml sterile 0.9% NaCl containing 20 µg OVA emulsified in 2.25 mg aluminum hydroxide 
gel (Sigma Chemical).  18-21 days after OVA immunization, mice were anesthetized, 
placed on a ventilator, challenged with a single i.v. infusion (via a jugular catheter) of 
500 µg of OVA in 50 µl of sterile 0.9% NaCl and airway measurements were taken every 
10 s for 3 min (26).  Control mice were challenged with an equal volume of sterile 0.9% 
NaCl.  Bar graphs represent the area under the curve.  
Acute anaphylaxis to OVA following induction of allergic airway disease: Mice 
were sensitized by i.p. injection of 20 µg OVA emulsified in 2.25 mg aluminum 
hydroxide gel in a total volume of 200 µl on days 1 and 14.  Mice were challenged (45 
min) via the airways with OVA (1% in saline) for 5 days (days 21 – 25) using an 
ultrasonic nebulizer (DeVillbiss Health Care, Somerset, PA).  On day 26 mice were 
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anesthetized, placed on a ventilator, challenged with a single iv infusion (via a jugular 
catheter) of 500 µg of OVA in 50 µl of sterile 0.9 % NaCl.  Airway measurements were 
taken every 10 s for 3 min.  Bar graphs represent the area under the curve.  
After airway measurements, mice were sacrificed and 0.5-1.0 ml of blood was 
collected by cardiac puncture.  Following coagulation, serum was collected.  Total IgE 
levels in the serum were measured by ELISA (R&D systems).  BAL was performed five 
times with 1.0 ml of sterile HBSS each time.  Cells present in the BAL were determined 
using a hemocytometer.  A differential cell count was conducted on a cytospin prepared 
from 150 µl of BAL fluid and stained with Diff-Quik solution (Sigma Chemical).  The 
remaining BAL fluid was centrifuged to remove cells.  Histamine levels were measured 
in the cell-free supernatant by ELISA (Beckman Coulter).   
Histology.  For histopathologic examination, lungs were fixed by inflation (20 cm 
pressure) and immersion in 10% formalin.  To evaluate airway eosinophilia, fixed lung 
slices were subjected to hematoxylin and eosin (H & E) staining.  H&E stained lung 
slices were digitally imaged midway along the length of the main axial airway, as well as, 
at both ends of the same airway.  Each of the three images was then divided into 4 
quadrants and the levels of inflammation in each quadrant were semi quantitatively 
assessed based on a score of 0 (no inflammation) to 3 (severe inflammation).  Scores 
from all quadrants for each of the 3 pictures representing 1 airway were then averaged 
together to represent the average H&E score of that airway (27).   To assess goblet cell 
hyperplasia, serial sections of the left lobes of the lungs that yield maximum longitudinal 
visualization of the intrapulmonary main axial airway were analyzed following Alcian-
blue/periodic acid-schiff reaction (PAS) staining. To avoid bias for a certain region, and 
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to consistently view the identical region in all slides, a 2-mm length of airway, located 
midway along the length of the main axial airway, was digitally imaged. Using ImageJ 
software (NIH, National Technical Information Service, Springfield, VA), the area and 
length of the PAS/AB-stained region in the sections were measured and the data 
expressed as the mean volume density (Vs = nl/mm2 basal lamina + SEM of 
PAS/Abstained material within the epithelium) as previously described (28). 
Inhibition of serotonin with 4-Chloro-DL-phenylalanine (PCPA).  Mice 
received a single i.p. injection of 0.2 ml sterile 0.9% NaCl containing 20 µg OVA 
emulsified in 2.25 mg aluminum hydroxide gel.  18-21 days after OVA immunization, 
mice were treated with PCPA (150 mg/kg, i.p.; 25 mg/ml in 1N HCl) and immediately 
challenged with 250 µg of OVA in 50 µl of sterile 0.9% NaCl (i.v.) to deplete serotonin 
stored in mast cells.  24 hours later, mice received a second treatment of PCPA (150 
mg/kg, i.p.) and were then anesthetized, placed on a ventilator, and challenged with a 
single i.v. infusion (via a jugular catheter) of 500 µg of OVA in 50 µl of sterile 0.9% 
NaCl and airway measurements taken every 10 s for 3 min.  Control mice were 
challenged with an equal volume of sterile 0.9% NaCl.  
After airway measurements, mice were sacrificed and 0.5-1.0 ml of blood 
collected by cardiac puncture with a syringe containing 20 µl 100 U/ml heparin.  The 
blood was then centrifuged at 12000 rpm for 5 min to collect plasma.  Serotonin levels 
were measured in the plasma by ELISA (Beckman Coulter).   
Sensory ablation.  Adults: Capsaicin was administered to ablate sensory neurons 
as previously described (29, 30).  For pretreatment, mice received a s.c. dose of 25 mg/kg 
capsaicin at 0 hrs and a second s.c. dose of 75mg/kg capsaicin at 24 hrs (5 and 15 mg/ml 
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capsaicin dissolved in 1:1:8 ethanol:Tween80:saline, respectively).  To minimize the 
respiratory effects associated with capsaicin injection, animals were first anesthetized 
with avertin (250 mg/kg, i.p.) and then treated with 10 mg/kg theophylline (s.c., 5 mg/ml 
in distilled water, Sigma Chemical) and 0.1 mg/kg terbutaline (i.p., 0.05 mg/ml in saline, 
Sigma Chemical).  Airway assessment was conducted 10-12 days after the final capsaicin 
treatment. 
Neonates: Pups were injected with 50 mg/kg capsaicin (15 mg/ml, s.c.) at day 2 to 
3 after birth to degrade sensory neurons.  Animals were aged to 8 weeks of age before 
conducting studies. 
To check for effectiveness of the treatment, a drop of 0.1 mg/ml capsaicin was 
instilled into one eye of each mouse and wiping movements were counted as previously 
described (31, 32).  For substance P measurements, lungs were lavaged with 0.4 ml 
chilled PBS containing 500 KIU/ml aprotinin (Sigma Chemical).  Substance P was 
measured from BAL by ELISA (R&D systems). 
Vagotomy.  A surgical vagotomy was conducted to assess the contribution of 
intact parasympathetic innervation as previously described (33).  Briefly, the right and 
left vagus nerves running parallel to the trachea were isolated and a piece of surgical 
string was passed underneath to facilitate cutting during mechanical ventilation.  In 
experimental animals, basal lung mechanics were established before severing of both 
vagus nerves.  Post vagotomy baseline was then reassessed prior to i.v. challenge. 
Control animals received a sham operation which involved simply lifting and releasing of 
the surgical string along with the nerve fibers. 
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MCh treatment in vagotomized mice.  Anesthetized, paralyzed, vagotomized, 
mechanically ventilated mice were treated with i.v. MCh (20 µg/ml, Sigma Chemical) 
administered through a jugular catheter in increasing doses (50 µl, 100 µl, and 200 µl) or 
an aerosolized dose response of MCh (12.5-50 mg/ml) delivered via a nebulizer through a 
side port in the ventilator circuit for 30 s at a rate of 200 breaths/min with a tidal volume 
of 0.15 ml.  Immediately following the aerosol challenge, the nebulizer was isolated from 
the inspiratory circuit and the original mechanical ventilation was resumed 
Statistical analysis.  Data are represented as means ± SEM.  Analysis Of 
Variance (ANOVA) followed by Tukey-Kramer Honestly Significant Difference for 
multiple comparisons was performed on complex data sets.  Statistical significance for 
single data points was assessed by Student’s two-tailed t-test.  A P value of <0.05 was 
considered statistically significant. 
 
Results 
Change in airway resistance during anaphylaxis is dependant on mast cells, 
primarily those located in the central airways.  
 We first determined the contribution of mast cells to changes in airway 
mechanics.  Previous studies have shown that in the mouse, antigen treatment following 
sensitization results in rapid decrease in lung conductance (GL) (26), which is the inverse 
of lung resistance (RL).  Similarly, we found that sensitization of wild-type C57BL/6 (B6) 
mice with OVA plus adjuvant, followed by exposure to antigen, resulted in a rapid and 
dramatic increase in RL (Figure 2.1A).  Similar immunization and challenge of C57BL/6 
KitW-sh/KitW-sh (Wsh/Wsh) mice, which lack mast cells, failed to induce changes in lung 
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mechanics, indicating that this response was dependent on the normal development of 
this cell population (Figure 2.1B).  To verify that the difference in RL was not due to a 
reduction in overall IgE production in the mast cell deficient animals, we compared total 
serum IgE levels in the B6 and Wsh/Wsh congenic pairs (Figure 2.1C).  There was no 
difference in IgE production between the two groups.   
 Mast cells are located throughout the airways including the trachea, bronchus, and 
sporadically in the parenchyma (34), yet it is unclear whether all of these cells contribute 
to changes in lung physiology during anaphylaxis.  To examine this point more closely, 
we monitored changes in airway mechanics after sensitization and exposure to OVA 
using FOT.  Interestingly, using this method we found that the changes in lung mechanics 
were largely limited to a parameter termed ‘airway resistance’ or Raw, which a number of 
theoretical and experimental studies suggest is sensitive primarily to changes in the 
central airways (35).  As can be seen in figure 2.1D, antigen induced a significant and 
robust change in Raw in B6 mice previously sensitized to OVA plus adjuvant and little to 
no change in G, a parameter termed ‘tissue damping’ which is associated with changes in 
the distal lung.  In contrast, no change in Raw was observed in mast cell deficient 
Wsh/Wsh mice after antigen challenge or in mice treated with vehicle (Figure 2.1E).  To 
further verify these findings, we examined changes in airway mechanics in a mouse 
model of passive anaphylaxis.  Mice received i.v. monoclonal anti-DNP IgE, and the 
following day, after establishment of baseline lung mechanics, mast cell degranulation 
was induced by i.v. delivery of antigen (DNP).  DNP induced similar increases in Raw as 
those seen during active anaphylaxis to OVA (data not shown).  Unlike antigen induced 
constriction, airway constriction induced with methacholine (MCh), a stable 
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acetylcholine analog, resulted in both changes in Raw and G consistent with both changes 
in the central and distal airways in response to this neurotransmitter (Figure 2.1F).  
Similar responses to both antigen and MCh challenge were also seen in the BALB/c and 
129/SvEv strains (data not shown).  This suggests that although the ability of 
methacholine to induce airflow obstruction is distributed throughout the lung, mast cell 
degranulation results in only central airway constriction, despite the presence of these 
cells in peripheral airways.   
We next asked whether this is also the case in mice with inflamed airways, 
particularly in those with allergic lung disease.  To do this we induced allergic lung 
disease in B6 and Wsh/Wsh mice by sensitization and challenge with OVA using an 
immunization protocol previously shown to induce similar levels of inflammation in both 
lines (36).  As expected, the absence of mast cells in the Wsh/Wsh mice did not 
significantly alter any of the disease parameters including IgE production, cellularity of 
the BAL fluid, mucus cell hyperplasia or the induction of the Th2 pathway (Figure 2.2A-
E).  Twenty-four hours after the last OVA challenge, changes in airway resistance in 
response to antigen were measured using FOT, monitoring both Raw and G changes in 
lung mechanics in the OVA treated mice.  Despite robust inflammation in the central and 
distal lung, changes in airway mechanics were limited to parameters associated with the 
central airways.  A significant increase in Raw was observed; however, no significant 
increase in G was observed after infusion of antigen into mice with inflamed lungs 
(Figure 2.3A).  Similar to actively sensitized animals, the increase in Raw after OVA 
challenge in mice with allergic airway disease was dependent on mast cells; Wsh/Wsh 
mice failed to respond to antigen challenge (Figure 2.3B).  As would be expected given 
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the absence of mast cells in the Wsh/Wsh mice, no histamine was detected in the 
Wsh/Wsh animals, while this mediator could easily be detected in the BAL from B6 mice 
following antigen challenge (Figure 2.3C).  Similar to the naïve airway, antigen induced 
constriction appears to be located within the central airways.  
 
Mast cell release of serotonin alone mediates airway constriction during 
anaphylaxis. 
To address the contribution of the various mast cell mediators to allergen-induced 
bronchoconstriction we took advantage of a number of pharmacological and genetic 
tools, examining the impact of loss of various pathways on the changes in Raw during 
anaphylaxis.  Anaphylaxis results in a measurable increase of leukotriene (LT) C4 in the 
BAL (37).  To examine the contribution of LTC4 to anaphylactic bronchoconstriction, we 
utilized animals lacking the enzyme 5-lipoxygenase (5LO), an enzyme required for the 
synthesis of all leukotrienes.  The inability of the mast cells to produce this lipid mediator 
did not alter bronchoconstriction after induction of passive anaphylaxis in 5LO-/- mice 
(Figure 2.4A).  Although prostaglandin (PG) D2 has been shown to be synthesized and 
released during IgE-dependent activation of mouse bone marrow-derived mast cells (38), 
no attenuation of airway resistance was noted in mice in which the production of 
prostaglandins was inhibited by treatment with the NSAID indomethacin (Figure 2.4B).  
Similarly, antagonists which block the H1 and H2 histamine receptors did not 
significantly alter anaphylactic bronchoconstriction (Figure 2.4C).  The most abundant 
mediator found in human mucosal mast cells, tryptase, has the ability to activate protease 
activated receptor 2 (PAR2) receptors, which can mediate airway constriction under some 
 96  
experimental conditions (39).  To determine whether this pathway was involved in 
bronchoconstriction associated with anaphylaxis, we examined this response in PAR2-/- 
mice (17); no difference in Raw was noted between the mutant and control animals 
(Figure 2.4D).  
Mast cells express the enzyme required for the production of serotonin (40), and 
previous studies have indicated that serotonin can mediate changes in lung resistance 
(41).  We therefore first asked whether the change in airway mechanics mediated by 
serotonin were also limited to the central airways.  As can be seen in figure 2.5A, 
exogenous serotonin induced a dose-dependent increase in Raw with little change in G, a 
pattern similar to what is observed after mast cell degranulation.  To address the role of 
serotonin in mast cell mediated bronchoconstriction more directly, we examined the 
impact of PCPA on airway resistance.  PCPA inhibits the activity of tryptophan 
hydroxylase, an enzyme which carries out the essential step in the synthesis of serotonin.  
Mice were sensitized with OVA and three weeks later treated with either vehicle or 
PCPA prior to the induction of anaphylaxis by injection of antigen.  Antigen exposure 
resulted in a robust increase in airway resistance in the vehicle treated animals.  In 
contrast, airway resistance was abolished in mice treated with PCPA, despite the normal 
degranulation of mast cells in these animals; histamine levels in the BAL collected 
immediately after induction of anaphylaxis were not significantly different between the 
two groups (Figure 2.5B).  Furthermore, no difference was observed between the PCPA 
and control animals in the ability of their airways to respond to MCh (Figure 2.5C).  As 
expected, anaphylaxis resulted in a measurable increase in plasma serotonin levels, but 
this increase was not observed in the PCPA treated mice (Figure 2.5D).  Thus, the 
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protection of the PCPA treated mice from bronchoconstriction was due to attenuated 
serotonin release and not to alterations in either smooth muscle function or the 
responsiveness of mast cells to antigen.   
To rule out a possible role for platelet-derived serotonin in this model, we 
examined the response to IgE and antigen in mice lacking the serotonin transporter.  
While mast cells express tryptophan hydroxylase and thus can produce serotonin, 
platelets acquire this mediator via the serotonin transporter as they pass through the 
intestinal circulation.  Thus platelets from mice and rats lacking the transporter also lack 
serotonin (42, 43).  5HTT-deficient mice demonstrate wild-type levels of constriction 
after antigen challenge (Figure 2.5E) indicating that platelet-derived serotonin is not 
critical for this response.  Serotonin-dependent constriction was also observed in BALB/c 
mice (Figure 2.6), which are commonly thought of as prototypical Th2 responders.  
If bronchoconstriction is mediated by mast cell-derived serotonin, it would follow 
that agents that block serotonin receptors would also attenuate changes in Raw.  
Serotonin-induced increases in Raw were abolished by both the non-specific antagonist 
methiothepin and the 5-HT2A-specific antagonist ketanserin, whereas the 5-HT3-specific 
antagonist ondansetron failed to attenuate this increase in airway mechanics (data not 
shown).  Both methiothepin and ketanserin abolished allergic airway constriction in 
passively sensitized mice (Figure 2.5F).    Together these studies indicate that while mast 
cells release many mediators that may modulate the inflammatory response, serotonin 
alone mediates the changes in airway resistance during anaphylaxis through its action on 
5-HT2A receptors. 
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Intact sensory innervation is not required for mast cell mediated 
bronchoconstriction 
 Our observation that the ability of mast cells to mediate bronchoconstriction was 
sensitive to the location of these cells in the lung, and our observation that serotonin 
alone mediated this response, suggested to us that the mast cell mediated constriction 
may result from indirect stimulation of sensory neurons, triggering a bronchial reflex.  To 
test this hypothesis we examined the ability of IgE and antigen to induce constriction in 
mice in which sensory neurons had been ablated by treatment with capsaicin.   Ablation 
of sensory C-fibers with capsaicin in both adults and neonates failed to significantly 
decrease Raw after antigen challenge in passively sensitized mice (Figure 2.7A-B), 
suggesting that capsaicin-sensitive C-fibers do not play a primary role in allergic airway 
constriction.  Substance P, the primary neurotransmitter stored in C-fibers, was measured 
to evaluate the efficacy of capsaicin treatment.  Antigen challenge in passively sensitized 
mice increased substance P levels in the BAL, but was attenuated in mice pretreated with 
capsaicin (Figure 2.7C), verifying that the capsaicin treatment ablated substance P 
containing C-fibers in these animals.     
 
Vagotomy abolishes anaphylactic airway constriction in both the naïve and allergic 
airway 
 The tone of ASM is largely dependent on parasympathetic innervation, which 
travels in the vagus nerve.  Mast cells have been observed close to the vagus nerve and 
parasympathetic ganglia in other organisms and tissues (7, 13, 44), raising the possibility 
of cooperation between mast cells and these cholinergic fibers in bronchoconstriction.  
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To test this hypothesis, we examined mast cell-mediated bronchoconstriction in mice in 
which the cholinergic pathways were disabled using a number of approaches. 
 Blockade of nAChRs with the nonspecific nicotinic antagonist mecamylamine, 
prior to antigen challenge, abolished antigen-induced increases in Raw in passively 
sensitized mice (Figure 2.8A).  Post ganglionic fibers release ACh which binds mAChRs 
expressed by smooth muscle cells to initiate contraction.  Blockade of mAChRs with the 
nonspecific muscarinic antagonist atropine resulted in complete absence of airway 
constriction after antigen challenge in B6 mice (Figure 2.8B).  To further define the 
muscarinic receptors required for mast cell mediated bronchoconstriction, we examined a 
series of mouse lines deficient in M1 or M3 mAChRs.  Complete attenuation of Raw was 
only observed in the mice lacking the M3 mAChR (Figure 2.8C), which has been shown 
to be expressed by airway smooth muscle (3).  
The observation that disruption of both nicotinic and muscarinic neuronal 
transmission inhibits anaphylactic changes in airway mechanics suggests that an intact 
parasympathetic pathway is required for this mast cell function.  If this is the case, we 
would expect that severing the incoming neural fibers would eliminate IgE/antigen 
mediated bronchoconstriction.  To test this hypothesis, mice were treated with either IgE 
or saline and the following day the vagus nerve was severed prior to treatment with 
antigen.  Control groups in which the nerve was isolated but not severed were also 
prepared.  Vagotomy abolished antigen-mediated airway constriction in B6 mice (Figure 
2.9A).  We next determined whether severing the vagus nerve altered the ability or extent 
of mast cell degranulation in the airways by measuring histamine levels in the BAL 
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immediately after measurement of airway parameters.  No difference in histamine levels 
was seen following vagotomy (Figure 2.9B).   
Inflammation results in the recruitment of cells to the lung.  This raises the 
possibility that, in such an environment, mast cells may bring about changes in airway 
caliber in response to antigen independent of parasympathetic pathways.  To test this, we 
induced allergic lung disease in mice and examined the impact of vagotomy on these 
animals.  Again, vagotomy abolished increases in Raw following antigen challenge 
(Figure 2.9C). 
Allergic airway constriction in BALB/c mice was also sensitive to atropine and 
vagotomy (Figure 2.10).  To verify that the vagotomy did not alter fundamental 
properties of the ASM, we confirmed that this surgical procedure did not alter the 
response of the mice to MCh (Figure 2.11).   
If serotonin released by mast cells collaborates with signals derived from the 
parasympathetic pathways, one would expect that constriction of the airways to 
exogenous serotonin to show similar sensitivity to changes in the activity of this system.  
Supporting the role of serotonin in neural mediated anaphylaxis, administration of 
exogenous serotonin exhibited dose dependent central airway constriction that was 
sensitive to both vagotomy and atropine (Figure 2.9D).  Additionally, pretreatment with 
a non-provoking dose of serotonin resulted in an additive effect on bronchoconstriction to 
a non-provoking dose of MCh (Figure 2.12). Together these studies support a model in 
which mast cell derived serotonin collaborates with cholinergic pathways of the lung to 
bring about changes in airway patency during anaphylaxis. 
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Discussion 
We show here that IgE-mediated degranulation of mast cells leads to an increase 
in the release of mast cell specific mediators in the mouse lung accompanied by changes 
in airway mechanics.  These changes in airway mechanics are dependent on both mast 
cell release of serotonin and intact cholinergic innervation of the lung.  Similar to 
previous studies (45) we show that there was a dramatic increase in total RL following 
antigen challenge, similar in magnitude to that generally achieved with 2 µg i.v. MCh 
(data not shown).  More recently it has become possible to evaluate changes in airway 
mechanics using FOT.  Using the input impedance of prime waves of various amplitudes, 
fit to the constant phase model of the lung, airflow obstruction following anaphylaxis can 
be distinguished between the central and peripheral airways (24, 35).  Using this method 
we found that while MCh affects parameters associated with changes in mechanics of 
both the central and peripheral airways, changes observed after mast cell degranulation 
were surprisingly limited to the central airways despite the fact that these cells can be 
found throughout the lung, including within the distal airways and lung parenchyma (34).  
A number of different explanations are possible for this observation.  First while mast 
cells are found throughout the lung in B6 mice, a larger concentration are localized 
within close proximity of bronchial smooth muscle while few are found in the alveolar 
spaces and within the lung parenchyma (34).  While antigen exposure may lead to 
degranulation of cells in the distal lung, the distribution of the receptor(s) sensitive to 
mast cell mediators may also be biased towards smooth muscle of the central airways.  
Alternate explanations are also possible.  For example, it is possible that cholinergic 
innervation is more abundant in the central airways, or that the mast cell localization in 
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respect to these neurons differs at different levels of the airways.  However, our 
observation that inhaled serotonin leads to changes in lung mechanics similar to that 
observed upon mast cell degranulation suggests that the distribution of serotonin 
receptors plays a role in limiting the response to the larger airways.  This finding differs 
from studies carried out on precision cut lung slices prepared from rats in which 
constriction of airways was observed in both the distal and proximal airways (46).  In this 
study antigen challenge of passively sensitized lung slices resulted in both stronger and 
faster constriction of the small airways when compared to the large conducting airways.  
Similarly, serotonin-provoked responses were also greater in the peripheral airways.  In 
addition, passively sensitized lung slices from humans have also been reported to have an 
increased response to antigen with decreasing airway size (47).  The difference in these 
findings underscores the continuing importance of verification of ex vivo findings in an 
animal model.  Alternately, this may reflect differences between species in the anatomical 
distribution of mast cells, ASM, airway receptors, or a combination thereof; and may also 
indicate that while bronchoconstriction in mice is restricted to central airways this may 
not be representative of all species. 
Mast cells produce a number of mediators that have been shown, both in vitro and 
in vivo, to mediate airway constriction, including LTC4/LTD4, PGD2, tryptase and 
histamine.  Direct testing using mice lacking 5LO indicated that leukotrienes are not 
required for IgE/antigen mediated airway constriction, at least in this species.  Likewise, 
inhibition of endogenous prostaglandin production using the NSAID indomethacin failed 
to inhibit antigen-induced increases in Raw, ruling out the involvement of PGD2 in this 
response.  Furthermore, mice lacking PAR2 responded similarly to wild-type animals, 
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indicating that, in the mouse, activation of PAR2 receptors by tryptase is not linked to 
allergic airway constriction.  Nor did we find evidence supporting a role for mast cell 
derived histamine in this response, despite the ability of inhaled histamine to induce an 
increase in airway resistance in humans (48) and to modestly increase Raw in some mouse 
strains (data not shown).  In contrast, both inhibition of serotonin synthesis and blockage 
of the serotonin 5-HT2A receptor completely abolished the change in airway mechanics 
after antigen challenge.  This finding is consistent with a number of previous studies 
using mice, in which pharmacological agents were shown to attenuate changes in airway 
mechanics.  For example, Eum et al. reported that pretreatment of antigen challenged 
mice with the non-specific serotonin receptor antagonist methysergide significantly 
attenuated anaphylactic bronchoconstriction (45).  5-HT2 receptor specific antagonists 
have also been shown to attenuate serotonin-induced increases in pulmonary mechanics 
(49). 
Serotonin has been reported to activate human airway smooth muscle ex vivo 
(50).  However, unlike LTC4 and histamine, serotonin inhalation does not lead to 
increased airway constriction, even in asthmatics (51).  Furthermore, until recently, it was 
believed that human mast cells, unlike the rodent counterpart, could not produce 
serotonin.   Careful study of these cells has revealed both the expression of tryptophan 
hydroxylase and the localization of serotonin (40); however, these findings are limited to 
cells derived ex vivo and levels were quite small relative to the amounts stored in rodent 
mast cell granules.  Despite the differing expression between human and mouse mast 
cells, a re-evaluation of potential roles for this pathway in human mast cells is warranted.  
For example it is possible that localized release of this mediator in close apposition to 
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nerves or ASM can produce a significant change in the activity of the parasympathetic 
pathway, and that this activity is not easily mimicked by delivery to the epithelial surface.   
The vagus nerve contains both the incoming parasympathetic efferents and the 
sensory nerves originating from the lung, and thus the loss of response in mice after 
vagotomy is consistent with a model in which mast cells release mediators that stimulate 
sensory neurons.  Sensory neuron activation can lead to both local release of mediators 
and a bronchial reflex resulting in increased activity of the parasympathetic pathway, a 
response lost in the vagotomized mice.  The serotonin 5-HT3 receptor is known to be 
involved in activation and depolarization of sensory neurons in several species including 
the mouse (15).  It is possible that serotonin released by mast cells activates sensory 
neurons to elicit a bronchial reflex.  Past studies in various species have suggested the 
involvement of sensory neurons in the allergic response.  For example, degranulation of 
purified human lung mast cells enhanced the excitability of rabbit visceral sensory C-
fibers in vitro (52).  Furthermore, antigenic stimulation of sensitized guinea pig bronchi 
caused increased sensitivity of sensory nerve endings (53).   Consistent with this, Yu et 
al. showed that mast cell degranulation enhanced the excitability of guinea pig 
esophageal C-fibers to mechanical and chemical stimulation (54).  In the rat, capsaicin-
sensitive neurons interact with mast-cells to influence lung solute clearance and chloride 
ion secretion in the trachea (10-12).  Our observation however does not support this 
mechanism, as pretreatment of the mice with capsaicin had little impact on mast cell 
mediated airway constriction while, as expected, release of substance P by these neurons 
was all but eliminated.   Consistent with this, pretreatment of mice with the 5-HT3 
receptor specific antagonist ondansetron did not attenuate serotonin-induced increases in 
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airway mechanics (data not shown).  While it is unlikely that substance P is involved in 
this reaction, as animals were treated both as adults and as neonates, the involvement of 
this neurotransmitter cannot be completely discounted as effects of specific NK receptor 
antagonists were not evaluated.  
A number of lines of evidence presented here support a critical role for 
parasympathetic neurons in mast mediated bronchoconstriction.  This includes the loss of 
the antigen-induced contractile response in vagotomized mice, the ability of antagonists 
of both nAChRs and mAChRs to block the response, and the inability of IgE and antigen 
to trigger bronchoconstriction in mice lacking the M3 receptor.   In recent years, studies 
have suggested that the cholinergic contractile response to serotonin depends on a non-
neuronal source of ACh, specifically, serotonin released from the epithelium (49).  This 
hypothesis was based largely on in vitro studies of mouse isolated trachea challenged 
with exogenous serotonin.  They showed that serotonin induced contractions of tracheal 
smooth muscle was sensitive to epithelial removal but not to inhibition of neural 
pathways, and that these contractions were dependent on the release of ACh.  Our studies 
do not support this hypothesis, as it would predict that severing the vagus nerve would 
have no effect on the ability of serotonin to induce bronchoconstriction.  Our data show 
that in vivo, airway constriction from both exogenous serotonin and mast cell-derived 
serotonin is sensitive to vagotomy. 
A number of models for mast cell interaction with the cholinergic neural pathway 
are possible.  First it is possible that mast cells increase transmission at the preganglionic 
terminal, either by increasing ACh release or augmenting the activity of nAChRs.  
Second, mast cell mediators could amplify the release of ACh from postganglionic nerve 
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terminals.  Finally, activation of serotonin receptors on ASM may lead to smooth muscle 
contraction only when ACh, which is released at low levels constitutively by the 
parasympathetic fibers, occupies M3 receptors present on ASM.   A number of studies 
support the models in which antigen challenge induces an increase in release of ACh.  Ex 
vivo studies have measured an increase in ACh levels after stimulation with antigen in 
both mouse and canine tracheal rings (55, 56).  Drugs which decrease ACh metabolism 
increased bronchoconstriction after either antigen or 5-HT challenge (45).  However, our 
finding that only the 5-HT2A receptor antagonist attenuates this response, coupled with 
evidence that supports the localization of this receptor to ASM (57) and not cholinergic 
fibers, supports the later model in which the impact of engagement of the 5-HT2A 
receptors is dependent on M3 receptors present on ASM.  The need for this “second 
signal” is not clear.  Serotonin alone can shorten smooth muscle in vitro and in ex vivo 
lung slices (57, 58), and therefore the observation that in the mouse its ability to alter 
smooth muscle activity in vivo is regulated by parasympathetic pathways is somewhat 
surprising.  However, it is interesting to speculate that this relationship represents one of 
a number of “checks and balances” designed to safeguard the patency of the airways, 
limiting the activity of smooth muscle modulators stored by mast cells, while at the same 
time allowing mast cells to safeguard the airway against infectious agents by rapid 
deployment of their arsenals of inflammatory mediators. 
 
 
 
 
 107  
 
0 20 40 60 80 10
0
12
0
14
0
16
0
80
120
160
200
240
280
320
OVA
saline*
*
*
*
*
*
*
Time (s)
%
 B
as
el
in
e 
R
L
C57BL/6 W sh/W sh
100
120
140
160
180
200
saline
OVA
**
%
 B
as
el
in
e 
R
L
0 20 40 60 80 10
0
12
0
14
0
16
0
80
120
160
200
240
280
*
*
*
*
*
*
*
* * * *
*
Time (s)
%
 B
as
el
in
e 
R
aw
0 20 40 60 80 10
0
12
0
14
0
16
0
80
120
160
200
240
280
OVA
saline
Time (s)
%
 B
as
el
in
e 
G
C57BL/6 W sh/W sh
100
125
150
175
200
**
%
 B
as
el
in
e 
R
aw
C57BL/6 W sh/W sh
90
115
140
165
190 saline
OVA
%
 B
as
el
in
e 
G
C57BL/6 W sh/W sh
0
50
100
150
200
250
Se
ru
m
 Ig
E 
(n
g/
m
l)
3.125 6.25 12.5 25 50
100
125
150
175
MCh (mg/ml)
%
 B
as
el
in
e 
R
aw
3.125 6.25 12.5 25 50
100
125
150
175
MCh (mg/ml)
%
 B
as
el
in
e 
G
A B C
D
E
F
 
 
 
 
 
 
 
 
 
 108  
Figure 2.1  Changes in airway physiology of wild-type and mast cell deficient mice 
in response to OVA and MCh.  (A) OVA challenge in sensitized mice (n=5) induced an 
immediate increase in RL that gradually returned to baseline.  Control animals (n=4) 
sensitized with OVA but challenged with saline had no change in RL over baseline 
(*P<0.05 compared to OVA/saline).  (B)  Increases in RL are dependent on mast cells, as 
there was no response in mast cell deficient Wsh/Wsh mice (n=8) after antigen challenge 
(**P<0.001 compared to all other groups).  (C)  IgE levels were comparable between 
wild-type (n=7) and mast cell deficient (n=7) mice sensitized and challenged with OVA.  
(D)  FOT measurement of airway mechanics after antigen challenge.  OVA challenge in 
sensitized mice (n=5) resulted in a significant increase in Raw but no change in G 
compared to controls (n=4) (*P<0.05 compared to saline).  (E)  Increases in Raw in 
sensitized mice are dependent on mast cells.  Sensitized Wsh/Wsh mice (n=8) had no 
response to antigen challenge (**P<0.001 compared to all other groups).  (F)  Aerosol 
methacholine (MCh) challenge in B6 mice (n=13) results in a dose dependent increase in 
both Raw and G. 
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Figure 2.2  Airway inflammation in B6 and Wsh/Wsh mice with allergic lung 
disease.  (A) There was no significant difference in serum IgE levels in wild-type (n=8) 
and mast cell deficient mice (n=6).  (B) The resulting cell profile was the same for the 
wild-type (n=6) and mast cell deficient mice (n=8), with the majority of the cells (>80%) 
being eosinophils.  (C) IL-13 levels were used to represent the amount of inflammation 
present in the airways.  There was no significant difference in IL-13 between the wild-
type (n=8) and mast cell deficient mice (n=9).  (D)  The average H&E score was semi 
quantitatively measured for each main axial airway, and did not differ between the 
C57BL/6 (n=9) and C57BL/6 KitW-sh/KitW-sh (n=9) mice.  (E) There was no significant 
difference in mucus levels in the wild-type (n=8) and mast cell-deficient (n=8) mice. 
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Figure 2.3  Anaphylactic bronchoconstriction in wild-type and mast cell deficient 
mice with allergic lung disease.  (A)  Allergic lung disease was induced by sensitization 
and repeated aerosol with OVA.  B6 mice with inflamed airways (n=5) exhibited a 
significant increase in Raw after antigen challenge but no change in G (*P<0.05 compared 
to saline).  Saline challenged controls (n=3) had no response.  (B)  Mast cell deficient 
Wsh/Wsh mice with an inflamed airway (n=7) failed to respond to antigen challenge 
(**P<0.001 compared to all other groups).  (C)  Histamine levels in B6 mice with 
inflamed airways were significantly increased after antigen injection (n=6) compared to 
levels after saline injection (n=3) (**P<0.001 compared to saline).  Histamine was 
undetectable in Wsh/Wsh  mice (n=7). 
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Figure 2.4  Pharmacological and genetic inhibition of mast cell mediator pathways 
during passive anaphylaxis.  (A) Passively sensitized leukotriene deficient (5LO-/-) mice 
and their wild-type C57BL/6 controls showed no difference in Raw after antigen 
challenge.  5LO+/+ - controls, n=3; IgE+DNP, n=6.  5LO-/- - controls, n=3; IgE+DNP, 
n=6 (*P<0.001, #P<0.001).  (B) Pretreatment of passively sensitized C57BL/6 mice with 
indomethacin (10 mg/kg), to deplete endogenous prostaglandin production, had no effect 
on Raw after antigen challenge.  Saline- controls, n=3; IgE+DNP+saline, n=6.  
Indomethacin- controls, n=3;IgE+DNP+indomethacin, n=7 (*P<0.001, #P<0.001).  (C) 
C57BL/6 mice were pretreated with either pyrilamine (40 mg/kg) or cimetidine (25 
mg/kg) to block histamine H1 and H2 receptors, respectively.  Antagonism of histamine 
receptors had no effect on anaphylactic airway constriction in passively sensitized mice.  
Saline- controls, n=3; IgE+DNP, n=13.  Pyrilamine- controls, n=3; IgE+DNP, n=10.  
Cimetidine- controls, n=3; IgE+DNP, n=13 (*P<0.001, #P<0.01, †P<0.001).  (D) 
Antigen induced airway constriction was equivalent in wild-type and PAR2-/- passively 
sensitized mice.  PAR2+/+ - Controls, n=4; IgE+DNP, n=6.  PAR2-/- - Controls, n=5; 
IgE+DNP, n=4 (*P<0.001; #P<0.001). 
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Figure 2.5  Changes in airway physiology in response to serotonin and after 
inhibition of serotonergic pathways.  (A)  Similar to antigen exposure, exogenous i.v. 
serotonin induces dose dependent increases in Raw, but no change in G (n=13).  (B)  
Vehicle treated mice (n=10) sensitized and challenged with OVA had a significant 
increase in Raw.  Pretreatment with PCPA (150 mg/kg, n=15) abolished anaphylactic 
airway constriction in actively sensitized mice challenged with OVA (**P<0.001 
compared to all other groups).  PCPA treatment had no effect on the ability of mast cells 
to degranulate; histamine levels were the same in both groups of OVA treated animals 
(n=10-15 per group).  (C)  PCPA treatment had no effect on the ability of the airway 
smooth muscle to constrict to aerosolized MCh administered after antigen challenge 
(n=3).  (D)  PCPA treatment significantly attenuated plasma serotonin levels in OVA 
challenged animals (n=4-6 per group) (*P<0.05 compared to all other groups).  (E)  
Passively sensitized serotonin transporter (5HTT)-deficient (n=4) and hererozygous mice 
(n=5) challenged with DNP had a significant increase in Raw compared to controls (n=2 
per group).  This response was similar to that of WT animals (n=5).  (*P<0.001; 
#P<0.001; §P<0.001).  (F)  Blockade of serotonin receptors with methiothepin (2 mg/kg, 
n=5) or ketanserin (12 mg/kg, n=5) abolished airway constriction after antigen challenge 
in passively sensitized animals (**P<0.001 compared to all other groups). 
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Figure 2.6 Serotonin mediates antigen-induced central airway constriction in 
BALB/c mice.  Vehicle treated mice sensitized with OVA and challenged with either 
PBS (Controls, n=2) or OVA (OVA, n=5).  OVA challenged mice had a significant 
increase in Raw.  Pretreatment with 150 mg/kg PCPA (OVA+PCPA, n=4) abolished 
anaphylactic airway constriction in actively sensitized mice challenged with OVA 
(**P<0.001 compared to all other groups). 
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Figure 2.7 Anaphylactic bronchoconstriction following ablation of sensory C-fibers 
with capsaicin.  (A)  Sensory ablation with capsaicin (25-75 mg/kg) in adults (n=6) had 
no significant effect on airway constriction after antigen challenge in passively sensitized 
mice (*P<0.001, #P<0.01).  (B)  Degradation of C-fibers with capsaicin (50 mg/kg) in 
newborn mice (n=7) had no effect on airway parameters after antigen challenge in 
passively sensitized mice (*P<0.001, #P<0.001).  (C)  Antigen challenge in passively 
sensitized mice (n=10) increased substance P content in the BAL.  Neonatal treatment of 
capsaicin (n=5) reduced BAL substance P after antigen challenge to levels seen in 
control animals (n=3) (**P<0.05, compared to all other groups). 
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Figure 2.8  Antigen-induced bronchoconstriction following cholinergic inhibition.  
(A) Blockade of cholinergic nAChRs with mecamylamine (4 mg/kg, n=8) abolished 
airway constriction following antigen challenge in passively sensitized wild-type mice 
(**P<0.001 compared to all other groups).  (B) Blockade of mAChRs with atropine (10 
µM/kg, n=6) resulted in complete loss of airway constriction after antigen challenge in 
passively sensitized mice (**P<0.01 compared to all other groups).  (C)  In passively 
sensitized animals, loss of the M3 receptor (n=6) resulted in abolishment of anaphylactic 
airway constriction, whereas M1 receptor deficiency (n=6) resulted in a significant 
attenuation, but not complete loss of the response to antigen (*P<0.001, **P<0.01, 
#P<0.001, ##P<0.001, §P<0.01). 
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Figure 2.9  Vagotomy attenuates antigen and serotonin-induced changes in airway 
resistance.  (A) Passively sensitized and challenged wild-type mice after dissection of 
the vagus nerve (n=18) or a surgical sham (n=28).  Antigen challenged mice showed a 
significant increase in Raw that was abolished in vagotomized animals (**P <0.001 
compared to all other groups).  (B) Histamine levels in the BAL fluid were measured 
after induction of passive anaphylaxis.  Vagotomy did not affect the levels of histamine 
in the BAL fluid (n=5 per group).  (C) Changes in Raw were abolished after vagotomy in 
OVA challenged sensitized mice (n=7-14 per group) with allergic lung disease 
(**P<0.001 compared to all other groups).  (D) Serotonin was delivered i.v. following 
either vagal dissection or pretreatment with atropine.  Exogenous serotonin (n=11) 
resulted in a dose dependent increase in Raw that was sensitive to both vagotomy (n=5) 
and atropine (n=6) (**P<0.01).   
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Figure 2.10 Antigen-induced bronchoconstriction following vagotomy and atropine 
in BALB/c mice.  Passively sensitized and challenged wild-type BALB/c mice after 
dissection of the vagus nerve or pretreatment with atropine.  Antigen challenged mice 
(n=6) showed a significant increase in Raw compared to controls (n=3).  Airway 
constriction was abolished in vagotomized animals (n=5). Blockade of mAChRs with 
atropine (10 µM/kg, n=6) resulted in complete loss of central airway constriction after 
antigen challenge in passively sensitized mice.  No significant change in G was observed.  
(**P<0.001 compared to all other groups) 
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Figure 2.11  Airway mechanics in response to MCh challenge after vagotomy.  (A) 
Vagotomy also did not significantly affect the response to iv MCh.  MCh, n=3; 
MCh+vagotomy, n=3.  (B) Constriction of airway smooth muscle following aerosolized 
MCh was not altered following dissection of the vagus nerve.  MCh, n=7; 
MCh+vagotomy, n=7. 
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Figure 2.12  Increased airway resistance in mice treated with non-provoking doses 
of both serotonin and MCh.  B6 mice exhibited increased sensitivity to serotonin when 
coupled with exposure to a non-provoking dose of MCh.  Low levels of either i.v. 
serotonin (0.075 pg, n=3) or aerosolized MCh (6 mg/ml, n=3) does not result in a 
significant increase in Raw compared to saline challenge.  A significant increase in Raw 
was detected after non-provoking doses of serotonin and MCh were delivered together 
(n=3) (**P<0.001 compared to all other groups). 
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Abstract 
Background    Studies in both human and mouse indicate that mediators released by mast 
cells can lead to bronchoconstriction, and thus these are important effector cells in life 
threatening anaphylaxis.  Much of our understanding of the various functions of mast 
cells emanates from the study of mice lacking theses cells, particularly mice carrying 
mutations in the tyrosine kinase gene Kit.   Definitive evidence for the role of mast cells 
in the altered immune response requires the demonstration that this response can be 
normalized by reconstitution of the mice with cultured bone marrow-derived mast cells 
(BMMCs). While many mast cell niches can be restored with BMMCs, this has not been 
demonstrated for mast cells present in the airways of the lung, cells poised to mediate 
bronchoconstriction during allergic responses.   
Objective  To determine if mast cell deficient KitWsh/Wsh reconstituted lines are an 
appropriate model for the study of the role of these cells in bronchoconstriction 
associated with allergic responses.    
Methods  KitWsh/Wsh mice were reconstituted with either whole bone marrow (WBM) or 
BMMCs and responses to IgE-mediated mast cell activation determined; including 
systemic hypothermia, mediator release, and bronchoconstriction in anesthetized, 
mechanically ventilated animals.   
Results  Engraftment of KitWsh/Wsh mice with WBM and BMMCs results in reconstitution 
of the central airways with mast cells.  While the treatment of the two groups of animals 
resulted in similar systemic changes when challenged with IgE/Ag in a model of passive 
anaphylaxis, bronchoconstriction was observed only in KitWsh/Wsh animal which had 
received a bone marrow transplant.  
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Conclusions  While BMMCs can populate the lung, they cannot restore IgE/Ag-mediated 
bronchoconstriction to mast cell-deficient animals.  This suggests that the mast cell 
population which mediates this function may be unique, and to fill this niche in the lung 
cells must undergo a specific developmental program, one that is no longer available to 
cultured mast cells.   
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Introduction 
Mast cells arise as precursors in the bone marrow.  This precursor cell is released 
into the blood stream and then migrates to various tissues where it undergoes its final 
differentiation, a process which is believed to be influenced by the local environment.  At 
all stages of maturation mast cells express the receptor tyrosine kinase (CD117, c-KIT) 
and require the Kit ligand, stem cell factor (SCF), for survival.  In the mouse, c-KIT and 
SCF are encoded at the white spotting (W) and steel (Sl) loci, respectively.  Mutations in 
the W and/or Sl loci results in deficiencies in the production of melanocytes, germ cells, 
and hematopoietic cells (reviewed in (1)).  While several mutations at this locus have 
been described, the most common mutations used for studying mast cells in mice are 
Sl/Sld, W/Wv, and Wsh/Wsh.  The KitW/Wv  (Wv) mouse, is a compound heterozygous 
animal, with the mutation deleting segments of the Kit coding region.  In contrast, 
analysis of Kit in KitWsh/Wsh  (Wsh) mice revealed no alteration in either the sequence or 
organization of the gene, but rather an inversion in the regulatory region (2, 3).  While all 
these mutations lead to profound mast cell deficiencies, as well as absence of coat 
pigment, Sl/Sld and W/Wv mutant mice are also anemic and sterile, phenotypes which are 
not seen in Wsh/Wsh mice.  Therefore, the Wsh mouse has increasingly been used for 
study of mast cell function: the fertility of these mice simplifies the generation of these 
animals and their intercross with lines carrying other mutations. 
Due to the lack of mast cells in the Wsh and Wv mice, alterations in the response 
of these lines to various pathogens and in models of autoimmune disease has been 
broadly used to support a role for the mast cells in these immune responses (4-7).  
However, because the phenotype of lines lacking mast cells is not limited to this cell 
 137
type, confirmation of mast cell function is dependant on the demonstration that the deficit 
in these mice can be corrected by restoration of the mast cell population.  This can be 
done in one of two ways.  The mice can be reconstituted with whole bone marrow 
(WBM) isolated from a wild type congenic animal.  Alternatively, mast cell cultures can 
be established from bone marrow of wild type animals.  Once the purity of these cultures 
is verified, these cells can be introduced into the Wsh or Wv mouse.  The primary 
advantage of this later approach is that only the mast cell compartment is of donor origin: 
when total bone marrow is used, other hematopoetic compartments are also restored.  The 
use of Wsh and Wv mice reconstituted with BMMCs has become increasingly common 
with the availability of mast cell cultures derived from mice carrying mutations generated 
by homologous recombination.  This has allowed the identification of the role of specific 
pathways within mast cells, as well as assignment of mast cell mediators to specific 
pathophysiological changes during the immune response.   
Mucosal type mast cells in the lung are intimately involved in allergic immune 
responses and are known to contribute to airway reactivity and hyperresponsiveness in 
models of anaphylaxis and asthma.  In normal mice, mast cells are located throughout the 
main airways including within the trachea and bronchus, with few mast cells being found 
within the parenchyma (8).   Histological analysis has demonstrated the presence of mast 
cells in the lung of Wsh mice reconstituted with both WBM and BMMCs (9-11).  In the 
latter case, however, there has been disagreement on the extent to which the BMMCs can 
reconstitute various regions of the lung.  Although it is generally accepted that BMMCs 
cannot reconstitute the trachea, histological studies by Wolters and colleagues (11) 
showed mast cells close to or within the smooth muscle layer of the airways of 
 138
reconstituted Wsh mice.  Conversely, studies by Grimbaldeston et al. (10) only noted 
reconstitution of mast cells in the lung parenchyma of Wsh mice engrafted with BMMCs.    
Immunological studies also indicate that BMMC reconstitution can restore the 
immune response of Wsh mice, including their response in ovalbumin-induced models of 
asthma (12).  Some studies have also evaluated airway hyperresponsiveness (AHR) in the 
reconstituted mice (12-14).  In these instances the response of the mice to inhaled 
methacholine, a stable derivative of Ach which acts directly on the smooth muscle wall to 
elicit airway constriction, was evaluated and shown to be restored in the reconstituted 
animals.  However, it is not unlikely that restoration of AHR in the Wsh mice that 
received BMMCs was the indirect consequence of normalization of the immune 
response.  The possibility remains that, while some mast cell functions are restored in the 
Wsh mice, the mechanism(s) by which these cells contribute to pathophysiology during 
inflammation may not completely mimic that of a normal animal.   
Recently we have shown that mast cells interacted with the parasympathetic 
pathways in the lung to mediate bronchoconstriction during anaphylaxis: the response 
was absent in Wsh mice but also absent in mice in which the parasympathetic pathways 
are inhibited (15).  This suggests that interactions between mast cells and neurons 
regulate airway caliber during inflammatory responses and raises the possibility that a 
unique subpopulation of mast cells may be required for this function.  To begin to address 
this question we evaluated the ability of culture bone marrow derived mast cells to restore 
this response in the Wsh mice.   
 
 
 139
Methods 
Experimental animals 
Mast cell deficient C57BL/6 KitW-sh/W-sh mice and their wild-type C57BL/6J controls were 
purchased from Jackson Laboratory.  All studies were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee (IACUC) guidelines of 
the University of North Carolina at Chapel Hill. 
 
Reconstitution of mast cell-deficient mice 
Whole bone marrow:  Bone marrow cells were collected from femurs of wild type 
C57BL/6J or C57BL/6 KitW-sh/W-sh mice.  Whole bone marrow (WBM) cells were 
centrifuged at 1200 rpm for 5 min and resuspended in PBS (200µl per animal of bone 
marrow).  Recipient mice were irradiated before WBM injection with a split dose of 10 
Gy (two 5-Gy doses 3 h apart).  WBM was injected i.v. via the tail vein into 4-8 weeks 
old C57BL/6 KitW-sh/W-sh recipient mice.  Animals were analyzed after 12 weeks. In order 
to distinguish the effect of mast cells in bone marrow reconstituted animals, we compared 
C57BL/6 KitW-sh/W-sh animals reconstituted with WBM from C57BL/6J mice with 
C57BL/6 KitW-sh/W-sh animals reconstituted with WBM from C57BL/6 KitW-sh/W-sh mice. 
BMMCs: Bone marrow was harvested from C57BL/6J mice and cultured in the 
presence of 5 ng/ml recombinant IL-3 and 10 ng/ml recombinant stem cell factor (SCF). 
Cells were cultured for 5 weeks, when cell populations consisted of >95% mast cells as 
assessed by expression of c-Kit and FcεRI on cell surface by fluorescence activated cell 
sort analysis (FACS).  Ten million BMMC in 200 µl of PBS were injected i.v. via the tail 
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vein into 3-9 week old C57BL/6 KitW-sh/W-sh mice.  Mice were analyzed 12-16 weeks after 
injection. 
 
Anaphylaxis protocols   
Passive systemic anaphylaxis (PSA): Mice were sensitized with 20 µg mouse 
monoclonal anti-DNP IgE (1.0 mg/ml, Sigma Chemical; 200 µl total volume in PBS) or 
an equal volume of PBS i.v. through the tail vein.  Approximately 19-24 hours after anti-
DNP IgE injection, mice were injected with 250 µl of 5 mg/ml DNP and rectal 
temperature monitored every 10 min for 40 min. 
IgE-dependent passive anaphylaxis:  Mice were sensitized with 20 µg mouse 
monoclonal anti-DNP IgE or an equal volume PBS i.v. through the tail vein, as described 
above.  Approximately 19-24 hours after anti-DNP IgE injection, mice were anesthetized, 
catheterized, tracheostomized and mechanically ventilated as previously described (16).  
Immediately following the baseline measurements, 250 µl of 5 mg/ml DNP (or an equal 
volume of PBS) was injected into the jugular vein.  After administration, airway 
mechanics were determined using the Forced Oscillatory Technique (FOT) every 10 s for 
3 min.   Bar graphs represent the area under the curve. 
 
Histology 
For histopathologic examination, lungs were fixed by inflation (20 cm pressure) and 
immersion in 10% formalin.  After paraffin embedding, 5-µm sections were cut and 
stained with toluidine blue.  Positively stained mast cells were counted in longitudinal 
sections through one mainstream bronchus.  Mast cell numbers for each mouse were the 
average of the counts in 10 randomly selected 10× high-power fields on each slide. 
 141
Receptor expression analysis of BMMCs 
RNA was collected from 1 million BMMCs using RNAbee reagent (Qiagen).  RNA was 
then converted to cDNA using a High Capacity cDNA RT kit (Applied Biosystems) and 
FcεRI-α, FcεRI-β, and tryptophan hydroxylase (Tph1) expression was assessed by real-
time PCR using commercially available probes (Applied Biosystems).  Results were 
standardized to GAPDH expression. 
 
Analysis of histamine release from mast cells 
Mice were sensitized with 20 µg mouse monoclonal anti-DNP IgE or an equal volume 
PBS i.v. through the tail vein, as described above. Approximately 19-24 hours after anti-
DNP IgE injection, mice were injected with 250 µl of 5 mg/ml DNP i.v. through the tail 
vein.  2 min following injection of antigen, mice were sacrificed by inhalation of CO2 and 
0.5-1.0 ml of blood collected by cardiac puncture with a syringe containing 20 µl 100 
U/ml heparin.  The blood was then centrifuged at 12000 rpm for 5 min to collect plasma.   
Bronchoalveolar lavage was performed five times with 1.0 ml of sterile HBSS each time.  
The recovered fluid (BALF) was centrifuged to remove cells.  Histamine levels were 
measured in the plasma and BALF cell-free supernatant by ELISA (Beckman Coulter).   
 
Statistical analysis 
Data are represented as means ± SEM.  Analysis Of Variance (ANOVA) followed by 
Tukey-Kramer Honestly Significant Difference for multiple comparisons was performed 
on complex data sets.  Statistical significance for single data points was assessed by 
Student’s two-tailed t-test.  A P value of <0.05 was considered statistically significant. 
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Results 
Engraftment with WBM and BMMCs can reconstitute peripheral responses to passive 
systemic anaphylaxis (PSA) 
Cohorts of Wsh mice were reconstituted with either cultured isogenic C57BL/6 
BMMCs or with WBM cells isolated from C57BL/6 mice.  Control groups received bone 
marrow cells from the Wsh mice. This provides a control for the repopulation of cell 
linages in addition to mast cells that may be absent or compromised in the Wsh mice.  
Wsh mice receiving bone marrow were exposed to low doses of irradiation.  Eight weeks 
after reconstitution we examined the response of the groups in a model of IgE mediated 
anaphylaxis which previously has been shown to be mast cells dependant.  Mice received 
i.v. monoclonal IgE and after 24 hours were exposed to antigen.  This treatment results in 
systemic anaphylaxis, characterized by lethargy, hypotension, airway obstruction, and 
hypothermia (17, 18).  To quantitate these changes, we monitored the drop in body 
temperature associated with this response.  No change in temp was observed in the Wsh 
mice, consistent with the lack of mast cells in these animals.  A rapid and sustained drop 
in body temperature was observed in the mice reconstituted with both the cultured 
BMMC and with the bone marrow cells.  This response was similar to that observed in 
wild type mice (Figure 3.1). 
 
WBM and BMMCs transfer results in reconstitution of mast cell populations in the 
central airways 
The systemic shock leading to drop in body temperature in response to IgE and 
antigen is mediated by the release of mast cell histamine in the blood stream (19), which 
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is thought to act in the hypothalamus to trigger this response (20), and therefore would 
not be dependent on reconstitution of various mast cell populations in the lung.  To 
address this, we therefore first carried out histological examination of the lungs, 
comparing the number and distribution of mast cells in wild type mice, mice reconstituted 
with BMMCs and mice reconstituted with WBM.  Consistent with previous studies of the 
Wv mast cell deficient line (9), no mast cells were detected along the main bronchi of 
Wsh mice (Figure 3.2A), locations at which these cells were easily observed in the 
C57BL/6 mice.   No mast cells were detected in the parenchyma of C57BL/6 mice or the 
Wsh animals (Figure 3.2B).  Reconstitution of Wsh mice with WBM or BMMCs 
resulted in remarkably increased numbers of mast cells along the central airways, as well 
as some mast cells present in the lung parenchyma (data not shown).  This increase in 
mast cell number was even more pronounced in the mice reconstituted with WBM 
(Figure 3.2C-E).  The increase in total mast cell numbers in the reconstituted animals 
was in part due to mast cells present in the parenchyma of the lung, a region in which few 
mast cells are observed in wild type mice.  No apparent difference was noted in the 
location of the mast cells within the airways of the wild type, BMMC, and WBM 
reconstituted animals. 
  
Allergic bronchoconstriction is recapitulated in Wsh mice after reconstitution with WBM 
but not with BMMCs 
As both BMMC and WBM reconstitution of Wsh mice resulted in mast cells 
present in elevated numbers in the airways and parenchyma, we next asked whether the 
reconstituted mice would respond to allergen and IgE with a comparable increase in the 
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level of bronchoconstriction.  To address this question we again treated mice with 
monoclonal IgE.  After 24 hour mice were anesthetized, tracheotostimized and 
mechanically ventilated.  Antigen was then delivered via a jugular catheter and the 
changes in airway resistance determined using the Forced Oscillation Technique to 
measure respiratory system input impedance and evaluate the Constant Phase Model. 
This technique allows for unique distinction between central and peripheral lung 
mechanics.  As expected, treatment of the B6 mice that had received anti-DNP IgE 
showed a significant central airway constriction (Raw) after challenge with DNP when 
compared with sensitized animals that received a PBS challenge.  This response was 
absent in antigen challenged Wsh mice: no bronchoconstriction was observed and their 
airway mechanics did not differ from the PBS-challenged controls.   
As expected, this response was observed in the Wsh mice in which the mast cell 
population had been reconstituted by a bone marrow transplant: the increase in airway 
resistance in the antigen treated animals did not differ significantly form the wild type B6 
animals (Figure 3.3A).  To verify that the response observed in these animals was in fact 
due to reconstitution of mast cells and not the indirect consequences of the bone marrow 
transplant we examined cohorts of Wsh reconstituted with Wsh marrow.  As expected, 
the airways of Wsh mice reconstituted with Wsh WBM did not constrict following 
antigen challenge. 
We next evaluated the response of Wsh mice in which the mast cell population 
had been reconstituted with BMMCs.  Again mice were treated with IgE, ventilated, and 
changes in airway resistance monitored during and after iv delivery of antigen.  No 
change in Raw was observed in these animals (Figure 3.3B).  This was surprising given 
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the high number of mast cells in the lungs of these animals and the hypothermia 
secondary to PSA observed on treatment of similar groups with IgE and antigen.  
 
Release of mast cell mediators in Wsh reconstituted populations   
 It is possible that lack of airway constriction in BMMC engrafted Wsh mice was 
due to improper receptor and/or mediator expression; therefore we characterized the 
BMMCs in vitro and analyzed their receptor expression and ability to degranulate.  FACs 
analysis revealed that BMMCs expressed both c-kit and the FcεRI receptor (Figure 
3.4A), two markers synonymous with mast cells.  Real-time PCR analysis of BMMCs 
also indicated the presence of both α and β chains of FcεRI (Figure 3.4B), and IgE-
dependent activation of BMMCs in vitro was confirmed by measuring hexosaminidase 
release after antigen challenge (data not shown).  It has been shown that mast cell-derived 
serotonin is responsible for antigen-mediated central airway constriction (15).  
Tryptophan hydroxylase, the enzyme required for serotonin synthesis, was also 
abundantly expressed in BMMCs (Figure 3.4B).   
  One possible explanation for the differences between the phenotype of the Wsh 
reconstituted by WBM versus BMMCs is that the BMMC-derived cells do not produce or 
release mast cell mediators necessary for bronchoconstriction in quantities similar to 
those released by mast cells differentiated from hematopoetic precursors.  To begin to 
address this we used histamine as a surrogate marker for mast cell degranulation, 
comparing histamine release in both the bloodstream and lungs of WBM and BMMC 
reconstituted Wsh mice after sensitization and challenge with antigen.  Antigen challenge 
of wild-type B6 mice resulted in elevated levels of histamine in both BALF and blood, 
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while histamine was undetected in both PBS challenged controls and mast cell-deficient 
Wsh mice (Figure 3.5A-B).  Following antigen challenge, histamine levels in both BALF 
and blood of WBM reconstituted Wsh mice were comparable to similarly challenged B6 
mice (Figure 3.5A-B).  Wsh mice reconstituted with BMMCs had significantly 
attenuated levels of histamine in their BALF after antigen challenge (Figure 3.5A).  
However, this deficit was limited to the airways as circulating levels of histamine were 
comparable to both B6 and WBM engrafted mice (Figure 3.5B).  Despite this difference, 
quantity of granules in lung mast cells of WT and reconstituted Wsh mice appeared 
equivalent after histological examination (Figure 3.6A-C). 
 
Discussion 
Antigen mediated degranulation of mast cells in the airways can lead to life 
threatening bronchoconstriction, presumably through the actions of chemical mediators 
stored in mast cell granules on airway smooth muscle.  Similarly in mice, an increase in 
airway resistance can be measured in response to treatment with IgE and antigen.  The 
dependence of this response on mast cells is supported by the failure to observe 
bronchoconstriction in Wsh mice (15).  The lack of mast cells in Wsh mice and the 
ability to restore many mast cell functions by reconstitution of this mouse line with 
cultured bone marrow derived mast cells suggests that this strategy could also be used to 
investigate the mechanism(s) by which mast cells alter smooth muscle physiology in the 
lung and mediate bronchoconstriction in response to antigen challenge.  However, we 
report here that, while mast cells are observed in Wsh mice reconstituted with BMMCs 
there are important qualitative differences between these populations and those in both 
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wild type mice and mice reconstituted with hemaotopoetic stem cells from whole bone 
marrow.  A critical mast cell function in the lung, the ability to alter smooth muscle tone, 
is not restored in these animals.   
There are a number of possible reasons for the lack of response in reconstituted 
Wsh mice.  Wsh mice carry a mutation in the regulatory region upstream of the ckit 
promoter which negatively effects the expression of ckit in a tissue-specific manner.  This 
limits the development of mast cells.  However, altered expression of ckit has additional 
consequences including cardiac hypertrophy, splenomegaly with expanded myeloid and 
megakaryocyte populations, and bone marrow abnormalities such as neutrophilia and 
thrombocytosis (21).  In addition, the Wsh mutation also results in alteration in the 
development of interstitial cells of cajal (ICC).  ICCs in the gut serve as “pacemaker” 
cells that trigger gut contraction and have also been shown to modulate 
neurotransmission (22, 23).  Other smooth muscle containing tissues are also known to 
contain these cells, although their function in other tissues is still being investigated.  
Therefore it is possible that the lack of ability of BMMCs to restore function may reflect 
the fact that attenuated bronchoconstriction is not due to the loss of mast cell function, 
but rather other physiological consequences of altered ckit expression, such as alteration 
of the smooth muscle physiology or innervation of the airways.   This is not supported by 
our demonstration that the response can be restored by treatment of mice with total bone 
marrow.  However, we cannot formally rule out the possibility that a population of cells 
of hematopoietic origin, in addition to mast cells, is restored under these experimental 
conditions.       
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It is also possible that the cultured mast cells cannot efficiently reconstitute the 
lung or migrate to specific compartment of lung.  However, similar to previous studies 
(10, 11), we report that resident mast cells are observed in Wsh mice reconstituted with 
either whole bone marrow or cultures of bone marrow derived mast cells.  In fact, in our 
study the number of mast cells was dramatically increased in the reconstituted animals 
compared to wild type B6 mice.  Because mast cell-mediated airway constriction occurs 
exclusively within the central airways of wild-type B6 mice (15), mast cell location after 
reconstitution may be of particular importance when studying this reaction.  Mast cells in 
wild-type B6 mice are extremely rare in the lung parenchyma but are commonly found 
within the trachea and around the bronchi, specifically within close proximity to 
bronchial smooth muscle (8).  Wolters et al. (11) reported that 12 weeks after i.v. 
injection of 107 BMMCs, the lungs, but not trachea, of reconstituted Wsh mice contained 
mast cells, and histologically the majority of these mast cells were seen in close 
proximity of the large airways.  Conversely, the study by Grimbaldeston et al. (10), while 
supporting the inability of the trachea to reconstitute mast cells, reported that in the 
reconstituted animals the majority of the mast cells were localized to the parenchyma.  
We observed higher total number of mast cells in the animals reconstituted with both 
WBM and BMMCs.  Mast cells were observed in the submucosa of the conducting 
airways of the BMMC reconstituted mice in locations that appeared similar to those 
observed in both WBM reconstituted animals and wild type B6 animals.  However, we 
cannot rule out the possibility that there are subtle but important differences, not apparent 
using the methods employed in this study, that distinguish the location of the mast cells in 
BMMC and WBM reconstituted animals.  For example, it is possible that the location of 
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the mast cells vis a vie the neurons present in the airways is not equivalent, and we have 
recently reported interaction between these cell types is essential for bronchoconstriction 
(15).   
A second possibility is that limited differentiation pathways are available to 
cultured BMMCs, and these alter the spectrum of physiological activities in which these 
mast cells can participate. We did however verify that the BMMCs used for the 
reconstitution experiments expressed c-kit and the FcεRI receptor, as well as tryptophan 
hydroxylase for serotonin synthesis, which is the mediator required for antigen-mediated 
bronchoconstriction (15).  In addition, BMMCs are able to degranulate following IgE-
mediated activation in vitro, as measured by hexosiminidase release (data not shown).  
The normal differentiation of the BMMC after reconstitution of Wsh mice is supported 
by our demonstration that these animals displayed other pathophysiological changes 
characteristic of passive anaphylaxis.  Treatment of these animals with monoclonal IgE 
and antigen resulted in a rapid drop in body temperature.  This response is attributed to 
the action of mast cell histamine in the brain, specifically through binding to histamine 
receptors on the hypothalamus (20).    Blood histamine levels following antigen challenge 
of sensitized mice were comparable to both WBM reconstituted and wild-type mice, 
consistent with the re-establishment of the PSA response in these animals.  However, we 
cannot rule out the possibility that this maturation is attenuated in the lung mast cells 
and/or that the production of other important mediators is compromised in the BMMCs, 
as the histamine release in BALF was attenuated in animals reconstituted with these cells.     
Several studies have used Wsh mice to analyze mast cell function in allergic 
inflammation and AHR to methacholine (13, 14).  In many of these studies the 
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attenuation of AHR in the Wsh mice was restored in mice constituted with wild type 
BMMCs.  However, in these studies antigen-mediated airway constriction was not 
assessed.  It is quite likely that the ability of the BMMCs to restore AHR to methacholine 
is the result of the production of inflammatory mediators by lung mast cells and the 
impact of these mediators and/or recruited inflammatory cells on smooth muscle 
physiology.  This likely reflects a different and additional role for the mast cell in airway 
physiology, one that is independent from the ability of preformed mediators in mast cell 
granules to initiate rapid constriction of smooth muscle upon mast cell degranulation by 
IgE/antigen.   
In summary, our study suggest that while functions of mast cells can be studied in 
vivo using the Wv/Wsh reconstitution model, this does not currently include the study of 
antigen/IgE mediated bronchoconstriction.  A further study of this model, however, may 
lead to the identification of the mechanism(s) by which maturing mast cells or their 
precursor cells develop the ability to populate very specific niches in the lung and in 
other organs.  It is interesting to speculate that differences in the propensity of the mast 
cell to populate these specific sites may profoundly alter the susceptibility of individuals 
to allergic disease and or the manifestations of various symptoms of these diseases once 
they are acquired.    
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Figure 3.1  Body temperature after induction of passive systemic anaphylaxis.   Mice 
were sensitized with anti-DNP IgE.  Following antigen challenge, rectal temperature was 
recorded every 10 min for up to 40 min.  Wild-type (B6, n=2) mice exhibited significant 
reduction in rectal temperature after antigen challenge, whereas the temperature of mast 
cell-deficient (Wsh, n=2) mice increased slightly.  Reconstitution of Wsh mice with 
either WBM (WBMÆWsh, n=2) or BMMCs (BMMCÆWsh, n=2) resulted in 
temperature drop after antigen challenge.   
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Figure 3.2  Airway mast cells.  Lungs of mast cell-deficient Wsh (A), B6 (B), WBM 
reconstituted Wsh (C), and BMMC reconstituted Wsh (D) were fixed in 10% formalin 
and stained with toluidine blue for mast cell identification and viewed at 10-20x 
magnification.  Mast cells were undetected in Wsh airways (A).  Mast cells were 
visualized in close proximity to the main central airway in B6 and in both WBM and 
BMMC reconstituted animals (B-D).  The average number of mast cells in the lung was 
quanitated by counting stained cells in 10 random fields along the mainstream bronchus 
(E).  Mast cells were undetected in Wsh mice.  Few mast cells were detected in wild-type 
B6 airways, while significantly larger quantities of mast cells were detected in both 
WBM and BMMC reconstituted animals. *P<0.001, #P<0.001, ψP<0.01. 
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Figure 3.3  Anaphylactic bronchoconstriction after mast cell reconstitution of Wsh 
mice.  A)  WBM was harvested from either wild-type B6 or mast cell-deficient Wsh mice 
and used to reconstitute Wsh animals.  Non-reconstituted B6 and Wsh mice were 
evaluated for comparison.  Mice were sensitized with anti-DNP IgE, anesthetized, 
paralyzed, and mechanically ventilated.  Experimental mice were then challenged with 
antigen (DNP) and airway mechanics measured.  Control animals (B6, n=2) were 
challenged with PBS.    Significant airway constriction was seen in B6 mice (n=3) and in 
Wsh animals reconstituted with B6 WBM (B6ÆWsh, n=3) after antigen challenge.  The 
airways of Wsh and Wsh animals reconstituted with Wsh WBM (WshÆWsh, n=2) did 
not differ from control animals treated with saline.   B) Mast cells were cultured from B6 
bone marrow and used to reconstitute mast cell-deficient Wsh animals.  Mice were 
sensitized with anti-DNP IgE, anesthetized, paralyzed, and mechanically ventilated.  
Mice were then challenged with DNP and airway mechanics measured.  The central 
airways of B6 mice (n=5) constricted significantly following antigen challenge.  There 
was no response to antigen in either the Wsh (n=5) or the reconstituted animals 
(BMMCÆWsh; n=6).   
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Figure 3.4  Characterization of BMMCs.  A) Cell surface expression of FcεRI and c-
Kit was verified by fluorescence activated cell sort analysis (FACS). Mast cells were 
exposed to IgE for 2 h and stained with FITC-labeled anti-IgE antibody (right panel 
gray), PE-labeled anti-c-Kit antibody (leftpanel gray) or rat IgG1-FITC (right panel 
transparent) and rat IgG2b-PE (left panel transparent) as isotype-matched controls.  B) 
Expression of the FcεRI receptor and tryptophan hydroxylase was verified using real-
time RT-PCR from RNA collected from 1 million BMMCs.  Relative expression was 
standardized using GAPDH as a control.   
 
 
 
 
 
FcεRI- c-Kit-
Tph1 FcεRI α FcεRI β GAPDH
0.00
0.25
0.50
0.75
1.00
Fo
ld
 C
ha
ng
e
A 
B 
 157
co
ntr
ol
Ws
h B6
B6
 W
BM
-->
Ws
h
B6
 B
MM
C-
->W
sh
0
100
200
300
400
500
600 *
*
#
#
B
A
LF
 H
is
ta
m
in
e 
(n
M
)
co
ntr
ol
Ws
h B6
B6
 W
BM
-->
Ws
h
B6
 B
MM
C-
->W
sh
0
5
10
15
20
25
30
35
Pl
as
m
a 
hi
st
am
in
e 
( µ
M
)
A
B
 
 
 
 
 
 158
Figure 3.5  Histamine release following IgE-dependent passive anaphylaxis.  Mice 
sensitized with anti-DNP IgE.  24 hours following sensitization, mice were challenged 
with either DNP or PBS.  2 min after challenge, animals were sacrificed and BALF (A) 
and plasma (B) collected for analysis of histamine release.  Significant levels of 
histamine was measured in the BALF of wild-type (n=2) and WBM reconstituted Wsh 
(n=3) mice.  Histamine was detected in the BALF of BMMC reconstituted Wsh (n=3) 
mice, although the level was significantly attenuated compared to both B6 and WBM 
reconstituted animals.  Large quantities of histamine were present in the plasma of wild-
type mice and both groups of reconstituted animals.  There was no significant difference 
in plasma histamine levels between those 3 groups.  No histamine was detected in the 
BALF or plasma of either Wsh (n=2) mice or B6 mice challenged with PBS (controls, 
n=2).  *P<0.05, #P<0.05. 
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Figure 3.6 Mast cell granules.  Lungs of B6 (A), WBM reconstituted Wsh (B), and 
BMMC reconstituted Wsh (C) mice were fixed in 10% formalin and stained with 
toluidine blue for mast cell identification and viewed at 100x magnification.  
Histologically, quantity of granules in lung mast cells is similar in all groups. 
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Abstract 
Thromboxane A2 (TXA2) is a potent lipid mediator released by platelets and 
inflammatory cells and is capable of inducing vasoconstriction and bronchoconstriction.  
In the airways, recent studies have demonstrated that TXA2 mediated increases in airway 
constriction is dependent on vagal innervation and that Tp receptor-mediated changes in 
airway constriction requires the expression of the M3 muscarinic acetylcholine receptor 
(mAChR).  To further define the mechanism underlying TXA2-meditated airway 
constriction, we generated mice carrying a Tp receptor locus that is sensitive to disruption 
by cre recombinase.  These mice were crossed with both nestin-cre transgenic mice, 
which express cre recombinase throughout both the central and peripheral nervous 
systems, and with SM22-cre transgenic mice, which express cre recombinase in smooth 
muscle cells.  Here we demonstrate that loss of the Tp receptor throughout the nervous 
system does not significantly affect naïve airway reactivity induced by the stable TXA2 
analog, U46619.  However, the resultant smooth muscle Tp-deficient animals 
demonstrate attenuated airway responses following aerosol challenges with U46619 and 
also exhibit attenuated TXA2-mediated airway hyperreactivity (AHR) to cholinergic 
stimuli.  Conversely, in the inflamed airway, receptor contribution switches to 
dependence on neural Tp receptors.  Following OVA-induced inflammation, smooth 
muscle Tp-deficient mice regain responsiveness to U46619, while the response in neural 
Tp-deficient mice is lost. These findings suggest that TXA2 mediates airway reactivity in 
the naïve lung through collaborations involving smooth muscle Tp receptors but through 
neural Tp receptors in the inflamed lung. 
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Introduction 
Since its discovery and description as the active extract from human platelets (1), 
thromboxane A2 (TXA2) has been the focus of intense research describing the 
interactions of this prostanoid with components of the cardiovascular system.  Production 
of TXA2 results in the promotion of platelet aggregation, increased cholesterol loading, 
and vascular smooth muscle proliferation (2).  However, in addition to balancing proper 
cardiovascular health, TXA2 is also capable of inducing potent smooth muscle 
constriction, which can influence diverse physiological processes including 
vasoconstriction, bronchoconstriction, uterine contractions, and intestinal contractions.  
Similar to other prostanoids, TXA2 synthesis is initiated by the oxidation of arachidionic 
acid (AA) by either cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) into 
prostaglandin H2 (PGH2).  The thromboxane synthase enzyme (TXAS) catalyzes the 
isomerization of PGH2 to generate TXA2, which has a very short half-life in aqueous 
solution and is rapidly hydrolyzed to the stable inactive metabolite thromboxane B2 
(TXB2).  Because of this instability, most experimental studies of TXA2 biology have 
utilized stable TXA2 mimetics such as U46619 (3-5).  TXA2 exerts its biological 
functions through interactions with the heterotrimeric G protein-coupled thromboxane 
prostanoid (Tp) receptor (6-9).  All of the known physiologic functions of TXA2 are 
dependent upon the expression of this receptor, which associates with the Gq family of 
proteins and asserts most of its physiological actions through the activation of 
phospholipase C (PLC) and increases in intracellular calcium concentrations ([Ca2+]i). 
Pharmacological assessments with selective TXA2 antagonists and conventional Tp 
receptor deficient mouse lines have been crucial in implicating TXA2 in a number of 
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pathophysiological conditions including cardiovascular disease (10), intrauterine growth 
retardation (11), various kidney diseases (12-14), and angiogenesis (15).  In addition to 
these disorders, pharmacological and genetic approaches have been essential in 
establishing TXA2 as a potent mediator of human and mouse airway constriction, where 
it has been shown to be capable of influencing a variety of mechanisms associated with 
lung diseases such as asthma and chronic obstructive pulmonary disease (COPD)(16-19).  
However, the intrinsic limitations of pharmacological assessments (potency, specificity, 
and dosage) have hampered efforts to explore many of the underlying mechanisms 
affecting these pathophysiological processes.  Likewise, conventional Tp receptor-
deficient mice, which lack functional Tp receptors in all cell types, lack the resolution to 
discern which Tp receptors are responsible for specific physiological outcomes.  This is 
especially troublesome in tissues where multiple cell types express Tp receptors. 
Bronchoconstriction is a dynamic process that involves airway smooth muscle 
(ASM) and parasympathetic innervation, and can also be influenced by bronchial 
epithelial cells and leukocytes.  Each of these cell types has been suggested to express Tp 
receptors (20-25), thus the classical pharmaceutical and genetic techniques are inadequate 
to further define the in vivo mechanism underlying TXA2 induced ASM constriction.  
Considerable evidence has suggested that TXA2 mediates ASM constriction through 
neural mechanisms affecting acetylcholine release (19, 26, 27).  Indeed, the Tp receptor 
has been found expressed on neurons and in discrete regions of the brain, where TXA2 
has been implicated in the proliferation and survival of oligodendrocytes (28, 29).  Direct 
evidence has also demonstrated that these receptors are present on peripheral and/or 
sensory nerves of the mouse, pig, and rabbit (30-32).  Here we directly assess the 
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contribution of neurally expressed Tp receptors in mediating airway reactivity by 
generating mice carrying a Tp locus that is sensitive to disruption by cre recombinase.   
In addition to neural expression, Tp receptors are also abundantly expressed on 
ASM cells.  To evaluate the role of these receptors, mice carrying the floxed Tp locus 
were crossed with a mouse line in which cre expression is under the control of the smooth 
muscle specific SM-22 promoter.  Here we demonstrate that, in vivo, smooth muscle-
specific Tp receptor-deficient mice exhibit attenuated increases in airway reactivity in 
response to U46619, as well as, attenuated U46619-mediated AHR to cholinergic stimuli 
in the naïve lung.  These findings suggest that TXA2-induced ASM constriction and AHR 
in the naïve airway are predominately mediated by Tp receptors expressed by the smooth 
muscle.  Conversely, in the inflamed airway, smooth muscle Tp receptor-deficient mice 
regain reactivity to U46619 following OVA-induced inflammation while neural Tp 
receptor-deficient mice are unresponsive.  This suggests differing mechanisms mediating 
TXA2-induced airway reactivity in naïve and inflamed airways.  
 
Methods 
 
Generation of mice carrying a Tp locus sensitive to Cre-mediated disruption.  
Segments of the Tp receptor gene were amplified by PCR.  The resultant PCR products 
were utilized to create a plasmid capable of undergoing homologous recombination with 
the endogenous locus and in doing so, introduce loxP sites flanking the major coding 
exon of the Tp receptor (Figure 4.1).  Three fragments of the Tp receptor gene were 
amplified using the following primer sets:  5’-ATAAGCTTGCGGCCGCAGTTT 
CCCTGGTGGTAC GTG-3’ and 5’-ATATCGATTAGCCCTAGCTGTCCTGGAA-3’ 
(to amplify a 3073 bp region of homology in intron 1), 5’-GCTGCCTCAAAG 
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AAAGGGTA-3’ and 5’-GTGCGG CCGCTCCTAAAGCCCCAAAGACCT-3’ (to 
amplify a 1032 bp region containing exon 2), and 5’-
GTGGATCCCTGCAGGATGTAACAGGAAAGA-3’ and 5’-GTGGTACCAGA 
ACCCATCCCAGTTCTGA-3’ (to amplify a 4424 bp region of homology in intron 2).  
These fragments were sub-cloned into the pCR 2.1 vector (Invitrogen) and sequenced to 
verify that the PCR amplification did not introduce mutations into essential sequences. 
The fragment corresponding to intron 2 was directly cloned into the pXenaLF2 vector, 3’ 
to the neomycin cassette and 5’ to the pgk-tk cassette (Figure 4.1). The pXenaLF2 vector 
contains the selectable marker gene for neomycin resistance (pgk-neo) flanked on both 5’ 
and 3’ sides by a loxP and frt site.  The fragments corresponding to intron 1 and exon 2 of 
the Tp receptor were subcloned 5’ and 3’ of the loxP cassette, respectively, in the 
pNebLox vector.  This generated a fragment of Tp receptor DNA with a loxP site placed 
in intron 1. This newly generated 5’arm-loxP-exon 2 cassette was subsequently removed 
from pNebLox and cloned into the pXenaLF2 vector, 5’ to its loxP cassette (Figure 4.1).   
The targeting plasmid was linearized with PvuI and introduced into embryonic 
stem (ES) cells derived from 129/SvEv mice and transformants were isolated using 
standard methodologies (33).  A DNA probe corresponding to the region immediately 
downstream of the targeted region (3’ probe) was generated as previously described (9) 
and a probe corresponding to exon 2 of the Tp receptor (internal probe) was generated 
using the following primer sets: 5’-GCTGCCTCAAAGAAAGGGTA-3’ and 5’-
GTGCGGCCG CTCCTAAAGCCCCAAAGACCT-3’.  These probes were used to 
identify targeted ES cells by Southern blot and were used to confirm the incorporation of 
loxP sites in successfully targeted ES cells.  These probes were also used to genotype the 
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resultant mice.  ES cells in which the plasmid integrated by homologous recombination 
and contained the loxP-exon2-loxP-flp-neo-flp cassette were used to generate chimeric 
animals, which in turn were bred to generate animals heterozygous for the floxed allele.  
The neomycin gene was then removed by breeding the heterozygous mice with 
C57BL/6J mice that express of flp recombinase in the germline (B6;SJL-
Tg(ACTFLPe)9205Dym/J, Jackson Laboratories).  Following digestion with BamHI, the 
exon 2 probe discussed above was utilized to confirm the removal of the neomycin 
cassette.   
Mice expressing cre recombinase under the control of the SM22 promoter are 
commercially available (STOCK Tg(Tagln-cre)1Her/J, Jackson Laboratory) and 
maintained on a mixed genetic background of 129S5/SvEvBrd, C57BL6, and SJL.  These 
animals have been shown to express cre throughout the smooth muscle from all tissues 
examined (34-36).  C57BL/6J mice expressing cre recombinase under the control of the 
nestin promoter are also commercially available (B6.Cg-Tg(Nes-cre)1Kln/J, Jackson 
Laboratory).  These mice express cre early in embryonic development in cell lineages 
that give rise to all neurons including sensory neurons, neurons of the CNS, and 
parasympathetic and sympathetic pathways (37).  The introduction of these transgenes 
onto the 129/SvEv background was initiated and animals were backcrossed for 7 
generations.   A DNA probe corresponding to the region immediately 5’ of the targeted 
region was generated by PCR (5’-AACCTGAGTCTGTGGG GTTG-3’ and 5’-
ACAAGCATCA AGGAGGGATG-3’) and was used, in conjunction with a BamHI 
digest, to assess Tp exon 2 removal by cre/lox in selected tissues.  129/SvEv Tp-/- mice 
were generated as previously described (9).  All animal studies were conducted in 
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accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals as well as the Institutional Animal Care and Use Committee 
(IACUC) guidelines of the University of North Carolina at Chapel Hill.   
Measurement of Tp expression in cultured airway smooth muscle cells and 
peripheral nerves.  Airway smooth muscle was isolated from tracheal explants.  Briefly, 
the trachea between the larynx and the mainstem bronchi was removed and placed in a 
sterile Petri dish containing HBSS solution with a 2X concentration of 
antibiotic/antimycotic (penicillin/streptomycin/genomycin).  The trachea was dissected 
free of surrounding tissues and epithelium was removed by rubbing the luminal surface 
with a plastic blade.  The trachea was then dissected into 2-3 mm segments and placed 
intima side down in a sterile culture dish.  Explants were allowed to adhere to dish and 
then covered with 3ml of DMEM+20%FCS+2X antibiotic/antimycotic and incubated at 
37◦C in a humidified chamber.  After 3 days of cell growth, FCS was reduced to 10% and 
antibiotic/antimycotic to 1X.  At confluent density, cells were harvested for RNA 
collection.  
Nodose and superior cervical ganglia (SCG) were collected from 5-6 mice and 
snap frozen in liquid nitrogen.  Pools of ganglia were homogenized using a glass pestle 
prior to RNA collection.  RNA was collected using RNAbee reagent (Qiagen) and was 
converted to cDNA using a High Capacity cDNA RT kit (Applied Biosystems) and Tp 
receptor expression was assessed by real-time PCR using a commercially available Tp 
probe and 18S probe as an internal control (Applied Biosystems).  Data is shown relative 
to 129Sv/Ev Tp+/+. 
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Measurement of Airway Reactivity in Intubated Mice.  Mice were 
anesthetized with 70-90 mg/kg pentobarbital sodium (American Pharmaceutical Partners, 
Los Angeles, CA), tracheostomized, and mechanically ventilated at a rate of 300 
breaths/min, tidal volume of 6 cc/kg, and positive end-expiratory pressure of 3-4 cm H2O 
with a computer controlled small-animal ventilator (Scireq, Montreal, Canada).  Once 
ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide.  Following 
baseline assessments, mice were exposed to aerosol challenges via an ultrasonic AeroNeb 
nebulizer (Scireq) connected through inspiratory line of the ventilator circuit.  Animals 
were ventilated at a rate of 200 breaths/min for 30 seconds with a tidal volume of 0.15 
mls.  Airway mechanics using the Forced Oscillatory Technique (FOT) were determined 
every 10 seconds for the following 3 minutes, as previously described (38).  Briefly, 
following passive expiration, a broadband (1-19.625 Hz) volume perturbation was 
applied to the lungs while the pressure required to generate the perturbations was 
assessed (38-40).  The resultant pressure and flow data were fit into a constant phase 
model as previously described (38, 41).  Similar to other studies assessing forced 
oscillatory mechanics, we confined our analysis to Raw (Rn; Newtonian resistance), 
which assesses the flow resistance of the conducting airways and G (tissue damping), 
which reflects tissue resistance (38, 39). To assess TXA2-mediated airway reactivity, 
mice were exposed to aerosol challenges of the stable thromboxane analog U46619 
(Caymen Chemical, Ann Arbor, MI) as previously described (17).  Briefly, mice were 
exposed to a 30-second aerosol dose response challenge of 10-5 M, 10-4 M, and 10-3 M.  
Following each aerosol challenge, airway responses were assessed for 3 minutes as 
previously described.   
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Because thromboxane has also been suggested to induce airway hyper-
responsiveness, we also assessed the increases in airway mechanics to methacholine 
(MCh), an acetylcholine analog, following pretreatment with a mildly provoking dose of 
U46619 in naïve mice.  Airways were exposed to a 30-second aerosol dose of U46619 
(10-5 M) or vehicle (10% EtOH) and changes in airway mechanics were assessed for 3 
minutes.  Following this exposure, mice were challenged with a 30-second aerosol dose 
MCh (3 mg/ml; Sigma Chemical, St. Louis, MO).  
Induction of allergic airway disease.  To evaluate the role of tissue specific Tp 
receptors in inflammatory cell recruitment and airway hyperresponsivenes mice were 
sensitized by i.p. injection of 20 µg OVA emulsified in 2.25 mg aluminum hydroxide gel 
in a total volume of 200 µl on day 1.  Mice were challenged (1 hour) via the airways with 
OVA (1% in saline) for 3 days (days 14-16) using an ultrasonic nebulizer (DeVillbiss 
Health Care, Somerset, PA).  On day 17 mice were anesthetized, placed on a ventilator 
and challenged with increasing doses of U46619 (10-5 M-10-3 M).  Airway measurements 
were taken every 10 s for 3 min.   
After airway measurements, mice were sacrificed and 0.5-1.0 ml of blood was 
collected by cardiac puncture.  Following coagulation, serum was collected.  Total IgE 
levels in the serum were measured by ELISA (R&D systems).  Bronchoalveolar lavage 
was performed five times with 1.0 ml of sterile HBSS each time.  Cells present in the 
bronchoalveolar lavage fluid (BALF) were determined using a hemocytometer.  A 
differential cell count was conducted on a cytospin prepared from 150 µl of BALF and 
stained with Diff-Quik solution (Sigma Chemical).  The remaining BALF was 
centrifuged to remove cells.  IL-13 levels were measured in the cell-free supernatant by 
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ELISA (R&D systems).  In some animals, the right lobes of the lung were snap frozen in 
liquid nitrogen and homogenized for RNA collection.  RNA was then converted to cDNA 
using a High Capacity cDNA RT kit and a surrogate marker of mucus production was 
assessed by real-time PCR using a commercially available Muc5a probe and an HPRT 
probe as an internal control (Applied Biosystems).  Data is shown relative to naïve lung. 
Histology.  For histopathologic examination, lungs were fixed by inflation (20 cm 
pressure) and immersion in 10% formalin.  To evaluate airway eosinophilia, fixed lung 
slices were subjected to hematoxylin and eosin (H & E) staining.  H&E stained lung 
slices were digitally imaged midway along the length of the main axial airway, as well as, 
at both ends of the same airway.  Each of the three images was then divided into 4 
quadrants and the levels of inflammation in each quadrant were semi quantitatively 
assessed based on a score of 0 (no inflammation) to 3 (severe inflammation).  Scores 
from all quadrants for each of the 3 pictures representing 1 airway were then averaged 
together to represent the average H&E score of that airway (42).   To assess goblet cell 
hyperplasia, serial sections of the left lobes of the lungs that yield maximum longitudinal 
visualization of the intrapulmonary main axial airway were analyzed following Alcian-
blue/periodic acid-schiff reaction (AB-PAS) staining. To avoid bias for a certain region, 
and to consistently view the identical region in all slides, a 2-mm length of airway, 
located midway along the length of the main axial airway, was digitally imaged. Using 
ImageJ software (NIH, National Technical Information Service, Springfield, VA), the 
area and length of the AB-PAS-stained region in the sections were measured and the data 
expressed as the mean volume density (Vs = nl/mm2 basal lamina + SEM of AB-PAS 
stained material within the epithelium) as previously described (43). 
 174
Statistical Analysis.  Data are presented as the means ± standard error of the 
mean (SEM).  Analysis Of Variance (ANOVA) followed by Tukey-Kramer HSD for 
multiple comparisons was performed on complex data sets.  Statistical significance for 
single data points was assessed by the Student’s two-tailed t-test. A p-value of less than 
0.05 was considered statistically significant. 
 
Results 
Generation of mice with tissue specific loss of the Tp receptor 
 The development of mouse lines in which loss of gene expression is restricted to 
specific populations of cells provides a powerful means with which to identify the 
effector population(s) through which a particular gene product contributes to complex 
physiological responses.  This experimental system requires the placement of loxP sites 
around a critical exon of the gene under study.  To obtain a Cre recombinase-mediated 
deletion of the Tp receptor, a targeting vector was designed which would introduce a Neo 
cassette flanked by loxP-frt sites downstream from exon 2.  A third loxP site was 
introduced into the first intron of the murine Tp receptor gene, thereby flanking exon 2, 
with loxP sites (Figure 4.1A).  Exon 2 contains the ATG start codon and encodes 6 of the 
7 transmembrane domains of the Tp receptor.  Following electroporation of the targeting 
plasmid, Southern blot analysis of the ES cell clones was used to identify those carrying a 
floxed TP allele.   
For the initial screen, ES clones were digested with BamHI and probed with a 3’ 
probe that lies outside of the targeting plasmid.  Digestion of the DNA from eight 
neomycin resistant clones produced the 7.4 kb fragment that is indicative of successful 
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integration of the targeting plasmid via homologous recombination (Figure 4.1B).  These 
clones were then probed with an internal, exon 2 specific probe to identify those 
producing a 6.5 kb fragment, which suggests that the floxed Tp exon 2 and loxP-frt-neo-
loxP-frt cassette were successfully integrated (Figure 4.1C).  The targeted ES cell clones 
were further analyzed to identify those in which the crossover event during homologous 
recombination resulted in the introduction of the 5’ loxP site in addition to the neomycin 
gene at the Tp locus.  DNA was digested with BamHI and EcoRI and analyzed by 
Southern blot using the exon 2 probe, which recognizes a 7.3 kb wild type allele and a 5.5 
kb fragment in those clones in which the crossover event failed to introduce the 5' loxP 
site.  The probe is expected to hybridize to a 3.3 kb fragment both in ES cells in which 
the targeting plasmid integrated randomly and in those clones which underwent 
homologous recombination with the desired crossover event.  Clone number 7, was the 
only ES cell clone identified as clearly carrying a floxed Tp receptor exon 2 allele 
(Figure 4.1D).  Subsequent mouse lines were generated from this ES cell line. 
 Removal of the neo gene from the Tp locus of the 129 ES cell-derived mice 
required crossing the mice with the germline-flp transgenic line, which is on a C57BL/6 
genetic background.  In addition, the nestin transgene was obtained on a C57BL/6 genetic 
background, while the SM22 transgene was on a mixed genetic background 
(129S5/SvEvBrd, C57BL6, and SJL).    All resulting mice were then backcrossed onto 
the 129/SvEv background for 7 generations. 
  Because of the difficulty of obtaining sufficient numbers of experimental animals 
by simply intercrossing the TploxTp/+ and cre-transgene positive TploxTp/+ mice (only 1 in 8 
mice would be expected to be useful), we first crossed the transgenic mice with Tp-/- 
 176
animals on a 129/SvEv genetic background.  The cre-transgene positive female Tp+/- 
mice were then crossed to mice homozygous for the TploxTp allele.  Four different 
genotypes of mice were generated from this cross at approximately equal frequencies.  
The TploxTp/+ mice should behave essentially the same as wild type mice, since the 
presence of the loxP sites in the introns of the Tp receptor is not expected to affect gene 
expression.  The TploxTp/- mice generated would be expected to have a slight attenuation 
of response to U46619 based on our previous studies showing a decrease in this response 
in heterozygous animals.  The response of these mice should be indistinguishable from 
that of the cre-transgene positive TploxTp/+ animals, if Tp expression is critical in the cre 
expressing tissues, as either the smooth muscle (TploxTp/+ Tgln+ve) or neural (TploxTp/+ 
nestin+ve) tissues will essentially be +/- for the Tp receptor.  If this is not the critical 
tissue type, then these mice should behave similar to a wild type mouse.  Finally, the cre-
transgene positive TploxTp/- mice are expected to have no expression of Tp in the smooth 
muscle (TploxTp/- Tgln+ve) or neural (TploxTp/- nestin+ve) tissues and are heterozygous for 
Tp in all other tissues.  Thus the appropriate comparisons should be made between the 
cre-transgene positive TploxTp/- mice and their TploxTp/- littermates.  In summary, we would 
expect if a particular tissue is critical for a response, the following rank order of 
responses is expected (from lowest to highest):  cre-transgene positive TploxTp/- < TploxTp/- 
= cre-transgene positive TploxTp/+< TploxTp/+.   
 Southern blot analysis was utilized on select tissues to confirm successful, tissue 
specific, disruption of the Tp receptor.  Tissues were harvested from TploxTP/+ mice, which 
either carried the cre transgene under the control of the SM22 (transgelin; Tgln) promoter 
(Tgln+) or were negative for the cre transgene (Tgln-) (Figure 4.2A).  Tissues were 
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harvested that demonstrate high concentrations of smooth muscle (trachea, intestine, and 
uterus), cardiac muscle (heart), and skeletal muscle (thigh muscles), as well as, high Tp 
receptor expression (kidney).  DNA was extracted from each of these tissues and digested 
with BamHI for Southern blot analysis with probes specific for cre (data not shown), 
exon 2 (data not shown), and for a region 5’ of exon 2.  All tissues demonstrate the 
endogenous 11.2 kb fragment indicative of the wild type allele and a 4.5 kb fragment 
indicative of the floxed Tp allele.  However, an additional 3.3 kb fragment is present in 
smooth muscle containing tissues, which suggests successful disruption of the Tp 
receptor, at least in some cells (Figure 4.2A).  To verify Tp receptor loss in the ASM, 3 
denuded tracheas were pooled together from TploxTp/+ and TploxTp/- mice, which either 
carried the SM22-cre transgene or were transgene negative (Figure 4.2B).  As with the 
SM22 mice, tissues were also harvested from TploxTp/+ and TploxTp/-, which carried the cre 
transgene under the control of the nestin promoter.  The brain, intestine, and kidney were 
harvested and Southern blot analysis was performed as described above.  Animals that 
are wild type for the Tp receptor (Tp+/+ and the TploxTp/+ mice) demonstrate an 11.2 kb 
fragment, while mice that carry the Tp receptor disrupted by insertion of a neomycin 
cassette (TploxTp/- nestin+, and TploxTp/- mice) demonstrate a 4.1 kb fragment (Figure 
4.2C).  In non-neuronal tissues (kidney and intestine) a 4.5 kb fragment is present that 
represents the intact floxed Tp receptor.  However, in the brain, a 3.3 kb fragment is 
generated in the nestin+ mice, which is indicative of successful neural disruption of the 
Tp receptor by cre recombinase (Figure 4.2C).   
 To verify loss of Tp receptors specifically in ASM and peripheral neurons in cre-
transgene expressing mice, Tp expression in tracheal smooth muscle cultures and 
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nodose/SCG ganglia pools was verified by real-time PCR (Figure 4.3A-B).  Relative to 
wild-type 129/SvEv, expression of Tp receptors in ASM and peripheral ganglia in  
TploxTp/- Tgln+ve mice (Figure 4.3A) and TploxTp/- Nestin+ve mice (Figure 4.3B), 
respectively, did not differ from that seen in Tp-/- mice, verifying the loss of this receptor 
in those tissues.  In addition, heterozygous mice exhibited approximately half the 
expression compared to wild-type animals.   
 
Neurally deficient Tp receptor mice demonstrate increased airway resistance (Raw) 
and tissue damping (G) following stimulation with U46619  
Initial reports suggest that TXA2 contributes to ASM constriction through the 
potentiation of vagal nerve neuro-effector transmission (18).  Inflammatory mediators 
such as TXA2 could affect neural activity at a variety of levels, including the primary 
afferent sensory nerve, autonomic ganglia, and autonomic neuroeffector junction.  If this 
hypothesis were true, we would expect that U46619 induced increases in Raw and G 
would be severely attenuated in mice with reduced neural expression of Tp receptors.  
U46619 induced a significant, dose dependent increase in both Raw and G in 129/SvEv 
wild type mice (Tp+/+), while Tp receptor deficient animals (Tp-/-) were unresponsive 
(Figure 4.4A-B).   No significant differences in Raw or G were observed between the 
TploxTP/+ wild type mice, the TploxTp/- nestin+ve neurally deficient Tp receptor mice, the 
TploxTp/- heterozygous mice, or the TploxTp/+ nestin+ve neurally heterozygous Tp receptor 
mice (Figure 4.5A-B).  
 
 
 179
Airway reactivity is attenuated in smooth muscle Tp receptor deficient mice after 
exposure to U46619 
 Neural disruption of the Tp receptor failed to significantly attenuate airway 
reactivity to U46619, suggesting that TXA2 mediated airway constriction may be 
mediated by other cell types known to express the Tp receptor.  TXA2 receptor 
expression by smooth muscle cells is well documented, as is the ability of Tp receptor 
activation to mediate increases in [Ca2+]i in cultured human primary ASM cells (44).  
Here, we sought to examine the possibility that TXA2-mediated increases in airway 
reactivity could be mediated by Tp receptors located directly on ASM cells.  If this 
hypothesis were true, we would expect that U46619-induced increases in Raw and G 
would be severely attenuated in mice with reduced expression of TP receptors on smooth 
muscle.  As mentioned above, U46619 induced a significant, dose dependent increase in 
both Raw and G in wild type mice (Tp+/+), while Tp receptor deficient animals (Tp-/-) were 
unresponsive.   Like the Tp-/- animals, the TploxTp/- tgln+ ve smooth muscle receptor 
deficient mice also demonstrated a significantly attenuated Raw response compared to 
both  TploxTp/- heterozygous and TploxTp/+ wild type mice.  The heterozygous TploxTp/- 
animals demonstrated an intermediate phenotype with a significantly enhanced Raw 
compared with the TploxTp/- tgln+ve smooth muscle receptor deficient mice and 
significantly attenuated compared with the TploxTp/+ wild type animals (Figure 4.6A).  
Similar to Tp-/- animals, no G response was observed in animals that were deficient of Tp 
receptors in their smooth muscle (Figures 4.6B).  Although a mild dose-dependent 
increase in G was seen following U46619 challenge, this response did not differ between 
the TploxTp/-, TploxTp/+ tgln+ve , and the TploxTp/+ groups.   
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Exposure to U46619 increases airway sensitivity to cholinergic stimuli in the naïve 
lung 
The ability of U46619 to induce AHR to muscarinic receptor agonists has been 
characterized in a variety of model organisms (45-47).  However, while this phenomenon 
has been identified in canine, guinea pig, and human studies, the mechanism behind this 
increased sensitivity is not well defined.  Therefore, we sought to assess and characterize 
this TXA2-mediated AHR in mice.  Both Tp+/+ and Tp-/- mice were exposed to a mildly 
provoking dose of U46619 (10-5 M).  The initial treatment with U46619 was followed, 3 
minutes later, by exposure to a weakly provoking dose of MCh (3 mg/ml).  Pretreatment 
with U46619 induced a robust MCh response in wild-type animals, but not in Tp-
deficient animals (Figure 4.7A-B).  Increased responsiveness to MCh after U46619 
challenge was evident in both the Raw (Figure 4.7A) and G (Figure 4.7B) parameter of 
Tp+/+ mice, signifying AHR in both the central and peripheral airways.  In contrast, 
U46619 pretreatment did not increase responsiveness to non-cholinergic stimulation with 
serotonin (5-HT), adenosine, PGD2, or PGF2α (Figure 4.8).   
Following the identification of a primary role for smooth muscle Tp receptors in 
mediating U46619-induced airway reactivity in the naïve model described above, we next 
wanted to assess whether induction of AHR is dependent on smooth muscle expression of 
Tp receptors, specifically the ability of U46619 to enhance the response to low doses of 
MCh in the smooth muscle Tp receptor-deficient mice and their controls (TploxTp/- 
heterozygotes).  TploxTp/- heterozygous mice had a significantly increased response to 
MCh in the central airways (Raw) following pretreatment with U46619 (Figure 4.7C).  
This AHR was not seen in the smooth muscle Tp-deficient animals.  Although the 
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heterozygous mice also trended towards AHR to MCh after U46619 challenge in the 
peripheral airways, this response was not statistically significant (Figure 4.7D).  
Pretreatment of smooth muscle Tp-deficient mice with U46619 also failed to increase 
responsiveness to MCh in the G parameter. 
 
Airway reactivity in the inflamed airway 
Allergic lung disease was induced by sensitization and repeated aerosol 
challenges with OVA.  Control animals were sensitized to OVA but challenged with 
saline.   Aerosol challenge of U46619 induced smooth muscle Tp receptor-dependent 
central (Figure 4.9A) and peripheral (Figure 4.9B) airway constriction in saline 
challenged animals.  Saline challenged Tp-/- and smooth muscle-deficient TploxTp/- 
Tgln+ve had no response to U46619 at any dose.  Surprisingly, OVA challenged TploxTp/- 
Tgln+ve mice showed significant airway reactivity when compared to saline challenged 
animals, which implies the loss of smooth muscle Tp-receptor dependence for airway 
constriction in the inflamed airway.  General airway inflammation was the same in both 
TploxTp/- and TploxTp/- Tgln+ve OVA challenged mice; there was no difference in the 
average H&E score (Figure 4.10A), total BALF cell count (Figure 4.10B), cellular 
profile (Figure 4.10C), BALF IL-13 levels (Figure 4.10D), serum IgE (Figure 4.10E) or 
mucus production (Figure 4.10F-G) between the two groups.  As expected, these 
parameters were all elevated compared to the saline treated animals (some data not 
shown).     
Aerosol challenge of U46619 induced dose-dependent central and peripheral 
airway constriction in saline challenged animals that was independent of neural Tp 
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expression (Figure 4.11A-B).  Surprisingly, while OVA challenge increased the 
responsiveness of TploxTp/- mice to U46619, OVA challenged neural deficient TploxTp/- 
Nestin+ve mice failed to respond to U46619 when compared to saline challenged 
animals, suggesting a dependence on neural Tp receptors for this response.  This change 
in airway response was not a result of altered inflammatory conditions in the airways, as 
there was no difference in airway inflammation, BALF cellularity, BALF IL-13, serum 
IgE, or mucus production between TploxTp/- Nestin+ve and TploxTp/- mice (Figure 4.12A-
G). 
 
Discussion 
 Extensive characterization of TXA2-mediated airway reactivity has suggested that 
this potent lipid mediator indirectly induces ASM constriction by potentiating the neuro-
effector transmission of cholinergic stimuli.  The basis for this hypothesis stems from 
microelectrode and tension recording assessments of smooth muscle cells and nerve 
preparations isolated from the canine trachea.  Under these ex vivo conditions, sub-
threshold levels of TXA2 (10-10-10-7 M, depending on study) do not affect the membrane 
potential, input membrane resistance, or the sensitivity to acetylcholine of canine trachea 
smooth muscle cells; however, this concentration is sufficient to significantly increase the 
amplitude of contractions evoked by electrical field stimulation (EFS) (18, 48).  This 
amplification has been shown to be sensitive to atropine, tetrodotoxin, and selective 
TXA2 antagonists.  Expanding upon these findings, the ability of TXA2 to augment the in 
situ central airway contraction of the canine trachea following efferent nerve stimulation 
was also assessed (49).  These studies monitored airway responses to intravenous drug 
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administration and vagal stimulation by in situ isometric measurements of tracheal 
smooth muscle tension.  These data demonstrate that U46619 substantially augments the 
tracheal contraction induced by vagal stimulation.  However, when acetylcholine was 
given instead of vagal stimulation, U46619 did not enhance the tracheal contractions 
(49).  It was therefore reasoned that U46619 potentiation is caused by a pre-junctional 
action rather than by nonspecific pre-contraction of ASM with another agonist.  Based on 
previous work demonstrating that U46619 did not enhance afferent vagal stimulation of 
canine ASM (50) and the observation that canine airways lack non-adrenergic 
innervation (51), the authors presumed that TXA2 augmentation depended on efferent 
pre-junctional vagal mechanisms (49). 
 In addition to data generated with canine tracheal preparations, data that supports 
the enhancement of neural signaling via TXA2 has also been generated by assessments of 
canine bronchial preparations.  As with tracheal preparations, U46619 has also been 
demonstrated to constrict bronchial smooth muscle.  To further characterize this 
constriction, microelectrode studies demonstrated that sub-threshold doses of U46619 
(10-9 M) greatly potentiated the amplitude (252%) and the duration (over 2-fold) of the 
EFS excitatory junction potential without significantly altering the membrane potential or 
tonic contractions of the ASM (21, 52).  This pre-junctional effect was shown to be 
sensitive to TXA2 receptor antagonists and therefore suggests that U46619 is capable of 
pre-junctionally stimulating nerves, via the Tp receptor, to enhance the release of ACh 
(21).    
Based on the extensive data suggesting that TXA2-mediated ASM constriction is 
dependent on a neural mechanism, it was surprising that we did not observe a more 
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dramatic phenotype in naïve mice lacking neural expression of Tp receptors, despite 
verified disruption of the receptor in both central and peripheral nerves by southern blot 
analysis and real-time PCR, respectively.  However, it is also apparent that this potent 
lipid mediator can also mediate airway constriction though post-junctional interactions 
with the Tp receptor.  Indeed, many of the studies discussed above that effectively 
demonstrated the presence of a neurally mediated mechanism underlying TXA2-induced 
ASM constriction, also characterized post-junctional activities.  For example, as 
previously discussed, Janssen and Daniel demonstrated that U46619 was capable of pre-
junctional stimulation of nerves.  However, they also observed that U46619-induced 
membrane depolarization and powerful ASM constrictions through a mechanism that 
utilized intracellular Ca2+ rather than extracellular Ca2+ in canine bronchial smooth 
muscle preparations (21, 48).  These contractions were sensitive to a Tp receptor 
antagonist (21) and were insensitive to TTX and atropine (52).  Together, these data 
suggest that ASM Tp receptors may also have some role in influencing airway 
constriction.  Extensive data clearly demonstrates that Tp receptors are expressed on 
smooth muscle (53-55) and as discussed above, several studies have suggested that these 
receptors may functionally contribute to ASM constriction.  Consistent with this, we have 
shown that U46619-induced constriction in the naïve mouse lung is dependent on Tp 
receptors specifically located on smooth muscle.   
 A number of models could be proposed to describe possible mechanisms 
involved in the modulation of smooth muscle Tp receptor signaling in the naïve lung 
that are consistent with previous work showing a dependence on the M3 mAChR for 
TXA2-mediated ASM constriction (17).  Because Tp receptors and M3 mAChRs are 
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both present on smooth muscle, one potential model suggests that stimulation of the Tp 
receptor fails to increase intracellular Ca2+ to levels sufficient to mediate constriction.  
However, binding of TXA2 to its receptor potentates the activity of the M3 mAChR 
receptor, thereby increasing the sensitivity of this receptor to basal release of 
acetylcholine.  While this is the simplest model, other possible models can be 
envisioned, which reflect a possible modulation of M3 mAChR signaling by the Tp 
receptor.  It is well established that G-protein coupled receptors (GPCR) function via 
distinct signal transduction pathways; however, it is also accepted that “cross-talk” or 
synergy can also occur.  This synergism can occur through mechanisms such as 
heterodimerization, cross-reactions among GPCR downstream effectors, and G-protein 
redistribution (56).  While downstream effector cross-signaling has not been defined for 
Tp receptors, some evidence does suggest the Tp receptors are capable of both 
heterodimerization and cross-talk with other GPCRs via redistribution of G-proteins.  Tp 
receptors have been shown to form heterodimers with the prostacyclin receptor (IP) in 
vascular smooth muscle cells (57, 58), suggesting the possibility of heterodimerization 
with M3 receptors on ASM.  Evidence for cross-talk stems from data suggesting 
synergism between platelet PAR1 receptors and Tp receptors, as well as, anecdotal 
evidence suggesting a similar synergism between platelet-activating factor (PAF) and 
Tp receptors (59).  The PAR1/Tp synergism model describes a dynamic equilibrium 
between the Tp receptor and other GPCRs that couple to the same Gα-subunits as Tp 
(56).  Following this model, a Gα driven competition may exist between Tp and other 
GPCRs.  Upon activation, the disassociation of the Gα-subunit from these GPCRs, and 
the subsequent Gα reassociation to Tp is capable of shifting Tp to a higher affinity state 
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and thereby enhancing Tp receptor mediated signaling events (59, 60).  It is temping to 
speculate a similar synergism may exist between the Tp receptor and the M3 mAChR. 
In addition to being capable of inducing direct airway constriction, TXA2 can also 
contribute to AHR.  While the contribution of TXA2 to cholinergic AHR has been 
identified, little progress has been made at addressing the underlying mechanism.  
Previous reports have speculated that inflammation is the underlying mediator of this 
TXA2 induced AHR (16).  However, the notion that inflammation is the only factor 
mediating TXA2-mediated AHR is not possible as previous studies have demonstrated 
that the U46619-mediated enhanced MCh response has been observed in ex vivo, 
blood/leukocyte free models (47), as well as, our data presented here showing U46619-
mediated cholinergic AHR in naïve animals.  Here we show that smooth muscle Tp 
receptor activation appears to be the primary contributing factor in TXA2-mediated AHR 
to MCh in the naïve lung.  However, OVA-induced inflammation has been shown to 
induce AHR to U46619 which was mediated by both the Tp receptor and M3 mAChR 
(17).  In the current study, we show that although smooth muscle Tp-deficient mice are 
unresponsive to U46619 in the naïve lung, they regain responsiveness similar to 
heterozygous animals in the inflamed airway.  In addition to this, following OVA 
treatment, neural Tp-deficient mice failed to respond to U46619 challenge.  This would 
imply a mechanistic switch from smooth muscle Tp receptors to neural Tp receptors in 
the inflamed airway.  From the data presented, it can be envisioned that in the allergic 
airway smooth muscle Tp receptors are responsible for initial “baseline” constriction to 
U46619 while neural Tp receptors mediate enhanced responsiveness to the agonist in the 
presence of inflammation.   
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Our data extends the findings that TXA2 contributes to the development of allergic 
airway disease, and in particular to changes in airway reactivity, through its ability to amplify 
the actions of ACh.  Based on the data generated here, it is likely that the primary mechanism 
by which TXA2 enhances subsequent responses to ACh in the naïve lung is via the same 
pathway by which Tp itself brings about changes in airway reactivity: through Tp receptors 
directly on ASM.  However, upon induction of allergic inflammation, neural Tp receptors 
activation mediates airway constriction.  It is still unclear whether or not TXA2 contributes to 
the nonspecific AHR observed in asthmatic individuals; however, the improvement in 
subpopulations of asthma patients following TXA2 antagonist therapy suggests that this 
mechanism may play an important, yet limited, role in asthma pathophysiology. 
 
 188
 
 
 
 
I.
II.
III.
IV.
V.
Exon 2 Probe
Targeting 
Plasmid
ATG Stop
pgk-neo
loxP loxP-frt-neo-loxP-frt
B
X X
Murine Tp Receptor
Endogenous Locus
1 kb
Targeted 
Locus
3’ Probe
Neo Probe
1 2 3B E E A E E A A E
11.2 kb
2
BAEA
3 A E E A A E
A
E E
pgk-tk
A
pgk-neo
loxP loxP-frt-neo-loxP-frt
2
BAEA
3 A E E A A E
A
E E1 B B
6.5 kb 7.4 kb
3.3 kb
5.5 kb 
7.3 kb
5’ Probe
5’ Probe 3’ Probe
Flp Recombinase Mediated 
Removal of pgk-neo
loxP loxP-frt
2
BAEA
3 A E E A A E
A
E E1 B B
4.5 kb 7.4 kb
loxP-frt
BA
3 A E E A A E
A
E E1 B B
3.3 kb 7.4 kb Cre Recombinase Mediated 
Removal of Exon 2
5’ Probe
5’ Probe
3’ Probe
3’ Probe
BamHI Digest
3’ Probe
4    7   11 32
11.2
7.4
Exon Probe
BamHI Digest
4    7 11 32
11.2
6.5
11   7  32
7.3
5.5
3.3
BamHI + EcoRI Digest
Exon Probe
A
B C D
 189
Figure 4.1  Schematic depicting the generation of a floxed TP allele in ES cells.  A) The 
organization of the endogenous locus, the targeting plasmid, and the Tp allele generated after 
homologous recombination of the plasmid with the wild type Tp allele are shown.   The DNA 
fragments required for assembly of the targeting plasmid were prepared from genomic DNA 
isolated from 129 derived ES cells and primers designed using the sequence for the TP gene 
available in the Celera mouse genome. Fragments were cloned into the vector pXenaLF2, which 
was constructed specifically for the rapid assembly of plasmids capable of generating floxed 
alleles.   LoxP sites are denoted with triangles, frt sites by diamonds, and the neo gene is 
represented by the shaded arrow.  Relevant restriction sites are abbreviated as follows: B, BamHI; 
A, ApaI; E, EcoRI.  Greyed boxes represent coding Tp receptor exons. B-D) Southern blot 
analysis of the ES cell clones to identify those carrying a floxed TP allele.  DNA was prepared 
from neomycin resistant clones obtained after electroporation of the targeting plasmid into ES 
cells.  A 3' probe not included in the targeting plasmid was used as a first screen to identify those 
ES cell clones in which the plasmid was integrated by homologous recombination.  Eight such 
clones were identified and further analyzed using a TP exon 2 specific probe.  Some of the 
targeted ES cell clones were further analyzed to identify those in which the crossover event 
during homologous recombination resulted in introduction of the 5' lox site in addition to the 
neomycin gene at the Tp locus.  To do this, DNA was digested with BamHI and EcoRI and 
analyzed by Southern blot using the exon 2 probe.  This probe recognizes a 7.4 kb wild type allele 
and a 5.5 kb fragment in those clones in which the crossover event failed to introduce the 5'lox P 
site.  The probe is expected to hybridize to a 3.3 kb fragment both in ES cells in which the 
targeting plasmid integrated randomly and in those clones which underwent homologous 
recombination with the desired crossover event.  Clone number seven clearly represents such an 
ES cell clone. 
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Figure 4.2  Southern Blot characterization of floxed Tp mice.  A) Southern blot 
analysis of organs and tissues from Tp receptor wild type mice carrying the floxed Tp 
allele (loxTp/+) either with (Tgln+) or without  (Tgln-) the cre transgene under the 
control of the SM22 (transgelin; Tgln) promoter.  Smooth muscle containing tissues 
(Intestine and Uterus) demonstrate smooth muscle specific disruption of the Tp receptor.  
B) Southern blot analysis of tracheas harvested and pooled from Tp receptor wild type 
(loxTp/+) or Tp receptor deficient (loxTp/-) mice carrying the floxed Tp allele either with 
(Tgln/+) or without  (Tgln/-) the cre transgene under the control of the SM22 promoter.  
Airway smooth muscle specific disruption of the Tp receptor was observed in the tgln/+ 
preparations.  C) Southern blot analysis of organs and tissues from Tp receptor wild type 
(loxTp/+) or Tp receptor deficient (loxTp/-) mice carrying the floxed Tp allele either with 
(Nestin+) or without (Nestin-) the cre transgene under the control of the Nestin promoter.  
Neural specific disruption of the Tp receptor was observed in brain preparations. 
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Figure 4.3  Expression of Tp receptors in airway smooth muscle and peripheral 
ganglia.  Expression of Tp receptors in airway smooth muscle and peripheral nerves was 
confirmed by real-time PCR on smooth muscle cells cultured from tracheal explants (A) 
and pools of nodose and SCG neurons (B).  Relative to wild type mice, heterozygous 
mice exhibited approximately 50% Tp expression, whereas Tp-/- mice had no Tp 
expression.  Tp receptor expression in TploxTp/- Tgln+ve and TploxTp/- Nestin+ve mice did 
not differ from Tp-/- mice, indicating effective disruption of Tp receptors in airway 
smooth muscle and peripheral nerves, respectively. 
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Figure 4.4  Mice heterozygous for the Tp receptor (Tp+/-) demonstrate an 
intermediate response to a U46619 dose response challenge.  Increases in both A) 
airway reactivity (Raw) and B) tissue damping (G) were observed in the Tp receptor 
wildtype mice (Tp+/+), while no increases were observed for the Tp receptor deficient 
mice (Tp-/-).  Mice that were heterozygous for the Tp receptor (Tp+/-) demonstrated 
intermediate phenotypes, which were neither significantly increased compared to the Tp-/- 
mice (with the exception of the 10-4M U46619 dose under the Raw parameter) nor 
significantly reduced versus the Tp+/+ animals. Tp-/-, n = 12; Tp+/-, n = 6; Tp+/+, n = 
18.  *P< 0.05; #P< 0.05. 
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Figure 4.5  Airway reactivity of mice deficient in neural Tp receptors to U46619.  
Neural specific deletion of Tp receptors does not significantly affect airway resistance 
(A) and tissue damping (B) induced by U46619 aerosol challenge.  Tp-/-, n=4; TploxTp/- 
nestin+ve, n = 8; TploxTp/-, n = 4; TploxTp/+, n = 4; TploxTp/+ nestin+ve, n = 5.  *P<0.05. 
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Figure 4.6  Airway reactivity of mice deficient in smooth muscle Tp receptors to 
U46619.  Smooth muscle specific deletion of Tp receptors significantly attenuates airway 
resistance and tissue damping induced by U46619 aerosol challenge.  A) Airway 
resistance (Raw) and B) tissue damping (G) are significantly reduced in Tp receptor 
deficient mice carrying the floxed Tp allele and the cre transgene under the control of the 
SM22 promoter (TploxTp/- tgln+ve).  The wild type mice carrying the floxed Tp allele 
(TploxTp/+) demonstrated a significant increase in the U46619 response.  The heterozygous 
wild type mice carrying the floxed Tp allele and the cre transgene (TploxTp/+ tgln+ve) 
(thus heterozygous for the Tp receptor on the smooth muscle) and Tp receptor-deficient 
mice carrying the floxed Tp allele but no cre transgene (TploxTp/-) (thus heterozygous in 
all tissues) demonstrated intermediate phenotypes in response to U46619 challenge.  Tp-/-
, n=5; TploxTp/- Tgln+ve, n = 6; TploxTp/-, n = 4; TploxTp/+, n = 5; TploxTp/+ Tgln+ve, n = 3.  
*P<0.05, **P<0.01, #P<0.05. 
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Figure 4.7  Non-provoking dose of U46619 increases airway sensitivity to cholinergic 
stimuli.  Airways were exposed to low levels of U46619 (10-5 M) followed by 
subsequent cholinergic stimulation with low levels of MCh (3 mg/ml).  Within 3 minutes 
of vehicle or U46619 treatment, mice were exposed to an aerosol produced from a 3 
mg/ml solution of MCh, which has been demonstrated to be only mildly provoking.  
Tp+/+ mice exhibited increased sensitivity to cholinergic stimuli after challenge with a 
non-provoking dose of U46619 in both the Raw (A) and G (B) parameters.  Sensitivity of 
Tp-/- mice to MCh did not change following U46619 challenge.  Control TploxTp/- 
heterozygous mice behaved similarly to wildtype animals; sensitivity of the central 
airways (Raw) to MCh was significantly increased following U46619 challenge (C).  
While the increased sensitivity of the peripheral airways (G) to MCh was not statistically 
significant, it trended in the same manner as wildtype mice (D).  Mice lacking Tp 
receptors in smooth muscle (TploxTp/- Tgln+ve) failed to exhibit increased sensitivity to 
cholinergic stimuli following U46619 challenge.  MCh only: Tp+/+, n=4; Tp-/-, n=3; 
TploxTp/- Tgln+ve, n = 3; TploxTp/-, n = 4.  U46619+MCh: Tp+/+, n=7; Tp-/-, n=6; TploxTp/- 
Tgln+ve, n = 7; TploxTp/-, n = 8.  *P<0.05, **P<0.01, #P<0.05.     
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Figure 4.8  Airway reactivity to non-cholinergic stimulation following exposure to 
non-provoking dose of U46619.  Airways were exposed to low levels of U46619 (10-4 
M) followed by subsequent stimulation with non-cholinergic agents.  Two groups of wild 
type 129/SvEv mice were intubated and baseline lung mechanics established.  The first 
cohort of wild type mice were then exposed to vehicle followed by an aerosol produced 
from a 1x10–4 M solution of U46619. The second group of wild type mice was only 
treated with vehicle. Within 3 minutes of vehicle or U46619 treatment, all groups of mice 
were exposed to an aerosol produced from non-provoking doses of non-cholinergic 
agents.  Data are shown as the % change in Raw or G observed between challenge 1 and 
challenge 2.  A-B) The effects of exposing mice to a mildly provoking dose of U46619 
(10-4 M) followed by exposure to serotonin (5-HT; 5 mg/ml), adenosine (6 mg/ml), 
prostaglandin D2 (PGD2; 10-4 M), and prostaglandin PGF2α (PGF2; 10-4 M) were also 
assessed.  No increases in AHR were observed for any of these mediators.  PBS/5-HT, n 
= 4; U46619/5-HT, n = 4; PBS/adenosine, n = 3; U46619/adenosine, n = 3; PBS/PGD2, n 
= 7; U46619/PGD2, n = 3; PBS/PGF2, n = 12; U46619/PGF2, n = 3. 
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Figure 4.9 Airway reactivity of smooth muscle-deficient Tp mice to U46619 in an 
inflamed airway.  Allergic lung disease was induced by sensitization and repeated 
aerosol with OVA.  Control animals were sensitized to OVA but challenged with saline.  
A dose dependent increase in both airway reactivity (Raw) (A) and tissue damping (G) (B) 
were observed in the saline challenged TploxTp/- heterozygous mice in response to 
U46619.  Saline challenged smooth muscle-deficient TploxTp/- Tgln+ve had no response to 
U46619 at any dose.  OVA challenged TploxTp/- Tgln+ve mice showed significantly 
increased airway reactivity when compared to saline challenged animals, similar to that 
observed in TploxTp/- heterozygous mice.  Saline: Tp-/-, n=3; TploxTp/- Tgln+ve, n=5; 
TploxTp/-, n=7.  OVA: Tp-/-, n=2; TploxTp/- Tgln+ve, n=5; TploxTp/-, n=6.  *P<0.05. 
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Figure 4.10 OVA-induced airway inflammation in smooth muscle-deficient Tp mice. 
Allergic lung disease was induced by sensitization and repeated aerosol with OVA.  
Control animals were sensitized to OVA but challenged with saline.  Airway 
inflammation (A), total cell recruitment (B), cellular profile (C), BALF IL-13 levels (D), 
serum IgE levels (E), and mucus production, as measured by AB-PAS staining (F) and 
MUC5a expression (G), were equal in OVA challenged TploxTp/- and TploxTp/- Tgln+ve 
mice.  Saline: TploxTp/- Tgln+ve, n = 8; TploxTp/-, n = 6.  OVA: TploxTp/- Tgln+ve, n = 8; 
TploxTp/-, n = 7.  **P<0.01. 
 
 206
10-5 10-4 10-3
90
130
170
210
250
290
Tp-/- saline
Tp-/- OVA
TploxTp/- Nestin+ve saline
TploxTp/- Nestin+ve OVA
TploxTp/- saline
TploxTp/- OVA
*
*
#
#
U46619 [M]
%
 B
as
el
in
e 
R
aw
10-5 10-4 10-3
90
110
130
150
170
190
210
U46619 [M]
%
 B
as
el
in
e 
G
A
B
 
 
 
 
 
 
 207
Figure 4.11 Airway reactivity of neural-deficient Tp mice to U46619 in an inflamed 
airway.  Allergic lung disease was induced by sensitization and repeated aerosol with 
OVA.  Control animals were sensitized to OVA but challenged with saline.  A dose 
dependent increase in airway reactivity (Raw) (A) and a slight increase in tissue damping 
(G) (B) was observed in the saline challenged TploxTp/-  and TploxTp/-  Nestin+ve mice in 
response to U46619.  An increase in airway reactivity following U46619 challenge was 
seen in TploxTp/- OVA-treated mice but not in OVA-treated TploxTp/-  Nestin+ve mice.  
Saline: Tp-/-, n=3; TploxTp/- Nestin+ve, n=4; TploxTp/-, n=4.  OVA: Tp-/-, n=3; TploxTp/- 
Nestin+ve, n=4; TploxTp/-, n=6.  *P<0.05, #P<0.01. 
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 Figure 4.12 OVA-induced airway inflammation in neural-deficient Tp mice.  
Allergic lung disease was induced by sensitization and repeated aerosol with OVA.  
Control animals were sensitized to OVA but challenged with saline.  Airway 
inflammation (A), total cell recruitment (B), cellular profile (C), BALF IL-13 levels (D), 
serum IgE levels (E), and mucus production, as measured by AB-PAS staining (F) and 
MUC5a expression (G), were equal in OVA challenged TploxTp/- and TploxTp/- Nestin+ve 
mice.  Saline: Tp-/-, n=3; TploxTp/- Nestin+ve, n = 4; TploxTp/-, n = 5.  OVA: TploxTp/- 
Nestin+ve, n = 5; TploxTp/-, n = 7.  *P<0.05, **P<0.01. 
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Mechanisms of airway reactivity in the mouse 
Chapters 2 and 4 of this dissertation detail allergic and non-allergic constriction of 
the mouse airways in response to allergen and thromboxane (TXA2), respectively.  
Briefly, allergic airway constriction in the mouse is a concerted effort between mast cell-
derived serotonin (5-HT) and neurally released acetylcholine (ACh), specifically 
requiring both the 5-HT2A receptor and M3 muscarinic acetylcholine receptor (mAChR).  
TXA2-mediated constriction in the naïve airway also requires some neural input (1), as 
well as cooperation between the M3 mAChR (1) and smooth muscle Tp receptors.  In 
these examples, the method of bronchoconstriction following different stimuli is 
surprisingly similar.  However, to further define the exact mechanism being employed, 
additional experimentation is needed in both cases. 
Identifying the 5-HT2A population involved in allergic constriction 
Like the Tp receptor, the 5-HT2A receptor is found on several cell types in 
addition to airway smooth muscle (ASM) including:  neurons, vascular smooth muscle, 
epithelium, and platelets.  Although pharmacological inhibition with receptor antagonists 
is a standard method in determining receptor involvement in a given response, there are 
certain pitfalls to this approach.  The specificity of the drug, as well as the dose delivered, 
is always of primary concern when using pharmacological agents.  When possible, using 
animals with a genetic deficiency for the gene of interest is a more reliable method.  
Using homologous recombination in mice, not only can gene deletions be developed, but 
also tissue- and temporal- specific deletions.  The next step in elucidating the mechanism 
of antigen-mediated bronchoconstriction would be to determine which subset of 5-HT2A 
receptors is involved in this response.  This could be accomplished through the 
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generation of mice carrying a 5-HT2A receptor locus that is sensitive to disruption by cre 
recombinase.  These mice can then be bred to various lines of mice expressing Cre in 
specific tissues, such as neurons (Nestin-cre), smooth muscle (SM22-cre), or pulmonary 
epithelial cells (FOXJ1-cre) (2-4), to create mice with tissue-specific deletion of the 5-
HT2A receptor.  Determining the location of receptor activation would help to define the 
tissue(s) involved and lend some insight into the role it plays in the response. 
Mechanisms of 5-HT2A /Tp receptor interactions with the M3 receptor 
 For both the 5-HT2A receptor and the Tp receptor, the simplest mechanism 
involving M3 mAChR cooperation would be one in which additive effects from 
concurrent receptor activation is needed to elicit downstream Ca2+ signaling to initiate 
contraction of ASM (Figure 5.1A).  In this case, the neural component is simply 
providing basal levels of ACh which activates M3 receptors, causing a slight increase in 
intracellular Ca2+ and giving the lung a baseline tone.  5-HT2A /Tp receptor stimulation 
also increases intracellular Ca2+, although levels are insufficient to cause contraction of 
ASM.  However, activation of both receptors increases Ca2+ levels sufficiently to activate 
the contractile apparatus.   
In vivo experiments in both Chapter 2 and Chapter 4 involving non-provoking 
doses of 5-HT or TXA2 in combination with a non-provoking dose of methacholine 
(MCh), an ACh analog and M3 agonist, provides suggestive evidence for this Additive 
Effects model.  For both 5-HT and TXA2, low doses that were insufficient to cause ASM 
constriction were able to induce moderate constriction when coupled with a non-
provoking dose of MCh.  Separately, these doses of 5-HT, TXA2, and MCh were  
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Figure 4.9  Schematic depicting possible models of 5-HT2A /Tp receptor and M3 mAChR-
mediated naïve airway smooth muscle constriction.  A) Additive Effects Model:  5-HT2A /Tp 
receptor stimulation fails to increase intracellular Ca2+ to levels sufficient to mediate smooth 
muscle constriction.  Acetylcholine acts on M3 mAChRs to maintain cholinergic tone.  However, 
binding of 5-HT/TXA2 to its receptor potentates the activity of the M3 mAChR, thereby 
increasing the sensitivity of this receptor to basal release of acetylcholine and leading to increased 
intracellular Ca2+ and smooth muscle constriction.  B) Dimer Formation Model:  I) and II) 
Agonist binding to a GPCR monomer drives heterodimer formation or III) the agonist could bind 
to a preexisting dimer.  Loading the GPCR with agonist induces a conformational shift that 
allows the accommodation of the heterotrimeric G protein binding. GPCR activation results in the 
dissociation of the G protein subunits ultimately resulting in increased intracellular Ca2+ and 
increased smooth muscle constriction.  
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insufficient to elicit a response, but in combination were able to provoke airway 
constriction.  Interestingly, low doses of 5-HT or TXA2 specifically required an addition 
of MCh to induce contraction, but low doses of 5-HT in combination with TXA2 was 
insufficient to induce airway reactivity.   
One step towards confirmation of this model would be to stimulate cultured ASM 
cells in vitro with combinations of 5-HT, TXA2, and MCh and measure the resulting 
increase in intracellular Ca2+.  Although this appears to be a straightforward approach, 
cultured ASM cells undergo a degree of differentiation that rapidly decreases M3 receptor 
expression (5).  However, several studies in canine primary ASM cells have shown that 
serum starvation can give rise to a subpopulation of cells that require high M3 expression 
(6, 7).  If this system were shown to function the same way in primary cultures of mouse 
ASM, these cells could be used to elucidate the interaction between the 5-HT2A /Tp 
receptor and the M3 receptor. 
 It has been well established that G protein-coupled receptors (GPCRs) can 
function as homo- or heterodimers, and specifically the M3 receptor has been shown to 
not only exist as a monomer but to also form heterodimers with other GPCRs (reviewed 
in (8)).  Furthermore, 5-HT2A receptor heterodimerization with mGluR2 receptors in 
cortical networks of the central nervous system have been identified (reviewed in (9)), 
and Tp receptors are known to form heterodimers with prostacyclin receptors (IP) in 
vascular smooth muscle (9-11).  In addition, 5-HT2A, Tp, and M3 are all Gq-protein 
coupled, a protein commonly associated with its role in promoting ASM contraction.  
Briefly, activation of these receptors initiates dissociation of the Gq+GTP complex and 
activation of phospholipase C (PLC), which then catalyzes the hydrolysis of PIP2 into 
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DAG and IP3.  IP3 initiates the release of Ca2+ from the sarcoplasmic reticulum into the 
cytosol, resulting in increased Ca2+ concentration, which promotes the binding of 
calmodulin (CaM).  The Ca2+/CaM complex activates myosin light chain kinase, which 
phosphorylates myosin light chains and promotes the ATPase activity of myosin, thereby 
promoting cross-bridge cycling and contraction. 
Knowing that these receptors are all coupled to the same G protein and are 
capable of forming heterodimers with unrelated GPCRs suggests coupling of M3-5-HT2A 
and/or M3-Tp receptors on ASM as a possible mechanism regulating antigen- and TXA2-
mediated airway constriction, respectively (Figure 5.1B).  This Dimer Formation Model 
could function in one of two ways.  Binding of ligand on either receptor could drive the 
formation of dimmers, which are needed for association of the G protein, which 
dissociates upon binding of the second ligand.  Alternatively, and more consistent with 
current knowledge of GPCR dimers, heterodimers preexist in the tissue and binding of 
both ligands is needed for dissociation of the G protein and consequent downstream 
signaling.   
 Several experiments could be done to verify/refute the ability of these GPCRs to 
form heterodimers.  Suggestive evidence can be obtained using ASM cultures treated 
with 5-HT or TXA2, activating 5-HT2A or Tp receptors, respectively.  This activation 
should trigger release of intracellular Ca2+.  However, if these receptors exist as 
heterodimers with M3 receptors, pretreatment with atropine should be able to block rises 
in Ca2+ resulting from 5-HT or TXA2 stimulation.  Alternatively, immunoprecipitation 
assays could be carried out on either primary ASM cells or cells co-transfected with 5-
HT2A or Tp receptors and M3 receptors.  If the GPCRs exist as dimers, 
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immunoprecipitation of one receptor would result in precipitation of the other receptor.  
Finally, cells can be co-transfected with 5-HT2A or Tp receptors labeled with a donor 
flourophore and M3 receptors labeled with an acceptor fluorophore.  Analysis of the 
molecular interaction of the two co-transfected receptors can then be dertermined using 
Fluorescence Resonance Energy Transfer (FRET).   
 
Representation of human disease in a mouse model 
 Determination of mechanisms involved in airway reactivity in experimental 
animals such as the mouse can lead to a better understanding of bronchoconstriction in 
humans with asthma.  It’s well understood that asthma is a complex disease involving 
both environmental and genetic factors that cannot be fully modeled in an animal that 
does not spontaneously develop the disease; however, modeling specific symptoms of 
asthma in the mouse can hopefully provide insight into the human condition.  In addition, 
in vitro data often does not completely correlate with in vivo data even from the same 
species, and most “in vivo” human studies are suggestive measurements of byproducts 
that are either elevated/decreased in asthmatic patients.  Although no animal model is 
going to perfectly portray the human condition, the inability to perform substantial in vivo 
experimentation on human subjects highlights the importance of using an animal model.   
Small size, simple housing requirements, short reproductive cycle, and ease of 
genome manipulation have made the mouse a desirable and common animal model for 
studying human disease.  The mouse has been the most common animal for modeling the 
classic Th2 asthmatic phenotype and for studying allergic responses in the airways 
(reviewed in (12)).  In addition, airway reactivity is easily measured in both conscious, 
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spontaneously breathing, as well as anesthetized, artificially ventilated animals.  This 
begs the question ‘how good is the mouse as a model of airway reactivity’?  
Neuronal involvement in asthma 
 A common theme in the research presented in this dissertation is the reliance of a 
neural component for allergen- and TXA2-induced airway reactivity.  In the mouse, we 
have seen that surgical vagotomy attenuates bronchoconstriction following challenge 
with either allergen or the TXA2 analog U46619; furthermore, pretreatment with atropine 
and the use of mAChR-deficient mice has shown the requirement of the M3 receptor in 
both models of airway reactivity (1, 13).  This data emphasizes the absolute requirement 
of an intact neural circuit for bronchoconstriction in the mouse, but can the same be said 
for humans?   
 Neural involvement in asthma is not a new idea.  As far back as the 1920s 
medical researchers have experimented with the ability of neural resection and lung 
denervation to cure the asthmatic condition (reviewed in (14)).  Although results 
generally varied, many patients improved and a few were even thought to be cured.  
Since then, anticholinergic treatment of asthmatics has also shown varied results.  
Anticholinergic treatment in combination with β2-agonists (bronchodilators) has been 
shown to improve lung function in children and adults with severe acute asthma; however 
addition of anticholinergics made no difference in patients with mild to moderate asthma 
(15).  Some studies have suggested that asthma is a result of neural dysregulation.  
Human parasympathetic nerves from patients with asthma have increased release of 
acetylcholine (ACh) in response to electrical field stimulation (16).  In addition M2 
agonists, which should prevent further release of ACh from parasympathetic nerves, fail 
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to inhibit bronchoconstriction in some patients with asthma (17), suggesting dysfunction 
of muscarinic receptors in asthma.  Like many other complex diseases, asthma can be 
divided into many different subsets, some of which appear to be at least partially 
dependent on cholinergic signaling. 
Serotonin and asthma 
We have shown that allergen-induced airway reactivity in the mouse is mediated 
by mast cell-derived 5-HT (13).  Although 5-HT has been shown to activate human ASM 
ex vivo (18), as well as increase Ca2+ signaling in cultured human ASM (19), it is 
generally accepted that inhalation of 5-HT does not lead to increased airway constriction, 
even in asthmatics (20).  However, some evidence for the involvement of 5-HT in asthma 
has been presented.  Levels of free 5-HT in plasma have been shown to be increased in 
patients with asthma, and these levels correlated positively with clinical status and 
negatively with pulmonary function (21).  Additionally, tryptophan hydroxylase and 
serotonin have been measured in human mast cells (22), albeit in much smaller amounts 
than seen in their mouse counterparts.  Although inhalation of 5-HT does not effect lung 
function in asthmatics, it may increase airway reactivity given that 5-HT receptor 
activation has been shown to facilitate cholinergic bronchoconstriction in human airways 
(23).   
A few clinical studies have suggested the possible involvement of serotonin in 
anaphylactic bronchoconstriction in man.  Inhibition of 5-HT2A receptors with droperidol 
successfully treated two asthmatic patients who where unresponsive to conventional 
therapy (24).  Another study by Lechin et al. (25) reported the use of  placebo and 
tianeptine, an antidepressant that induces uptake of 5-HT by platelets, in a double-blind 
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cross-over study to reduce the levels of free serotonin in patients with asthma.  Tianeptine 
treatment provoked a dramatic decrease in clinical rating and increase in pulmonary 
function.  These results suggested the potential for 5-HT modifiers in the treatment of 
asthma; however, no 5-HT modifiers are currently used for the treatment of asthma. 
Thromboxane and asthma 
Human allergic airway constriction modeled in precision cut lung slices (PCLS) 
was shown to be mediated by a combination if leukotrienes and thromboxane (26), 
although no in vivo studies have been done to link thromboxane to allergen-induced 
bronchoconstriction in asthmatics.  Clinical studies have been done to asses the role of 
TXA2 on airway hyperresponsiveness (AHR) to cholinergic agents, and have shown that 
inhibition of either thromboxane synthetase or Tp receptors improves AHR in asthmatic 
patients (27, 28).   
Inconsistent with the human PCLS studies, leukotriene- and Tp-deficient mice 
have no defect in allergen-mediated bronchoconstriction.  However, the TXA2 analog 
U46619 has significant dose-dependent effects on airway reactivity in the mouse.  
Chapter 4 details the involvement of specific subsets of Tp receptor in airway reactivity 
in both the naïve and the allergic.  Briefly, smooth muscle Tp receptors facilitate 
U46619-mediated airway constriction in the naïve lung, while both smooth muscle and 
neural Tp receptors are involved in constriction and AHR in allergic airways.  Because 
little is known about specific receptor subset involvement in airway reactivity in human 
asthma, it is tempting to speculate a similar mechanism to that seen in the mouse, 
although studies to confirm this would be difficult at best. 
 
 226
Making the mouse more like us 
 Given the differences between humans and the mouse, attempts have been made 
to “humanize” the mouse.  For example, transgenic mice have been made that express the 
human leukotriene receptor, cycLT1R (29).  In these animals, the inability of the mouse 
airways to respond to leukotriene challenge is partially corrected, making their airways 
more representative of human airways.  Using advanced homologous recombination 
techniques it is now possible to completely replace specific mouse genes with their 
human counterparts, including regulatory regions.  Once mechanisms are elucidated in 
the mouse using both in vivo and in vitro methods, these mechanisms can be compared to 
what is known about the human condition and steps to “humanize” the mouse through 
replacement with human genes can initiated.  This method has the potential to provide a 
more reliable mouse model for studying human disease.   
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